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Introduction 
Options for imaging in acute stroke are expanding with the potential to select 
therapy based on imaging targets, as well as providing additional diagnostic and 
prognostic information. Multimodal CT has been used to image the ischemic 
penumbra, infarct core, and to detect leptomeningeal collateral flow although 
the optimum way to image these variables is not clear. 
Methods  
In addition to a systematic literature review of imaging for leptomeningeal 
collaterals, Data from observational studies of acute stroke which employed 
multimodal CT imaging on admission and follow up was used to evaluate 
feasibility of acute stroke imaging with CT and MRI, Perfusion thresholds for core 
and ischemic penumbra, methods to quantify leptomeningeal collateral flow and 
sensitivity of non contrast CT for detecting infarct core pixels.  
Results 
Advanced imaging in acute stroke and at follow up was more feasible with CT 
compared to MRI with the possible suggestion that imaging with MRI alone could 
introduce a bias regarding age and clinical severity for patients entered into 
clinical studies 
Heterogeneity in grading and detecting collateral flow was found in the 
literature providing an opportunity to devise a novel assessment method.  
Well developed collaterals were associated with imaging and clinical markers for 
good outcome as well as some potential biomarkers including atrial fibrillation 
and blood fibrinogen level. 
Relative cerebral blood flow and delay time were found to be the best 
predictors on infarct core and ischemic penumbra after derivation of optimum 
perfusion thresholds and subsequent validation in independent patient groups. 
3 
Pixel based comparison of infarct core on CT perfusion and non contrast CT 
highlighted the lack of sensitivity of CT for detecting infarct core based on 
Hounsfield unit value alone. 
Conclusion  
Multimodal CT for acute stroke assessment offers the potential for measuring 
infarct core, ischemic penumbra and leptomeningeal collateral flow status 
rapidly according to novel grading scales and thresholds and provides 
information on tissue viability which cannot be detected on non-contrast CT. 
Further evaluation on the impact additional imaging should have in clinical 
practice is needed.  
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Chapter 1. Introduction 
Stroke is defined as a rapidly progressive focal or global brain dysfunction of 
vascular origin lasting more than 24 hours or leading to death within 24 hours(1). 
As one of the leading contributors to death and disability worldwide, the burden 
of stroke is felt physically, socially, economically and emotionally on patients, 
their families and health care services (2).Within stroke, several subtypes exist 
with ischemic stroke representing the majority, accounting for between 67 and 
80 % of stroke cases reported in epidemiological studies (2). Ischemic stroke is 
more often disabling rather than fatal but remains the most common life 
threatening neurological disorder(3). 10 % of patients with ischemic stroke will 
die within 30 days of stroke onset, while half of those who survive have 
persistent disability 6 months later(4).The remaining 20% of stroke cases are due 
to intracerebral or subarachnoid haemorrhage which are also potentially 
devastating conditions with 30 day mortality of primary intracerebral 
haemorrhage approaching 50%(5-7). 
Causes of ischemic stroke are wide(8) .Stroke aetiology may been classified into 
5 main groups using the TOAST  classification or subsequent variations on 
TOAST(9-11): 
●Large artery atherosclerosis 
●Cardiac embolus 
●Small vessel occlusion 
●Stroke of other determined aetiology  
●Stroke of undetermined aetiology 
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1.1 Ischemic Stroke Pathophysiology 
1.1.1 The Ischemic Cascade 
Transient or permanent occlusion of a cerebral artery by a thrombus or embolus 
causes a reduction in normal cerebral blood flow in the affected vascular 
territory. The brain has a high demand for oxygen and glucose delivery for 
energy production via oxidative phosphorylation which is compromised by the 
collapse in cerebral blood flow resulting in reduced nutrient delivery to grey and 
white matter(12). Without the ability to store energy supplies for future use, 
reduced cerebral blood flow results in the inability to maintain ionic gradients 
across cell membranes. Persistent or sufficiently severe blood flow reductions 
result in neuronal death at a rate of approximating 1.9 million neurones per 
minute(13). Reduced territorial blood flow is not uniform however and 
interrupted blood flow to the white matter and cortex results in a gradient of 
hypo perfusion, rather than complete and homogeneous ischaemia of the entire 
territory(14). The source of persistent blood flow in the setting of complete 
arterial occlusion is from collateral vessels which may be different depending on 
the site of occlusion and between different individuals due to other factors(15). 
 The mechanisms ultimately responsible for cell death in the setting of cerebral 
ischemia are many and complex, occurring at different times after the onset of 
ischaemia depending on the pathological process(16).Regions suffering the most 
severe degrees of hypo perfusion progress most rapidly to necrosis and 
irreversible cell death,  while other regions with more modest blood flow 
reductions may become infarcted at later time points. This late cell death is 
mediated via apoptosis at less severe blood flow reductions, and neuronal tissue 
may be particularly vulnerable in this alternative mode of cell death(17). The 
potential for tissue infarction late after stroke onset therefore may represent a 
target for therapeutic intervention. 
 With loss of energy-dependent cellular processes, ionic potentials across cell 
membranes are lost and excitatory amino acids are released to the extra cellular 
space. Glutamate accumulation activates post synaptic NMDA and AMPA 
receptors leading to Ca2+ and Na+ influx, and K+ efflux, from cells. This results in 
cell death due to excito-toxicity(12). Anion influx to cells is followed by net 
18 
water influx and resultant cellular oedema and ultimately lysis. Loss of normal 
ionic potentials because of excitotoxicity results in cellular depolarisation which 
if permanent also results in cellular necrosis. Transient but repeated cellular 
depolarisation and repolarization can occur in regions with less severe 
reductions in blood flow which surround the necrotic infarct core in 
experimental stroke models. Repolarization requires energy and ongoing 
exposure to glutamate stimulates depolarization again. The likelihood of 
permanent depolarisation and cell death increases with the number of peri-
infarct depolarisations seen in animal models(12). These depolarisations can 
occur several hours after stroke onset and contribute to the growth of the 
infarct with time. Glutamate mediated Ca2+ influx to cells also leads to 
intracellular production and release of pro-inflammatory cytokines such as TNF 
and IL-1beta, expression of adhesion molecules on cellular surface and 
recruitment of neutrophils and macrophages and activation of the complement 
cascade. The resultant post ischemic inflammatory reaction can further 
contribute to cell damage by direct toxin production as well as contributing to 
cell apoptosis. Apoptosis is also linked to activation of intracellular enzymes. 
Caspase activation after Ca2+ influx and loss of mitochondrial function results in 
the generation of reactive oxygen species, intracellular DNA damage, and 
activation of programmed cell death via apoptosis, potentially occurring with 
milder levels of blood flow reduction than those responsible for earlier cellular 
necrosis(18). The time scale for apoptosis induced cell death is over hours to 
days, while excitotoxicity induced cell necrosis occurs over minutes to hours 
(Figure 1.1). 
 Different mechanisms for cell death over time which ultimately contribute to 
tissue infarction have been the target for neuroprotectant therapies targeting 
the ischemic cascade. Although the neuroprotectant trials targeting these areas 
have been negative to date, the cellular processes involved in stroke evolution 
represent logical targets for therapy. Clinical trials of neuroprotection, for 
example using therapeutic hypothermia which targets a number of different 
steps within the ischemic cascade are promising interventions and are currently 
ongoing(19). Trial design and heterogeneity of subjects recruited to such trials 
may explain why neuroprotectants targeting cellular processes have failed, and 
it may be that these treatments could be of benefit in certain stroke subtypes 
19 
with specific tissue characteristics. Identifying these subgroups on clinical 
grounds alone is difficult, highlighting the need to explore additional imaging to 
identify stroke subtypes(20). 
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Figure 1-1 Cascade of Damaging Events in Cerebral Ischemia 
Tissue infarction after cerebral ischemia may be induced by different mechanisms at different time 
points after stroke. Reproduced from “Dirnagl U, Pathobiology of ischemic stroke: an integrated 
view” Trends in Neuroscience 1999 
 
1.1.2 Evidence for Reversible and Permanent Ischemic Damage 
Experimental stroke models have shown that impaired brain functional activity 
and loss of brain structural integrity occur at separate and distinct thresholds of 
CBF (21).  Tissues in receipt of low rates of cerebral blood flow have reduced 
electrical activity as demonstrated by EEG and cortical evoked potentials (22, 
23) . Some or all of this electrically silent tissue may have the capacity to 
recover function however, as the ion concentration changes due to K+ efflux 
typically associated with neuronal death may be absent at the level of 
hypoperfusion required to produce absent EEG activity(24) . The concept of 
tissue states which can be defined according to blood flow thresholds appeared, 
with two close but distinct thresholds being determined; the threshold for 
reduced cortical evoked potentials (responsible for the clinical deficit) and the 
threshold for K+ efflux and loss of neuronal integrity (responsible for tissue 
infarction). Tissue between these thresholds, structurally intact but electrically 
silent, has been defined as the ischemic penumbra, the volume of tissue 
surrounding the irreversibly damage infarct core resembling the shaded zone 
surrounding the centre of a complete solar eclipse(14). An important feature 
was that reversal of the ischemic lesion causing symptoms could actually reverse 
the clinical deficit, but that interruption to blood flow for long periods 
ultimately resulted in tissue infarction (25). Hence the presence of penumbra in 
animals was confirmed and the prompt restoration of flow to penumbral tissue 
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resulted in recovery of function, supporting the development of strategies to 
restore flow to ischemic tissue in stroke.  
However the original identification and definition of penumbra in animal models, 
reflecting electrically silent but structurally intact tissue, has limitations when 
translating the concept of ischemic penumbra to clinical practice as the methods 
used in the original definition are not practical for examining stroke in humans. 
The ischemic penumbra has therefore undergone multiple operational definitions 
since originally proposed, which to varying degrees have defined penumbra 
according to different imaging modalities and clinical markers. A current 
definition that embodies many of the concepts of the penumbra is: 
“The ischemic penumbra is ischemic tissue which is functionally impaired and is 
at risk of infarction but has the potential to be salvaged by reperfusion and/or 
other strategies. If not salvaged this tissue is progressively recruited into the 
infarct core, which will expand with time into the maximal volume originally at 
risk”(26). 
While this definition describes the key features of the penumbra, incorporating 
the mechanism(s) of penumbral salvage into the definition is a possible 
shortcoming, as putative mechanisms of future tissue rescue arguably should not 
define the actual state of the tissue in question. 
1.1.3 Normal Response to Ischemia 
In order to identify core and penumbra using imaging, the normal response to 
ischemia must be known in order to distinguish tissue which is normal from 
tissue which is at risk of infarction or irreversibly damaged. CBF is determined 
by the combination of CPP (cerebral perfusion pressure) and CVR 
(cerebrovascular resistance).  CBF is maintained to a degree despite fluctuations 
in CPP by autoregulation which protects against hypoxia in the setting of low 
CPP and against oedema with high CPP (27). In stroke, occlusion of an extra or 
intracranial artery results in reduced CPP. In an attempt to maintain normal 
CBF, resistance vessels dilate causing a reduction in CVR and an increase in CBV 
due to autoregulation. If maximal vasodilation and increases in CBV cannot 
maintain CBF, tissue hypo perfusion ensues. OEF increases to maintain cerebral 
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metabolism and function despite the reduction in CBF, and reaches a maximum 
level in a state of “misery perfusion”(28). If this is insufficient to maintain 
normal metabolic function, an energy deficit ensues, normal metabolism 
becomes impaired and CMRO2 reduces.  The response to progressive reduction in 
CPP is demonstrated visually below, revealing that CBF is maintained by 
increasing CBV and OEF then increases, but progressive and severe reduction in 
CBF finally results in a collapse in CBV after loss of autoregulation: 
 
Figure 1-2 Consequences of Reduced Cerebral Perfusion Pressure 
As CPP falls, CBF is maintained by vasodilation and increasing CBV until compensation is 
maximal. As CBF falls OEF increases but with ongoing reduction in CPP CBV falls and 
autoregulation is lost. Adapted from “Markus H. Cerebral perfusion and Stroke. Journal of 
Neurology Neurosurgery and Psychiatry 2004; 75: 353-361” 
Although reductions in CBF are ultimately responsible for tissue to become 
penumbral or infarcted, indices such as OEF and CMR02 clearly can be used to 
define tissue according to metabolic activity and which ultimately reflect 
neuronal integrity. These parameters, obtained using PET imaging represent the 
gold standard methods by which tissue in different states of metabolic and 
haemodynamic compromise can be determined in humans. 
1.1.4 Identification of Penumbra in Humans with PET 
The topography and time course of penumbra in human stroke has been 
examined using numerous techniques, but the gold standard measurement has 
been using PET. PET, using oxygen15 provides quantitative measurement of the 
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parameters of interest in stroke and penumbra, namely CBF, CMR02 and OEF. 
Tissue in the state of misery perfusion, with reduced CBF but normal CMR02 is 
consistent with the concept of penumbral tissue existing between life and 
death(28). But to meet the above definition of penumbra, the fate of misery 
perfusion tissue requires examination. To achieve this, Baron and colleagues 
performed PET imaging in a series of stroke patients between 5-18 hours after 
onset of stroke symptoms and, in the survivors , obtained final infarct imaging 
with CT to assess tissue outcome on a voxel by voxel basis(29). In survivors with 
visualised infarcts, tissue in the misery perfusion state with CBF ranging from 10-
22ml/100g/min and OEF above 0.70 was shown to be incorporated into final 
infarct volume, proving that hypoperfused but metabolically active tissue is truly 
tissue at risk of infarction and therefore can be defined as penumbra. The 
viability of tissue suffering from misery perfusion has already been observed in 
animal stroke models examining the effect of reperfusion at different time 
points after stroke (25) , proving that this tissue state fulfils the ideal definition 
of penumbra.  Importantly, putative penumbral tissue was also seen in non 
infarcted tissue at follow up. Normal, peri-infarct voxels with penumbral 
signature on initial PET were found in patients with clinical improvement, the 
extent of which correlated strongly with the volume of penumbra salvaged 
suggesting that the penumbra can be salvaged with a corresponding clinical 
improvement. Irreversibly damaged tissue can also be demonstrated using PET, 
with a reduction in CBF in tandem with a reduced CMR02 due to loss of normal 
cerebral metabolism(30).  
PET was the first modality to measure penumbra in human stroke. The 
measurements obtained are quantitative, reflect both blood flow and metabolic 
activity and remain the accepted gold standard measurement for penumbra. 
However PET imaging is limited to a small number of sites, is not a routine 
imaging modality for stroke, is time consuming and requires arterial 
catheterisation. Therefore, although being the accepted modality for penumbra 
detection, its use remains as a research tool only. The characteristic PET 
signatures of penumbra and core have been built upon to achieve penumbra 
imaging with alternative methods.  These include SPECT, CT, MRI, Xenon CT and 
variations of PET imaging using other tracers such as 11C-Flumazenil, 18F-
fluoromidazole and 15O. MRI and CT represent the methods used in clinical 
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practice with potential to visualise core and penumbra and will be discussed in 
more detail. 
1.1.5 Factors Affecting the Fate of the Penumbra 
The ischemic penumbra exists between life and death with the potential to be 
rescued, and is therefore subject to influences which determine its ultimate 
fate. Recovery of penumbra is associated with magnitude of clinical recovery 
(29) suggesting treatments focussed on maintaining it or rescuing it completely 
would have a positive impact. The potential influences on penumbral salvage are 
more than the culprit arterial occlusion however with a number of additional 
factors implicated; 
Time 
Reperfusion of the penumbra is a target of hyperacute acute stroke treatments 
which are severely limited by time. Stroke is a dynamic process with neuronal 
death occurring at times due to different underlying mechanisms. Ultimately 
however, penumbra becomes recruited to the infarct core with time if not 
rescued.  
After focal ischemia was induced in a group of monkeys, the clinical outcome 
was dependent on the duration of ischemia with full recovery possible with early 
reperfusion after stroke onset(25). The interaction between CBF reduction and 
duration of ischemia is demonstrated in figure 1.3. 
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Figure 1-3 Interaction Between CBF Threshold for Infarction and Time 
The CBF threshold for infarction increases with time from stroke onset. Adapted from “Jones TH, 
Morawetz RB, Crowell RM et al. Thresholds of focal cerebral ischemia in awake monkeys. 
J.Neurosurg. 1981; 54:773”, courtesy of the American College of Chest Physicians. 
Neuronal loss over time has been quantified in a model of supra-tentorial stroke, 
suggesting that almost 2 million neurons are lost per minute ultimately 
contributing to the final infarct extent (13). The importance of time is 
underlined most obviously in the administration of therapies that currently exist 
to restore perfusion to ischemic tissue, with odds of obtaining good clinical 
outcome with thrombolytic agents decreasing dramatically with increasing time 
from symptom onset such that on a population level benefits may not outweigh 
risks from treatment  beyond 4.5 hrs(31).  Despite the clear importance of time, 
it is likely that some patients, such as those with good collateral flow or minimal 
established ischemic change on imaging, presenting beyond the usual time 
window would still benefit from treatment if selected appropriately .Although 
the results of this pooled analysis are not based on documented penumbral 
salvage, it is likely that infarct extent is greater and penumbral salvage is lesser 
with increasing time after symptom onset, and the benefit from early 
reperfusion is due to recovery of penumbral tissue. Stroke is a dynamic process, 
infarction evolves over time, and for acute stroke, the popular phrase “time is 
brain” is appropriate.  
Blood Glucose 
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Persistent hyperglycaemia >7mmol/L is strongly associated with expansion of 
infarct volume over time while admission hyperglycaemia is associated with 
increasing lactate production, demise of salvageable tissue and worse clinical 
outcomes using MRI and MR Spectroscopic imaging(32, 33) . Hyperglycaemia 
therefore has an independent influence on the fate of tissue likely to be 
penumbral at the time of imaging. While this offered a potential therapeutic 
target, trials to date have not shown a therapeutic benefit from using insulin in 
post-stroke hyperglycemia as lowering blood glucose did not attenuate infarct 
growth and resulted in episodes of hypoglycaemia (34-36). Hyperglycemia may 
therefore represent a marker for poor outcomes after stroke, but may not be the 
direct cause for this effect. 
Age 
Increasing age is an independent factor in the risk of penumbra tissue 
progressing to become infarcted. In an MRI based study using DWI and PWI 
imaging, Ay et al showed that increasing age was associated with progression of 
ischemic tissue to become infarcted, with each year of increased age 
contributing to an additional 0.65% of additional penumbral tissue becoming 
infarcted(37). Animal studies have revealed that with increasing age, white 
matter susceptibility to ischemia increases and is mediated predominantly via 
glutamate release and AMPA and kaianate-type glutamate receptors(38). The 
impact of age and loss of penumbra interacts with sex, as younger women 
tended to have 50% less penumbral tissue loss than male counterparts, but older 
patients had less obvious differences .This interaction of sex and age mirrors 
cardiovascular risk profiles which are also lower in younger women compared to 
men, and likely reflects the impact of blood oestrogen levels on cardiovascular 
risk as well as increased blood flow and decreased vascular tone mediated by 
increased oestrogen(39).  
Severity of hypo perfusion / Collateral flow 
The presence of compensatory collateral circulation in the territory of ischemia 
may ameliorate the effects of ischemia to a degree(15). Well formed collaterals 
correlate with less severe hypoperfusion measurements and larger volumes of 
oligemia. Severity of hypoperfusion does not correlate with the total volume of 
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ischemic tissue, but does correlate with the volume of irreversibly damaged core 
within the ischemic zone, suggesting that when development of residual 
collateral flow is poor, hypoperfused tissue is more likely to become irreversibly 
damaged (40). 
Haematocrit 
Haematocrit contributes to blood viscosity and contributes to poor outcome 
after ischemic stroke. In a study using serial MRI at intervals up to 90 days after 
stroke, elevated haematocrit was associated with less reperfusion, more infarct 
expansion and a trend towards reduced penumbral salvage (41). 
1.2 Treatment Options in Acute Ischemic Stroke 
The potentially devastating consequences of stroke highlight the need to utilise 
effective treatments to minimise disability. The spectrum of stroke treatments 
is wide, involves multiple disciplines and comprises various different 
interventions depending on the time point and clinical requirement. Given the 
focus of this thesis will be on acute stroke, treatments given within the first 
hours after stroke onset will be discussed. 
The only licensed treatment of acute ischemic stroke is the administration of rt-
PA as a thrombolytic agent in selected individuals (42-45). Trial evidence now 
supports the administration of rt-PA up to 4.5 hours after symptom onset, 
although earlier treatment is associated with higher odds for achieving good 
clinical outcomes (46). 
Several randomized controlled clinical trials have been performed using rt-PA in 
various time windows, with pooled results showing the efficacy and time 
dependant nature of treatment (31). A total of 6705 patients have been 
randomised to rt-PA or placebo in several trials with odds ratio of a good clinical 
outcome after stroke ranging from 2.55(95% CI 1.44-4.52), 1.64 (95% CI 1.12-
2.40) and 1.34 (95% CI 1.06-1.61) for 0-90, 91-180 and 181-270 minute time 
windows respectively, where good clinical outcome was defined as 3 month mRS 
of 0-1(31). This is despite an increased likelihood of intracerebral haemorrhage 
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with rt-PA versus placebo (OR 5.37 95% CI 3.22-8.95). These trials confirm the 
time dependent benefit of thrombolysis for acute stroke. 
Other acute stroke therapies exist and are worthy of mention. Alternative 
thrombolytic agents with theoretical benefits over alteplase include 
Desmoteplase and Tenecteplase. Desmoteplase in the 3-9 hour window was 
associated with increased reperfusion rates which corresponded to favourable 
clinical outcomes in a phase II trial using MRI selection criteria. Extended time 
window desmoteplase using MRI and CT selection was negative however, possibly 
relating to less severe clinical severity at entry masking potential clinical benefit 
of desmoteplase (47, 48) and is the subject of ongoing study. 
Tenecteplase is a genetically modified version of TPA with higher fibrin 
specificity and greater resistance to inhibition in vivo (49) which has been 
evaluated in dose finding studies and has shown some promise although slow 
trial recruitment has hampered early studies(50). Low dose tenecteplase 
(0.1mg/kg) showed better rates of recanalisation and reperfusion than alteplase 
when selected using multimodal CT imaging, and compared to historical controls 
(51). In a randomised trial using advanced imaging for patient selection, Parsons 
et al showed that Tenecteplase had superior recanalisation reperfusion and 
clinical outcomes in patients with proximal arterial occlusions (52). The results 
relate to a specific patient cohort with proximal occlusions but suggest that 
alternative agents could have a superior effect to Alteplase in ischemic stroke 
but further study is required to identify other subgroups that may benefit.  
Recanalisation is strongly associated with good clinical outcome and may be seen  
as a surrogate marker for clinical outcome(53) . IV rt-PA is not associated with 
high rates of recanalisation however, with proximal occlusions being the least 
likely to recanalize (54, 55). The association between recanalisation and 
outcome, and the low recanalisation rates seen with IV therapy alone has 
prompted investigation of intra-arterial therapies to improve recanalisation. 
Intra arterial lysis and mechanical clot retrieval are additional treatment options 
to achieve recanalisation.  
Intra arterial thrombolysis has been evaluated in a number of trials with PROACT 
II demonstrating efficacy of IA pro-urokinase and heparin against heparin therapy 
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alone with better clinical outcome at day 90 despite an excess of haemorrhage 
(56). Only a small proportion of screened patients were eligible for recruitment, 
but IA lysis resulted in 66% recanalisation and 40% achieved a good clinical 
outcome (mRS 0-2), both of which were superior to heparin alone. PROACT II 
also demonstrated that IA therapy may be efficacious up to 6 hours from 
symptom onset. The MELT trial was terminated early but suggested improved 
clinical outcome in patients with MCA occlusion treated with IA urokinase 
compared to control subjects (57). 5 randomised trials of IA fibrinolysis have 
been undertaken in total with meta-analysis of these suggesting IA fibrinolysis 
results in improved clinical outcome and higher recanalisation rates compared to 
controls treated with IV fibrinolysis but also increased rates of both symptomatic 
and asymptomatic haemorrhage but no difference in mortality (58). Pro- 
Urokinase, the only agent found to have a positive individual trial result did not 
get approval for use by the American Food and Drug agency and in the meantime 
mechanical devices to remove cerebral clots have been developed and have 
achieved higher recanalisation rates meaning IA Fibrinolytic agents are now 
seldom used. 
Mechanical clot removal or dispersal devices offer some theoretical advantages 
over chemical fibrinolysis such as improved recanalisation rate and fewer 
systemic side effects of therapy(59). The MERCI device is a corkscrew shaped 
device designed to remove blood clot and has been the most widely evaluated 
device demonstrating up to 69% recanalisation rate in observational non-
randomised studies of patients who had failed IV therapy or who were deemed 
ineligible for IV therapy (60). Intracerebral haemorrhage rate of 9.8 %, good 
clinical outcome in only 36% and mortality of 34% with the new generation MERCI 
device are higher than for IV therapy but a direct comparison has not been done 
in clinical trials. This device has been approved by the FDA for achieving 
recanalisation but superiority to IV rt-PA has not been demonstrated for clinical 
outcome. The Penumbra Pivotal Stroke Trial was a single armed study in patients 
with intracranial occlusion evaluating the penumbra device, a mechanical 
suction device which can fragment and remove intra-arterial thrombus. 
Recanalisation rate was 81.6%, although symptomatic intracerebral haemorrhage 
was seen in 11.2% and only 25% had a good clinical outcome at day 90(61). More 
recent advances in intra-arterial therapy include the use of stent retriever 
30 
devices which combine the features of angioplasty devices and clot retrieval. 
The SOLITAIRE device has been studied in patients who did not respond to intra-
arterial rt-PA or to attempted clot retrieval with the MERCI device and achieved 
a 90% recanalisation rate along with 10% symptomatic haemorrhage and 20% 
mortality in a single armed pilot study (62). Further multicentre study of the 
SOLITAIRE device has demonstrated a similar recanalisation rate of 85% with 
good clinical outcome in 55% of those treated (63) while a comparison with the 
MERCI device has shown higher recanalisation rates and better outcomes with 
the SOLITAIRE device (64). Additional options for stent retrieval such as the 
TREVO device are being developed which have been shown to have superior 
recanalisation rates to the MERCI retriever(65) (66).  
While the recanalisation rates are higher with IA rt-PA and mechanical devices, 
their clinical efficacy compared to the standard IV therapy has not yet been 
demonstrated. The recently published IMS III trial demonstrated that clinical 
outcomes were unchanged between IA and IV therapies despite superior 
recanalisation in the IA group (67). In the smaller SYNTHESIS trial, superior 
recanalisation with IA therapy compared to IV was not associated with improved 
outcome (68). Reasons for the lack of impact on outcome despite improved 
recanalisation may be due to multiple factors. Timing of recanalisation is likely 
to be of critical importance, and delayed transfer to angiography is likely to 
result in infarct growth, even if subsequent recanalisation occurs. Patients 
selected for IA therapy have more severe clinical deficits than in trials for IV 
lysis which also influences outcome. Additional trial design limitations , such as 
lack of non-invasive angiography in IMS III prior to randomisation would be 
considered unusual in routine clinical practice and constitute a limitation to the 
interpretation of the study results, as well as low recruitment rates in centres 
with experience in delivering IA therapy for stroke, suggesting that those who 
underwent randomisation may not reflect the bulk of patients treated with IA 
therapy routinely in those centres(67).Therefore despite the higher 
recanalisation rates associated with IA stroke treatment, improved clinical 
outcomes have yet to be demonstrated when compared to IV thrombolytic 
therapy, meaning further evidence from additional trials is needed to prove the 
benefit of these promising new treatment options prior to their routine use in 
stroke (69, 70). 
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Imaging for all but one of the randomised trials for IV rt-PA was with non 
contrast CT prior to therapy (31), to exclude stroke mimics and rule out major 
established ischemic change prior to treatment. Options for imaging prior to 
therapy have expanded however, and are now being used as part of the 
selection criteria for some trials in order to reduce heterogeneity of the patient 
cohort and also to enable outcome measures other than clinical outcome to 
show proof of efficacy (47, 52). Imaging measures including infarct volume, 
reperfusion, recanalisation and infarct growth and may be determined using CT 
or MR imaging and can be used as markers of response to treatment. Additional 
imaging techniques are likely to be of importance for trial purposes for proof on 
concept studies and also potentially for enhancing clinical decision making in 
acute stroke. 
1.3 CT Imaging for Acute Stroke 
1.3.1 Non Contrast CT 
The most widely available and used imaging modality for stroke patients remains 
non contrast brain CT, used to confirm diagnosis and exclude other mimics such 
as intracerebral haemorrhage, subdural haematoma and tumour.  CT imaging 
detects different amounts of water content in cerebral tissue measured in HU. 
Early ischemic changes seen on CT include focal tissue swelling and parenchymal 
hypoattenuation, grouped together in practice as signs of ischemia, but which 
may reflect different stages of ischemia and tissue viability (71).  
Hypodensity on CT correlates with PET defined infarct core and reduced cerebral 
blood volume on PWI MRI supporting hypodensity as a marker for irreversibly 
damaged infarct core (72, 73). Hypodense areas on CT early after symptom 
onset continue to appear hypodense on follow up CT scanning, emphasising the 
specificity of hypodensity for infarct core(74). While CT-based hypodensity is 
highly specific for infarct core, CT has reduced sensitivity for detecting early 
ischemia. The time taken for hypodensity to appear following symptom onset is 
longer than for corresponding DWI abnormalities and the degree of hypodensity 
seen on CT correlates with increasing time from symptom onset (75, 76). 
Diffusion restriction occurs early after ischemia but does not increase with time 
beyond 1.5 hours to the same extent as CT hypodensity, which appears later but 
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continues to evolve with time even after diffusion restriction changes have 
ceased, which may reflect differences in early cytotoxic oedema, seen with DWI 
and subsequent vasogenic oedema due to net water uptake demonstrated with 
CT(75, 77) 
Focal swelling (e.g. loss of normal cortical sulcal pattern without hypodensity) is 
considered to reflect early ischemic changes which are not irreversible and may 
have increased blood volume suggesting autoregulation consistent with 
penumbra(71). Detection of focal swelling and hypodensity may not be possible 
due to limited sensitivity for CT to demonstrate the changes, although 
hypodensity and focal swelling have high specificity for infarct core and 
penumbra respectively when seen. Interobserver agreement for presence of 
ischemic changes can also be low(71). 
Extent of ischemic change on CT is associated with increased risk of 
haemorrhage following thrombolysis and patients with established ischemic 
change involving more than 1/3 of the MCA territory have been excluded from 
randomized controlled trials of thrombolysis (44, 78). Detection of ischemic 
changes varies between readers with improved detection by neuroradiologists 
compared to non expert raters(74). Systematic evaluation of plain CT in order to 
improve scan interpretation is possible using scoring methods such as ASPECTS 
which encompasses both swelling and hypodensity into a composite score for 
ischemia in the MCA territory examined in ten anatomical regions (79). 
Interobserver agreement using ASPECTS was shown to be superior to agreement 
scores on one-third MCA territory ischemia (κ=0.67-0.82 and 0.27-0.76 
respectively). Patients with ASPECTS score ≤ 7, indicative of more severe 
ischemia were more likely to be functionally dependent at outcome and to 
suffer symptomatic intracerebral haemorrhage after thrombolysis demonstrating 
the prognostic significance of ischemic signs on CT in the acute stroke phase 
(79). 
Presence of hyperdense vessels due to clot may help confirm the diagnosis in the 
absence of hypodensity or swelling, although the sensitivity for this sign is low 
(30%)(80). Specificity is generally high, although false positive hyperdense 
vessels can occur. Comparison to the normal hemisphere and measurement of 
HU intensity can be used to confirm if the vessel is truly hyperdense(81). 
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Hyperdense vessels have been associated with poor outcomes after stroke, but 
their presence only suggests an occlusion without independent predictive value 
as patients with dense vessels had greater clinical stroke severity than control 
patients at baseline (82, 83). Disappearance of the sign at follow up CT is 
considered a marker for recanalisation with improved clinical outcome, but the 
lack of sensitivity of the sign to begin with limits the use of this finding to 
determine response to therapy (84). Low sensitivity and high specificity for 
hyperdense vessels is also seen with more distal MCA clot in the Sylvian fissure, 
known as the Sylvian dot sign, and proximal clot termed the hyperintense 
carotid artery sign (85, 86). The presence of thrombus on non contrast CT may 
be visualised more readily using thin slice acquisitions where clot contrasts 
surrounding structures more clearly due to reduced volume averaging effects 
than thicker slice CT(87). Thin multi-slice CT may improve sensitivity for 
thrombus detection and has also shown that in patients with MCA or ICA 
occlusion, actual clot burden is increased in patients with hyperdense vessels 
compared to proximal occlusions not associated with a hyperdense vessel(88). 
Clot burden assessed with thin slice CT may be important in assessing likelihood 
of response to thrombolysis and could help select patients for intra-arterial 
therapy(87).  In addition to clot burden, clot composition may affect the 
likelihood of a hyperdense vessel sign being visualised, with low amounts of 
fibrin content contributing to a reduced clot density appearance(82).  High 
haematocrit which may be associated hyperdense vessels in the absence of 
thrombus, but the appearances should be bilateral if due to elevated 
haematocrit alone(89). 
CT is the most widely used imaging modality for stroke with high sensitivity for 
mimics such as intracerebral haemorrhage, high specificity for ischemia when 
hyperdense vessels or areas of hypoattenuation are seen but low sensitivity for 
detecting ischemic change is a limiting factor. 
1.3.2 CT Angiography 
The limitations of plain CT in terms of sensitivity for detecting ischemia are of 
obvious importance when assessing acute stroke but improved diagnostic 
accuracy and information on vascular status is possible with CTA (90). CTA is 
widely available, non invasive and can be performed without moving the patient 
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after the initial non contrast CT acquisition making it a feasible adjunct in acute 
stroke imaging (91). Retrospective analysis of outcomes for patients exposed to 
IV contrast and those having non-contrast studies alone prior to thrombolysis has 
demonstrated that contrast administration is not associated with increased risk 
of haemorrhage following rt-PA administration(92). 
CTA is obtained with a volumetric helical acquisition with timed imaging after 
delivery of a bolus of contrast material, at either a fixed time interval or with 
scanning triggered automatically by contrast concentration reaching a pre-
specified threshold within a ROI placed in the ascending aorta (89).Analysis of 
CTA may involve interpretation of CTA source images or reconstructions of raw 
data using multiplanar reformatted images and maximal intensity projections 
depending on the information required. Coverage by CTA varies between 
protocols, but may include intracranial imaging alone or an acquisition from the 
aortic arch superiorly to include neck and intracranial vessels. 
Vascular imaging is important in defining stroke subtype and for choosing 
secondary prevention therapy(9) so the coverage and spatial resolution offered 
by CTA is of importance. CTA from aortic arch distally permits visualisation of 
carotid vessels and millimetre exact measurement of carotid artery calibre and 
stenosis, as well as imaging plaque and vessel wall soft tissues(93). As a carotid 
imaging modality, it is less widely available than Doppler but the results are 
reliable, have high specificity and can be crosschecked by different observers in 
cases of doubt using the same initial acquisition (94). The added benefits of CTA 
for measuring carotid stenosis is of particular importance in lesser grades of 
carotid stenosis (50-69%) where it almost twice as sensitive as Doppler with 
similar specificity (95). As patients with these degrees of stenosis may still 
benefit from early carotid endarterectomy this is a potentially important finding 
when considering options for imaging carotid stenosis on stroke and TIA 
patients(96). Aortic arch plaques are a risk factor for stroke and for recurrent 
strokes after initial cryptogenic stroke, which may be visualised with CTA but 
not with carotid Doppler alone which is restricted in terms of coverage (97). An 
additional risk factor for stroke which is increasingly recognised is arterial 
dissection. While some controversy still exists about which imaging modality is 
best for detecting dissection within carotid or vertebral arteries, CTA may be 
used to make the diagnosis of dissection, is probably of equal preference to MRA 
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for detecting carotid dissection and may be superior to MRA for vertebral 
dissection(98). 
CTA findings can also be useful in acute stroke assessment as an adjunct to non –
contrast CT. CTA source images (CTA-SI) reveal parenchymal hypoattenuation 
more readily than CT or even post contrast CT (99). When compared to non 
contrast CT, CTA-SI are more sensitive for detection of vascular territory and 
stroke subtype classification(90). Lesions visible on CTA-SI are strongly 
correlated with acute DWI and final infarct volume suggesting its use as a marker 
for infarct core which can produce similar findings to acute DWI (99, 100). The 
additional predictive value of CTA-SI was confirmed when using the ASPECTS 
template for image analysis in hyperacute stroke, where patients with normal or 
near normal ASPECTS on CT were shown to have hypoattenuation on CTA-SI 
which correlated with the final extent of hypoattenuation on follow-up imaging 
(101). CTA-SI is also of benefit in posterior circulation stroke where sensitivity of 
non-contrast CT is a limiting factor. CTA-SI showed increased sensitivity for 
ischemic change compared to plain CT in patients with acute basilar thrombosis, 
with lesion extent on CTA-SI correlating with functional outcome at 3 months 
(102). CTA –SI also correlates more precisely with baseline clinical stroke 
severity and final neurological outcome than non contrast CT (54). As CTA-SI 
lesions correlate with final lesion extent, they are considered a marker for 
irreversibly damaged tissue, but the extent of agreement with other markers for 
viability and irreversible damage is debatable. Correlation with DWI and CBV 
lesions suggest loss of autoregulation and irreversible tissue damage, although 
this may be related to the timing of contrast administration and scan protocol  
which may mean that CTA-SI reflect reduced cerebral blood flow rather than 
reduced cerebral blood volume depending on the acquisition parameters(103). 
More recent analysis of perfusion measurements for infarct core suggest that 
reduced CBF may be more accurate than reduced CBV for measuring infarct 
core(104). Together these findings suggest that hypoattenuation on CTA-SI is 
likely to represent a marker for irreversibly damaged tissue in ischemic stroke. 
As well as demonstrating changes in parenchymal attenuation, CTA may be 
reconstructed to show vascular anatomy in detail, demonstrating excellent 
sensitivity and specificity in the assessment of large vessel occlusion and patency 
(105). When compared to catheter angiography, CTA has a sensitivity and 
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specificity of 98.4% and 98.1% respectively, with an overall accuracy of 99% 
(106). Clot location is of prognostic importance and correlates with other clinical 
markers of stroke severity as proximal occlusions on CTA are associated with 
higher initial NIHSS scores, while distal/absent occlusions predict early 
independence after stroke(107). Clot status on CTA can also be used to guide 
acute treatment decisions beyond usual guidelines for IV thrombolysis. For 
example, in basilar artery thrombosis both the site of occlusion and the clot 
burden extent can be assessed using CTA prior to deciding on additional 
interventions such as mechanical clot retrieval/ IA thrombolysis, although the 
evidence base for the additional interventions is not yet clear(108, 109). 
Demonstrating the presence or absence of occluded vessels on reconstructed 
CTA could be used to select patients more accurately for different reperfusion 
therapies depending on vascular status (91). The response to therapy in terms of 
recanalisation is an important marker for clinical outcome, meaning CTA both 
acutely and sub-acutely has the potential to be used for surrogate measures of 
outcome in clinical trials(53). 
 3-D reconstructions of CTA data into MPR and MIPS can demonstrate the site of 
vascular occlusion and extent of vessel filling via collaterals (110). The impact of 
collateral flow may be an independent predictor of outcome after stroke 
although the method which best defines collateral adequacy is not clear(111) 
(Miteff). Occlusions detected by MIP CTA are highly sensitive and specific, with 
strong correlation between CTA and DSA (91). A comparison between CT, CTA 
MIP reconstructions and CTA-SI is shown in figure 1.4 
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Figure 1-4 NCCT, CTA MIP and CTA-SI in patient with right MCA occlusion 
Comparison of NCCT (A), 3D CTA reconstruction (B), and CTA-SI (C) in a patient with proximal 
right MCA occlusion. NCCT shows no obvious ischemic change. There is a filling defect evident in 
3D reconstruction (B, arrow shown) while parenchymal hypoattenuation in MCA territory is evident 
on CTA-SI. This diagram highlights the increased sensitivity of CTA in detecting ischemic lesions, 
and that 3D or source images from CTA permit visualisation of ischemic change beyond that of 
NCCT alone. Reproduced from Tan et al “CT angiography clot burden score and collateral score: 
correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct” AJNR 2009 
 
1.3.3 CT Perfusion 
CT Perfusion is a functional imaging technique which derives quantitative brain 
perfusion parameter measurements by repeated imaging over a portion of the 
brain during the passage of a bolus of intravenously administered contrast 
material (112). Multidetector scanners capable of imaging more than one slice of 
brain per second detect changes in Hounsfield unit values per pixel over time, 
which are used to derive a number of different perfusion measures including 
MTT, CBF, CBV and TTP (113). These perfusion measurements provide 
information on various aspects of tissue integrity and ischemia which may be 
used to detect features such as infarct core and penumbra. The extent of brain 
coverage possible with CT perfusion is dependent on the number of detectors 
and with more modern scanning technology, increasing coverage for perfusion 
imaging is possible (114). If only limited brain coverage is available, some 
centres choose to perform 2 CTP scans at different locations to increase brain 
coverage obtained with CTP, although this is at the expense of increased 
radiation and contrast exposure meaning the additional imaging should be 
clinically indicated to be justified (113). The additional radiation exposure for a 
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multimodal CT examination is approximately 10 mSv, although this is variable as 
the contribution of CTP may vary between 1.1 and 5 mSv with the total exposure 
measuring approximately 3 times the annual background rate (115). Vigilance in 
CTP protocol design is of importance as excessive radiation doses have been 
administered with potentially serious results(116).  
Perfusion map derivation 
Imaging in the Cine-mode over a pre-specified slab of brain tissue is used to 
quantify perfusion measurements in each pixel. Protocols vary between sites but 
image acquisition time usually occurs over 45-90 seconds. Post processing of raw 
CTP data is then undertaken to generate a number of perfusion maps:   
1: CBV is defined as the total volume of blood flowing in a given volume of brain, 
with measurements in ml/100g of tissue 
2: CBF is defined as the volume of blood moving through a given volume of brain 
per unit time and is measured in millilitres of blood per 100 gram of cerebral 
tissue per minute 
3: MTT is defined as the average transit time of blood through a given region of 
brain, measured in seconds. 
4: TTP is defined as the time it takes from the arrival of contrast in a selected 
arterial pixel to the peak height of the tissue concentration-time curve.  
Derivation of each perfusion measure may be according to different 
mathematical techniques which vary between vendors in how calculations are 
obtained. The clinical relevance of variations between software packages is 
unclear, although it appears that some software packages produce maps which 
overestimate the extent of ischemic tissue due to utilisation of processing 
packages which are sensitive to the effect of delayed bolus arrival, e.g. in the 
setting of extracranial stenosis (117).  
Different mathematical models to obtain perfusion measurements have been 
used for CTP.  
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Maximal slope model 
As contrast material enters the area being imaged, the signal intensity of the 
time-concentration curve, measured in HU rises linearly( Figure 1.5) (118). The 
amount of accumulated contrast material Q (t) is the product of CBF and the 
difference on arteriovenous concentration: 
 
Q (t) =CBF•∫
T
0
[C artery (t) – Cvein (t)] dt 
In order to make the CBF calculation less complicated, it is assumed that the 
output from the capillary bed into the venous system is zero, termed the no 
venous outflow assumption (119). To satisfy this assumption, injection rates 
must be very rapid. 
Using these assumptions, the equation can be simplified as 
Q (t) =CBF•∫
T
0
C artery (t) dt 
This equation is known as the Mullani- Gould formulation (120).  
The rate of contrast accumulation is related to the CBF and the arterial 
concentration at time (t) and from the Mullani Gould equation the peak rate of 
contrast accumulation will occur when arterial concentration is maximum: 
 
[
dt
tdQ )( ] max = CBF•[C artery (t)] max 
 
The ratio of the maximal slope of Q (t) to the maximal arterial concentration 
can therefore be used to measure CBF: 
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Figure 1-5 The Maximal Slopes Method 
CBF can be calculated from the ratio of maximal slope of Q (t) to the maximal arterial 
concentration. Different maximal slopes in different ROIS reflect different CBF values. Reproduced 
from “Konstas A.A. et al, Theoretic basis and technical implementations of CT perfusion in acute 
ischemic stroke, part 2: technical implementations. AJNR 2009. 30; 5: 885-92” 
Thus CBF can be determined. However, this equation relies upon assumptions 
that may influence calculation of CBF. Specifically it is assumed there is no 
venous flow of contrast flow before the peak arterial enhancement which in turn 
requires that injection rates of 10-20ml/sec are used to reduce the possibility of 
venous contamination(119). In clinical practice these rates are not achievable 
and therefore CBF calculations may be inaccurate(121). As rates of injection for 
IV contrast material are typically no more than 5ml/sec alternative methods to 
interpret the time – concentration curves must be considered. 
 
Deconvolution 
Use of deconvolution to derive perfusion measures does not rely on the 
assumption of no venous outflow, but instead considers outflow in the 
calculation. The tissue concentration at any time or tissue residue function can 
be related to CBF (F) and contrast media concentration [Ca (t)]. If a unit mass of 
contrast material is deposited into the tissue instantaneously then the tissue 
residue function becomes the impulse residue function R (t). Assuming the 
contrast remains within the vascular space, the shape of the impulse residue 
function will be as follows(Figure 1.6)(122): 
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Figure 1-6 The Impulse Residue Function 
Schematic representing the impulse residue function in a vascular network where the tracer 
remains intravascular. Reproduced from Eastwood et al “CT perfusion scanning with deconvolution 
analysis: pilot study in patients with acute middle cerebral artery stroke” Radiology 2002; 222:227-
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The rate of contrast delivery to capillary vessels following IV contrast 
administration is calculated as: 
F•Ca(t) 
Assuming F is constant and that the mass of contrast in the capillary network is 
linearly related to the arterial input function (AIF), the following can be 
calculated: 
Q(t)=F•Ca(t)* R(t) 
Where * is a convolution operator. Q(t) and Ca(t) can each be measured and 
deconvolution produces F•R(t) which is plotted over time. CBF is obtained from 
the peak height of the curve, while CBV is the area under the curve.  Once CBF 
and CBV are derived, MTT can be calculated according to the Central Volume 
Principle (123): 
CBF= 
MTT
CBV
 
Thus deconvolution permits calculation of perfusion parameters with lower 
injection rates but which are in practice easier to achieve.  
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An additional element in quantifying perfusion measurements with CTP is 
correction for delayed arrival of contrast bolus. Factors such as extracranial 
stenosis, congestive cardiac failure or atrial fibrillation may result in delayed 
bolus arrival, which in turn underestimate values for CBF as deconvolution 
analysis is sensitive to the effects of delayed transit between the reference AIF 
and the pixels examined in the tissue concentration-time curves(124). The 
Anterior cerebral artery is the most widely used AIF for CT perfusion but the 
assumption that this represents an instantaneous input of contrast material to 
the brain parenchyma is not met particularly when bolus arrival is truncated 
(125). Choosing an alternative AIF could theoretically overcome this problem but 
standardisation of site for AIF placement would be problematic in addition to the 
likely influence of partial volume effects from selection of AIF from vessels with 
small calibre. Additional methods to correct for delayed bolus arrival require a 
delay insensitive deconvolution method such as block circulant Singular Value 
Decomposition (126). The mathematical modelling behind this is not discussed in 
this thesis, however the importance is of potential clinical significance as 
perfusion scans processed without delay correction have been shown to 
overestimate final infarct volume more frequently and to a greater extent than 
those with a delay-corrected algorithm (127). 
CTP Application in clinical practice 
The perfusion maps obtained with CTP provide information on various aspects of 
tissue integrity in stroke patients. Sensitivity for detecting ischemic lesions is 
generally high for CTP, with TTP maps revealing a sensitivity of 93% for the 
presence of ischemic stroke, with the “false negative” cases occurring in 
brainstem and lacunar stroke subtypes rather than territorial hemispheric 
strokes in patients with acute stroke imaged within 6 hours of symptom onset 
(128). Patients who have undergone spontaneous recanalisation / reperfusion by 
the time imaging is acquired may also have “false negative” scans. Perfusion 
lesion extent has been shown to correlate with baseline clinical stroke severity, 
while final infarct volume in those who did not recanalize matched baseline 
lesion extent and was equal or smaller in those who did recanalize, suggesting 
that CTP can detect the presence of viable tissue but which is at risk of 
undergoing subsequent infarction (129). When qualitative interpretation of all 
CTP maps was performed and compared to final infarct volume using the 
43 
ASPECTS system, CBV maps were close predictors of outcome lesion extent in 
patients with major reperfusion by 24 hrs, while MTT and CBF were predictive of 
infarct extent in those who did not have major reperfusion (130). This finding 
that different perfusion measures predicted infarct volume depending on the 
individuals’ response to treatment suggests that both infarct core and ischemic 
penumbra can potentially be detected according to different measurements 
using CTP. Reduced CBV has therefore been considered a marker for infarct core 
with prolonged MTT (but with normal CBV) being a marker for ischemic tissue at 
risk of infarction(113). Attempts to apply thresholds to CTP maps in order to 
quantify core and penumbra have revealed different results and validated 
thresholds for each have not yet been defined. When CTP was compared to 
acute DWI (taken as a measure for infarct core), ROC analysis revealed that 
absolute CBV<2.0ml/100g was the best measurement of core, while MTT of 
≥145% of normal value was the best predictor of infarct volume in those patients 
with baseline occlusions which did not recanalize on follow up(131). The 
difference in these two volumes has become a widely used measurement of 
penumbra in clinical practice being incorporated onto post processing platforms 
for use in clinical decision making. These volumes for core and penumbra were 
shown to provide similar results to acute MRI/PWI in terms of mismatch ratio and 
influence on clinical decision making to the extent that they have been used as 
part of the imaging criteria for core and penumbra for subsequent clinical trials 
of novel thrombolytic agents (47, 132). However , threshold derivation from 
other groups suggested a product of CBV and CBF was the best predictor of core 
pixels for white matter(133) while ROC analysis using more stringent criteria for 
defining ischemic tissue which is actually “at risk” has suggested relative CBF 
rather than absolute CBV provides the closest measurement of infarct core(134). 
Therefore it remains unclear whether thresholds applied to CTP can be used 
reliably to measure core and penumbra. Systematic review of the literature 
surrounding thresholds and the acquisition parameters has highlighted this lack 
of consensus on agreed definitions(135).  
Different post-processing packages for CTP may yield different results on the 
same raw data which limits the generalisability of suggested core and penumbra 
thresholds (117). It may be that delayed bolus arrival needs to be corrected for 
to prevent apparent “ Pseudo-reversibility” of some lesions with reduced CBV, 
44 
although it has been suggested that there may be important information within 
the delayed contrast bolus (such as in atrial fibrillation or high grade carotid 
stenosis), and therefore the need to correct for this could be questioned (136).  
Definitions for core and penumbra using CTP require further investigation which 
will form part of this thesis. Despite some limitations, at present multimodal CT 
examination for acute stroke patients is the routine in many centres used as part 
of clinical decision making. It is widely accessible, faster than MRI and has fewer 
contraindications than MRI, meaning that additional diagnostic and prognostic 
information can be obtained relatively quickly with CT. Although guidelines 
require a non contrast CT alone, a multimodal CT examination permits 
evaluation of the “4 P”s of stroke imaging- parenchyma, pipes, perfusion and  
penumbra(137) which could ultimately result in tailoring therapy based on the 
individuals response to ischemia rather than on a rigid and limited time window. 
Further prognostic information on the risk of developing intracerebral 
haemorrhage after thrombolysis may be possible using CTP with alternative post-
processing to measure blood brain barrier permeability. At present, evidence 
based decision making prior to thrombolysis is based on a clinical diagnosis of 
stroke, a known time of onset, and absence of clinical or imaging 
contraindications to treatment. Extensive ischemic change on CT brain affecting 
>1/3 of the MCA territory is usually applied as a “rule of thumb” but is imprecise 
and using imaging to predict haemorrhage more precisely would be 
attractive(45). In a retrospective review, Aviv and colleagues found that patients 
who had haemorrhagic transformation following thrombolysis had greater 
extents of permeability, measured as surface area product (PS) than those who 
did not have ICH(138) .  This finding requires further evaluation but may be 
limited in practice as the duration of image acquisition to satisfy the theoretical 
assumptions in measuring permeability is much longer than is obtained in most 
CTP protocols (139, 140). 
The use of CT perfusion in addition to CTA and CT requires prospective 
evaluation within randomised clinical trials, but further research is needed 
initially to assess which perfusion thresholds and imaging patterns represent 
meaningful therapeutic targets. 
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1.4 Magnetic resonance Imaging in Stroke 
A number of MRI sequences are available for stroke imaging for clinical and 
research purposes. The most widely used methods for determining infarct core, 
ischemic penumbra and vascular status will be discussed. 
1.4.1 DWI 
The normal diffusion of molecule or liquid in a gas is random, but diffusion 
restriction of water molecules is decreased in ischemic brain tissue and these 
appearances are evident soon after the onset of ischemia representing cytotoxic 
oedema (141, 142). The presence of DWI lesions has been widely used as a 
surrogate marker for irreversibly damaged infarct core and subsequently forms 
part of the perfusion-diffusion mismatch concept for identifying tissue at risk of 
infarction (143). Although frequently used as a marker for infarct core, the DWI 
lesion may actually be at least partly reversible(144). PET characteristics for 
penumbra have been found in DWI “core” lesions supporting the finding that 
elements of the DWI lesion may be reversible(145). The true extent and 
significance of DWI reversibility is debated however as the evidence is limited 
and definitions for reversibility are variable, but a systematic review suggested 
that approximately 20% of a typical DWI volume may be spontaneously 
reversible(146). More dedicated image analysis including correction for CSF 
space and atrophy suggests the reversibility is not clinically meaningful, although 
this analysis is limited to the 3-6 hr time window alone which may limit the 
applicability of this finding(147). While some reversibility may occur, DWI 
remains highly sensitive for detecting ischemic lesions with sensitivities ranging 
between 83 and 100%, outperforming other MRI sequences and plain CT in the 
same time window along with high specificity of up to 100% in appropriate 
clinical context (148-151). Additional prognostic value is obtained from DWI 
lesion volumes with larger volumes on DWI associated with poor outcome 
regardless of treatment administered, response to treatment, or extent of 
mismatch tissue (152, 153). 
1.4.2 FLAIR 
FLAIR imaging reveals Ischemic lesions as visually hyperintense areas and 
demonstrates parenchyma well due to heavy T2 weighting and reduction of 
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signal from CSF. The anatomical detail afforded by FLAIR has resulted in its use 
as the sequence for measuring final infarct volume in several imaging based 
stroke trials (153, 154). The timing of FLAIR to optimally measure infarct volume 
has most often been at day 90 after stroke, although evolution of infarct beyond 
earlier time points at 30 days or even as soon as 3-7 days after stroke onset may 
not be significant, supporting the use of an earlier time point to measure infarct 
volume for trial purposes(155, 156) (157). The time taken for an ischemic lesion 
to appear on FLAIR is longer than that taken for the same lesion to appear on 
DWI, but most FLAIR hyperintensities appear within 6 hrs of symptom onset. The 
use of this “mismatch” between timing FLAIR and DWI lesion appearances has 
been suggested as a surrogate marker for strokes of recent onset (within 6 hrs) 
and therefore may be used for trial purposes targeting therapy at patients with 
wake-up strokes who are usually excluded from thrombolysis(158).  In addition 
to revealing parenchymal change, FLAIR imaging has been used to visualise 
leptomeningeal collateral flow, with vessel related hyperintensities on FLAIR 
being associated with smaller DWI volumes and larger mismatch volumes in 
patients with MCA occlusion suggesting better collateralisation (159). Presence 
hyperdense vessels on FLAIR are also associated with smaller final infarct volume 
suggesting preservation of blood flow via collateral routes (160). 
1.4.3 Gradient Echo Imaging 
GRE is used in stroke imaging protocols primarily to detect cerebral 
haemorrhage due to the sensitivity of the sequence to detect the presence of 
paramagnetic blood substances.  GRE has a higher sensitivity for haemorrhage 
than other MRI sequences. Haem breakdown products including 
deoxyhemoglobin, methemoglobin and haemosiderin are paramagnetic and 
detectable on GRE. The sensitivity for detecting haemorrhage with GRE is equal 
to CT when comparing both modalities on patients with acute ICH within 6 hours 
of symptom onset (161). Importantly, GRE can also detect small cerebral 
microbleeds which cannot be detected with CT, and which may confer an 
increased risk of haemorrhage after ischemic stroke (162). Presence of 
microbleeds on GRE has not been shown to be associated with haemorrhagic 
transformation after thrombolysis for ischemic stroke in a large multicentre 
study, but the number of patients with large numbers of microbleeds were small 
in this study which limits any conclusions which can be drawn about using GRE to 
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identify patients who should not receive rt-PA due to risk of haemorrhagic 
transformation (163). 
1.4.4 Magnetic Resonance Angiography 
MRA can be acquired using time of flight imaging (TOF), Phase contrast or 
contrast enhanced MRI after the administration of gadolinium. MRA, like CTA can 
be used for intracranial vascular assessment as well as for extracranial imaging 
to determine aetiology and subsequent management (e.g. dissection, carotid 
stenosis)(164). When compared to the gold standard of catheter angiography, 
TOF-MRA agreed on the presence of a surgical lesion in 80% of cases, although it 
tended to overestimate the degree of stenosis (165). It is sensitive and specific 
for detecting intracranial occlusions in acute stroke patients and compares 
favourably to catheter angiography (84.2% and 84.6% for sensitivity and 
specificity respectively) although the median time interval between imaging 
sequences was long(166). Definitions for occlusion on MRA such as the TIMI scale 
adapted for intracerebral occlusions have been used for trial purposes to classify 
site and severity of arterial obstruction on admission as well as a marker of 
response to therapy by recanalisation (154, 167). 
1.4.5 Perfusion Weighted Imaging 
PWI combined with DWI has been the most widely studied method for identifying 
infarct core or tissue at risk (168). PWI images are obtained by bolus tracking, 
tracing the passage of a paramagnetic contrast agent through the brain over a 
period of time (169). An advantage of PWI over CTP is complete brain coverage 
meaning all potentially ischemic tissue can be assessed by PWI which is not 
possible for most CTP protocols at present. Lesions on DWI and PWI provide 
information on likely viability of cerebral tissue and penumbra has been defined 
operationally as a difference between the extent of abnormalities on each 
sequence(143). The fate of hypoperfused tissue has been examined using PWI, 
with DWI lesions expanding into the PWI lesion over time in those patients who 
had evidence of mismatch on admission, and this expansion can be attenuated 
with IV fibrinolysis (170). Perfusion maps generated using PWI include CBV, MTT, 
CBF and Tmax( Time to maximum of the residue function)(171). Thresholds for 
defining tissue at risk are not yet agreed using PWI/ DWI mismatch. 
48 
Multimodal MRI for imaging acute stroke is used routinely in some institutions for 
obvious reasons such as high sensitivity and specificity for detecting ischemic 
lesions and prognostic information afforded by measuring lesion volumes. Its use 
may however be limited by contraindications which prevent some patients 
undergoing MRI such as implantable defibrillator devices and claustrophobia 
emphasising the importance to develop alternative imaging methods (172). 
Multimodal CT may be able to provide similar information to MRI with the 
advantage of increased availability and fewer contraindications. 
1.5 Conclusion 
Therapies for acute stroke are evolving and studies evaluating new treatments 
increasingly use image based markers for outcome. MRI offers excellent 
sensitivity and diagnostic accuracy, but has restricted availability, some 
contraindications and takes longer to obtain imaging than CT (20- 30 Mins for MRI 
compared with 10-15 for CT). CT is widely available and rapidly obtained with 
few contraindications, but gives less diagnostic accuracy than MRI, involves 
ionising radiation and at present usually has restricted brain coverage for CT 
perfusion scanning. While MRI has perhaps been more extensively evaluated, the 
availability and speed of imaging with CT suggests that additional evaluation of 
the ability of multimodal CT to enhance understanding of acute ischemic stroke 
is needed, and this will form the basis of the subsequent work in this thesis.  
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Chapter 2. Collateral Circulation 
2.1 Introduction 
Collateral flow in the cerebral circulation refers to the collection of different 
vascular channels which can contribute to cerebral blood flow when principal 
pathways of antegrade flow fail(15). Collateral vessels provide an alternative 
route for cerebral blood flow to compensate for reduced flow via the usual 
vascular channels when the primary source of blood flow has been diminished. 
Different sources and descriptions of collateral flow exist depending on the 
vessel size and location which provide a route for collateral flow to occur. 
Primary collateral pathways refer to the different segments of the circle of 
Willis, namely the anterior and posterior communicating arteries which allow for 
diversion of flow towards areas with reduced perfusion, occurring from anterior 
to posterior circulation or vice-versa depending on the site of arterial 
obstruction. Secondary collateral flow is considered to occur via ophthalmic and 
leptomeningeal vessels which are probably invoked once primary collateral flow 
has been exhausted or cannot contribute to supply of ischemic tissue(15). In 
chronic arterial occlusion proximal to the circle of Willis (e.g. chronic carotid 
occlusion), primary collateral flow may prevent stroke from occurring when flow 
to the ischemic territory is derived from the contralateral carotid territory via 
the anterior communicating artery. Intracranial occlusion distal to the circle of 
Willis cannot be compensated for by flow in primary collaterals due to 
anatomical reasons in which cases secondary flow in the leptomeningeal 
collateral circulation may be invoked to augment cerebral blood flow to that 
territory. 
2.2 The Cerebral Blood Supply 
The brain requires approximately 20% of the oxygen required by the body and 
derives this from the internal carotid arteries anteriorly and the vertebral 
arteries posteriorly.  
The internal carotid arteries arise from the common carotid arteries in the neck 
bilaterally and terminate at the bifurcation to the MCA and ACA. The 
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extracranial (Cervical) portion of the ICA extends from the carotid bifurcation to 
the skull base and does not have any branches in the neck (173). The origin of 
the ICA is a site where atheroma may develop preferentially and from which 
emboli may originate causing distal occlusions in “large vessel” stroke cases(9). 
Intracranial segments of the ICA include Petrous, Cavernous and Supraclinoid 
portions, which may be further sub-divided according to the sites of embryonic 
precursor vessels(174) .  The Petrous ICA portion extends from the skull base to 
the cavernous sinus giving tympanic branches along its route(175).  The 
cavernous portion travels within the cavernous sinus giving hypophyseal and 
ophthalmic branches and ends as the artery pierces the dura at the roof of the 
carotid sinus (173).The supraclinoid portion begins as the artery passes the 
anterior clinoid process to enter the subarachnoid space and terminates at the 
carotid T(176).  
The Middle cerebral artery arises as the larger of the two terminal branches of 
the ICA, approximately 75% of the calibre of the ICA.  Its trunk is divided into 4 
segments: The M1 (Sphenoidal segment) extends laterally within the Sylvian 
Fissure and gives rise to a series of Lenticulostriate branches along its path 
which supply deep structures including the Internal Capsule, Globus Pallidus, 
Putamen and Caudate nuclei. The MCA divides as a bifurcation (78%), 
trifurcation (12%) or into multiple smaller branches (10%). The M2 (Insular) 
segment begins at the MCA genu and is the segment where most branching 
occurs. The M3 (opercular) segments begin at the circular sulcus of the insula 
and course over the fronto-parietal and temporal opercula. The M4 (cortical) 
branches begin at the surface of the Sylvian fissure and extend over the cortical 
surface of the hemisphere(177). The anatomy of the MCA is demonstrated in 
figure 2.1 
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Figure 2-1 Anatomy of the Middle Cerebral Artery 
Anterosuperior view of the right middle cerebral artery and branches with frontal lobe removed 
showing relationship of the M1, M2, M3 and M4 segments to the temporal lobe (temp lobe). The 
M1 segment crosses the upper surface of the anterior pole of the temporal lobe and divides into a 
superior (Sup.Tr.) and inferior (Inf.Tr.) trunk. The M2 Segment lies on the insula, the M3 segment 
crosses the transverse temporal gyri (Trans.Temp.Gyr.)and the M4 segment passes inferiorly 
across the superior (Sup Temp.Gyr.) and middle temporal gyri (Mid.Temp.Gyr.). The anterior 
cerebral artery (A.C.A.) arises from the carotid artery (C.A.) and passes above the optic nerve 
(O.N.) and chiasm (O.Ch) where it gives rise to the recurrent artery (Rec.A.) .The Lenticulostriate 
arteries ( Len.Str.A) enter the anterior perforated substance (Ant.Perf.Subst.). An early branch ( 
Early Br.) to the temporal lobe arises from the M1 segment. The frontal horns of the lateral 
ventricles ( Lat.Vent.) lie above the anterior cerebral arteries. Reproduced from Gibo et al, 
“Microsurgical anatomy of the Middle Cerebral Artery” Journal of Neurosurgery, 1981, 54;2: 151-
169.  
 
The ACA originates at the ICA bifurcation and travels antero-medially to cross 
over the optic nerve and chiasm to communicate with the contralateral ACA via 
the Anterior Communicating artery. Up until this point the segment is known as 
the A1 segment which has inferior and superior perforator branches supplying 
the optic nerve, anterior commisure and hypothalamus. The distal A2 vessel 
segment extends from the ACOM to the bifurcation and gives rise to the 
recurrent artery of Heubner, orbito-frontal and frontopolar branches. The distal 
A3 peri-callosal artery is the terminal segment of the ACA (178). 
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The right and left vertebral arteries originate from the subclavian arteries 
bilaterally and travel superiorly in the foramen transversarium to the upper 
cervical region. The V1 segment extends from the subclavian artery to the C6 
transverse process, and is prone to atherosclerotic change at the origin 
(179).The V2 segment extends until the vertebral artery exits the axis which 
then continues as the V3 segment until it pierces the dura. The V4 segment is 
intracranial and extends from the dura until the confluence at the basilar 
origin(180) . The PICA is the most distal branch of the VA 12-13mm proximal to 
the vertebro-basilar junction supplying the cerebellum and medulla(180).  The 
Basilar artery begins at the junction of the two V4 segments and courses 
superiorly along the Pons until its bifurcation to the two PCAs. Paramedian and 
circumferential branches supply the Pons and Cerebellar peduncles. The Anterior 
inferior Cerebellar artery leaves the basilar at variable points along its course 
and the superior Cerebellar artery is a distal branch originating close to the PCA 
origin bilaterally(180). 
The bifurcation of the basilar artery gives rise to the PCA bilaterally. The 
proximal P1 segment is a short segment from the origin to the PCOM and has 
some small thalamic perforating branches. The P2 segment runs from the PCOM 
to the midbrain , while P3 and P4 segments are within the quadrigeminal cistern 
and calcarine fissure respectively(181). A foetal PCOM variant is present when 
the PCA is supplied from the anterior circulation via a large PCOM with a small or 
absent P1 ipsilaterally. PCA stoke can have a variety of symptoms depending on 
the territory affected, including hemianopia, Balint syndrome and reading 
disorders.  
 
2.3 The Circle of Willis 
The anastomotic vascular network at the base of the brain is named after Sir 
Thomas Willis, (1621-1675) whose studies into human and animal anatomy led 
him to conclude that “the cerebrum is the primary seat of the rational soul in 
man, and of the sensitive soul in animals. It is the source of movements and 
ideas”(182).His post-mortem studies in Cerebri Anatome revealed an early but 
informative description of the anastomotic capacity of the cerebral vessels in 
vascular disease states : When describing post mortem results on a patient who 
53 
died from a mesenteric tumour, he wrote “When his skull was opened we noted 
amongst the usual intracranial findings, the right carotid artery, in its 
intracranial part, bony or even hard, its lumen being almost totally occluded; so 
that the influx of the blood being denied by this route, it seemed remarkable 
that this person had not died previously of an apoplexy: which indeed he was so 
far from, that he enjoyed to the last moments of his life, the free exercise of his 
mental and bodily functions. For indeed, nature had provided a sufficient 
remedy against the risk of apoplexy in the vertebral artery of the same side in 
which the carotid was wanting, since the size of this vessel was enlarged, 
becoming thrice that of the contralateral vessel"(183). Experimental evidence of 
the connections of the circle of Willis has been shown in his additional 
description : “ The cephalick arteries, via the carotids and the vertebrals do so 
communicate with another and all of them in several places, are so in grafted 
one in another mutually that if it happen that many of them should be stopped 
or pressed together at once, yet the blood being admitted to the head by the 
passage of one artery only, either the carotid or the vertebral, it would 
presently pass through all of those parts both exterior and interior; which indeed 
we have sufficiently proved by an experiment, for that ink being squirted in the 
trunk of one vessel either carotid or vertebral quickly filled all the sanguiferous 
passages, and everywhere stained the brain itself” (183, 184). 
The circle of Willis functions as an anastomotic network connecting arterial 
networks from either side as well as anteriorly and posteriorly. Anteriorly, right 
and left carotid territories are connected by the anterior communicating artery 
which provides a route for inter-hemispheric blood flow in the setting of 
unilateral carotid hypo perfusion, and reversed flow in the proximal ACA can be 
seen in this scenario (15).Cross flow via segments of the circle of Willis can be 
seen using ultrasound in the setting of proximal vessel stenosis or occlusion(185). 
Posteriorly, the PCOMs allow for flow from anterior to posterior or vice-versa 
depending on the direction of flow required. When both posterior 
communicating arteries are present in addition to an anterior communicating 
artery, the circle of Willis can be considered to be complete, but this pattern is 
seen in only the minority of patients examined with angiography(186). 
Considerable variation in the anatomy of the Circle of Willis exists, with up to 30 
% of people having a hypoplastic or absent posterior cerebral artery, absence of 
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anterior communicating artery in 1% and hypoplasia or absence of the proximal 
anterior cerebral artery in 10%(187). 
Along with the ophthalmic arteries, the segments of the Circle of Willis serve as 
primary collateral routes(15). In carotid occlusions, the presence of flow via the 
circle of Willis is associated with low prevalence of watershed infarction(188) 
and with fewer or less marked symptoms than those without  established 
collateral flow(189). Presence of Willisian collaterals is associated with 
tolerance of carotid occlusion during angioplasty and stenting (190).Examination 
with ASL has shown that in independent patients with unilateral ICA occlusions 
the ipsilateral MCA derives flow from the vertebro-basilar system while the ACA 
territory is supplied from the contralateral ICA, highlighting the functional 
capacity of different circle of Willis components in the setting of proximal 
occlusion (191). Fluctuating demands may reveal the dynamic nature of primary 
collaterals with hypoplastic segments enlarging according to need(192) which 
may contribute to the different outcomes seen in carotid occlusion(193). 
2.4 Leptomeningeal vessels 
While primary Willisian collateral vessels are of obvious importance in the 
setting of proximal vascular occlusions and stenosis, they are unable to fully 
compensate for reduced flow in more distal occlusions. Distal intracranial 
occlusions are anatomically beyond the circle of Willis but may still receive 
collateral flow from smaller leptomeningeal vessels. Presence of residual flow 
via collaterals is something that is of increasingly recognised importance, 
although the contribution made by these secondary collateral routes has not 
been studied in detail and their capacity for delivering meaningful blood flow via 
small diameter vessels has been debated for many years(194). 
2.4.1 Historical Context 
The cortical anastomoses between different arterial territories by 
leptomeningeal vessels were first studied in detail by Heubner in 1874, who 
observed that after ligation of a single intracranial artery distal to the circle of 
Willis, other arteries in both hemispheres were filled through a network of 
meningeal arteries he termed “ Kanalnetzwerk”(Cited by Brozici(194)) . The 
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importance of LMA in terms of providing a meaningful contribution to cerebral 
blood flow was contested by other investigators like Duret and Charcot who 
considered that LMA were of too fine a calibre to provide a meaningful 
connection between arterial territories, implying that each of the three main 
arterial territories are in practical terms independent(Cited by Vander 
Eecken(195)). The anatomy and significance of LMA were examined in a series of 
20 adult cadavers by Vander Eecken and Adams in 1953 after injection of a lead 
based solution into the cerebral arteries(195). They described direct 
anastomoses between ACA and MCA, MCA and PCA, ACA and PCA, ACA and ACA, 
and between the Cerebellar arteries. They also asked the question “ Is it 
possible that the adverse effects of cerebral ischemia following occlusion of a 
major artery can be ameliorated by collateral blood flow through these pre-
existing anastomotic channels?”.  In several case examples they demonstrated 
limited infarction in given arterial distributions despite the presence of proximal 
occlusions and noted the presence of dilated meningeal vessels reflecting local 
vascular reaction in the ischemic territory. They concluded that individual 
variation in the number size and distribution of anastomoses exists, that there is 
little flow through leptomeningeal vessels under normal conditions, and that 
they serve a protective function as less extensive infarction is seen if the 
anastomotic vessels are large and numerous rather than small and poorly 
developed(195). The ability of neighbouring arterial territories to directly 
perfuse the MCA territory was demonstrated by de Seze who injected fluid into 
the ACA and PCA under pressure and demonstrated retrograde flow to the origin 
of an already occluded MCA, concluding that satisfying irrigation could be 
obtained without recanalisation of the occluded artery (From Brozici(194) 
,article in French). 
2.4.2 Collateral Circulation in Animal Models of Stroke 
Animal studies into collateral anatomy and function have been performed in 
several species, with most work focussing on rodent stroke and control models. 
Distal branches of the major intracerebral arteries in the rat form an 
anastomotic network over the surface of the brain providing a source of flow 
between neighbouring territories(196). 
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In rats of different ages, the absolute amount of native anastomoses between 
the ACA and MCA territories has been shown to be constant with time from birth 
suggesting that the absolute number of collateral anastomoses remains constant 
for an individual(196). Inspection of collateral vessels by Coyle at post-mortem 
in Wistar rats who underwent MCA ligation has revealed that the diameter of 
anastomotic vessels were significantly larger ipsilateral to the stroke compared 
with the normal hemisphere and also relative to control specimen rats 
suggesting that collateral vessel diameter is a variable and can enlarge in 
response to ischaemia in an neighbouring arterial tree(197). Tortuosity is a 
measurement for collateral vessel extent being calculated by dividing vessel 
length by the straight line distance between two vessel ends. Vessel tortuosity 
has been shown to be increased ipsilateral to an MCA occlusion as a response to 
focal ischemia.  MCA occlusion in the Wistar rat model results in minimal 
infarction which is considered as evidence of how well-developed 
leptomeningeal collateral vessels can compensate for occlusions which occur 
distal to the capacity of primary collaterals(197). 
Much additional research into rodent models of stroke has focussed on the 
spontaneously hypertensive stroke prone rat (SHRSP). In contrast to the Wistar  
and Sprague Dawley rats, obstruction to the MCA in SHRSP  always results in a 
large infarct within the MCA territory and therefore these rodents have been 
frequently studied for infarct analysis at post mortem (198). The severity of and 
propensity to tissue infarction in SHRSP models is not solely related to 
hypertension however, with additional mechanisms being implicated such as 
collateralisation. Large infarcts are seen after stroke in young SHRSP before 
hypertension has even developed highlighting the need to consider additional 
mechanisms for development of large stroke volumes (199, 200). The importance 
of factors other than blood pressure is further supported by the finding that non 
SHRSP rats who had hypertension induced to similar levels as SHRSP prior to MCA 
occlusion did not suffer large infarcts suggesting other mechanisms were the 
reason for large infarct volumes (201).Absolute number of anastomoses between 
arterial territories are the same in both SHRSP and WKY rats at baseline but the 
internal diameter of anastomotic vessels is smaller in SHRSP and this diameter 
reduces with increasing age and is not related to hypertension (202). When 
regional cerebral blood flow was measured and compared between SHRSP and 
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WKY rats there was no significant difference in blood flow at baseline between 
strains(203). After MCA occlusion, blood flow was reduced significantly more in 
SHRSP than WKY, whereas vascular tone was increased in SHRSP compared to 
WKY(204).Combined, these studies suggest that the number of collaterals does 
not change in an individual, that size and length of collateral vessels can change 
in response to ischemia, that the reduction in blood flow following occlusion is 
augmented to varying extent in different strains due to the ability of collateral 
vessels to compensate for arterial obstruction. Collateral heterogeneity between 
strains may point to genetic, anatomical and biochemical differences controlling 
collateralisation.  
Mechanisms for Collateral Flow Differences 
When infarct volumes following MCAO were measured with MRI in WKY , SHRSP 
and hybrid SHRSP/WKY rats, the propensity to larger infarction in SHRSP was 
confirmed, as was the finding that the infarct volume was independent of the 
degree of pre-stroke hypertension (205).The infarct distribution was identical in 
SHRSP and in the hybrid SHRSP/WKY offspring which suggested a dominant trait 
for tendency towards large infarct volumes Genetic susceptibility to ischemic 
damage in SHRSP following MCAO has been co-segregated with a region on the 
rat’s chromosome 5(206). As collateral capacity in response to ischemia is 
different between rat strains, a genetic component to adequacy of collateral 
response is a possible. The genetic influence on collateral flow has been further 
evaluated in mice. Zhang et al measured collateral length and number of 
penetrating arterioles following MCAO in 15 different inbred mouse strains and 
found a wide variation in the extent of native collaterals between strains, that 
infarct volume correlated inversely with collateral number and density and that 
change in anastomotic diameter in response to ischemia also displayed wide 
genetic variation(207). When the two strains with the most difference in 
cerebral collaterals were compared, variation in native collaterals was evident 
during the embryonic phase, and the strain with least collaterals displayed 
slower outgrowth of the cerebral arterial tree which resulted in larger distances 
between branches of neighbouring arterial territories (208). Levels of VEGF-A, 
Angiopoietin-2 and PDGF-B expression due to genetic differences were 
considered as potential mechanisms behind the variation in collaterals between 
strains(208). Genetic influence on the development of collaterals in skeletal 
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muscle has also shown the importance of VEGF and Chloride intracellular 
Channel 4 in determining the number and size of collaterals as well as their 
effect on tissue perfusion(209, 210). 
Reduced functional compliance within collateral vessels in response to ischaemia 
is considered a potential mechanism for the larger infarction, possibly due to 
reduced CNS nitric oxide synthetase activity resulting in impaired vasodilation or 
an excessive inflammatory response(211). The role of NO in stroke has revealed 
that it may decrease or increase infarct volume, but it may be the source of NO 
release that is important. NO derived from endothelial cells causes vasodilation 
and reduces infarct size, while NO derived from, neurones is neuro-toxic and 
causes an increase in infarct volume. (212, 213)NO release and infarct volumes 
were measured by Kidd et al to evaluate the effect of NO on collateral flow. 
(198)NO release measured by a porphyrinic microsensor was significantly 
reduced in SHRSP compared to control Sprague Dawley rats, which inversely 
correlated with infarct volume. When control rats had NO release inhibited by a 
NO synthetase blocker (NG –nitro-L- Arginine [L-NNA]), NO measurements were 
reduced which correlated with an increase in infarct volume as well as increased 
wall thickness. The authors concluded that reduced endothelial NO release may 
be a contributory cause of reduced collateral flow(198). The importance of 
endothelial NO release has also been confirmed in mice models of stroke where 
endothelial NO synthetase (eNOS) knockout mice were shown to have larger 
infarct than wild-type mice as well as reduced CBF confirming that endothelial 
NO exerts a protective role by inducing vasodilation of the collateral circulation 
and thereby increasing flow capacity in collateral vessels(212, 214). 
Presence of leptomeningeal collateral flow has been considered a marker of 
severe cerebral hypo perfusion induced after the circle of Willis has failed, but it 
is the actual reduction in cerebral perfusion which is an important factor for 
inducing flow via leptomeningeal pathways (215). Adult mice after common 
carotid artery occlusion showed increased ipsilateral leptomeningeal vessel 
diameter compared to sham operated mice and this change to collateral 
architecture was dependant on time(216). Cortical perfusion measured by laser-
doppler flowmetry was more severely reduced in the MCA rather than ACA 
territory following CCA occlusion, demonstrating a pressure gradient between 
the neighbouring arterial territories and that this pressure gradient is 
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responsible for collateral vessel growth (216). Possible mechanisms include 
increased fluid shear stress in collateral vessels or increased activity of 
monocytes/macrophages. 
The impact of hyperglycaemia on collateral flow has also been evaluated in 
animal models. After MCA occlusion followed by reperfusion in Diabetic (Goto-
Kakizaki [GK]) and control (Wistar) rats, expression of VEGF reduced significantly 
in GK rats, while angiostatin, an anti-angiogenic factor, was increased compared 
to controls. These correlated with reduced capillary density in GK rats, 
suggesting impaired collateral ability in diabetic rats which may be due to 
impaired collateral growth/ enlargement (217).Comparing the effect of 
hyperglycaemia in different rat strains to evaluate the effect on collaterals is 
limited however by the fact that any perceived effects could be related to 
genetic factors rather than solely due to hyperglycaemia(218) When coronary 
collaterals in diabetic dogs were evaluated, impaired collateral development 
was seen in chronic hyperglycaemia in association with increases in angiostatin 
and MMP-9(219).  
Hypoxia has an additional influence on angiogenesis and collateral flow, and 
adaptation to hypoxia is regulated by hypoxia inducible factors (HIF) which 
regulate the expression of genes involved in metabolism, vascular remodelling 
and collateral development(220). When HIF- containing plasmids were placed on 
the cortex of male Wistar rats prior to MCAO, the length of collateral vessels was 
significantly increased compared to control rats that also underwent MCAO(220). 
As a target gene of HIF is that of erythropoietin (EPO) which has been associated 
with tolerance to stroke in mouse models, response to hypoxia mediated by EPO 
has been considered as a means of inducing collateral flow. EPO levels have also 
been associated with better degrees of collateral flow in the coronary 
circulation in human patients with stable angina(221). 
2.4.3 Collateral Therapeutics in Animal Stroke Models 
The genetic link to ischemia following MCAo in SHRSP has been linked to 
chromosome 5(206). This region is where genes responsible for 20-
hydroxyeicosatetraenoic acid (20-HETE) are located. 20-HETE, is derived from 
arachadonic acid(AA) by cytochrome P-450 and acts as a potent vasoconstrictor 
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which controls vascular tone and autoregulation(222, 223).Levels of 20-HETE are 
significantly increased in SHRSP compared to WKY rats, and this increase is 
specific to the cerebral circulation.(224)This increase appears to be independent 
of blood pressure, as levels of 20 HETE were not significantly different between 
WKY controls and WKY rats treated to induce hypertension, implying that 
elevated levels, although associated with hypertension in SHRSP are not markers 
of hypertension, but rather of another characteristic of the SHRSP’s 
susceptibility to stroke. When synthesis of 20 HETE was blocked by a selective 
inhibitor, HET0016, infarct volume was significantly reduced as was the amount 
of reactive oxygen species generated (224). When 20 HETE was selectively 
inhibited by TS-011 in different rat strains, reduction in 20-HETE levels, infarct 
volume and neurological deficits were seen (225-227). As 20 HETE causes 
vasoconstriction, and reduced collateral diameter is associated with larger 
infarct in SHRSP, the beneficial effects of blocking 20 HETE may be due to 
improved collateral flow following MCAO, but this has not been confirmed. 
As stated previously, the action of macrophages has been linked to 
leptomeningeal collateral growth following CCA occlusion in mice (216). 
Granulocyte-macrophage colony stimulating factor (GM-CSF) is produced by 
macrophages/ monocytes, and has receptors on endothelial cell surfaces(228). 
GM-CSF injection following CCA occlusion but prior to a subsequent permanent 
MCA occlusion was associated with significantly increased vessel diameters, 
while GM-CSF treatment did not alter vessel diameters in sham operated mice. 
GM-CSF treatment also significantly reduced infarct volume following MCA 
occlusion (216). This model suggests that hypo perfusion is essential for the 
diameter of leptomeningeal collaterals to be altered and also that growth 
factors could be associated with increased collateral dimensions and a 
subsequent reduction in infarct volume. 
2.4.4 Collateral Therapeutics in Human Stroke 
The potential role of endothelial NO in determining blood flow and infarct 
volume has been discussed in animal models. Statins lower cholesterol by 
inhibition of HMG-CoA reductase, but they also exert other effects including 
improved endothelial function and increased NO bioavailability(229). Statins 
reduce risk of recurrent stroke and TIA(230) but the effect may be independent 
61 
of cholesterol level, as other cholesterol lowering mechanisms do not have the 
same effect(231, 232). In addition to reducing stroke risk, statins may improve 
outcomes after ischemic stroke. In a follow up of the SPARCL study, there was a 
trend towards less severe strokes in those patients randomized to receive 
Atorvastatin compared to placebo (233).The potential mechanisms for this effect 
are many, including neuro-protection against glutamate effects, reduced super-
oxide production, reduced cytokine gene expression, and up-regulation of NO-
synthetase. Statin therapy prior to stroke has been associated with better 
degrees of collateral flow on angiography, with no difference in clinical stroke 
severity at baseline (234). These findings suggest that statins may improve 
microcirculatory capacity increasing collateral flow in stroke patients which may 
be a contributory factor to the suggestion of better outcomes following statin 
therapy, although the association between statins and collaterals requires 
confirmation.  
Transdermal Nitrates may lower BP and maintain cerebral blood flow in recent 
stroke via enhancing flow in leptomeningeal collaterals (235). The effect of 
nitrates on stroke outcome is the subject of ongoing investigation, although 
evaluation of collaterals is not part of the study(236). Additional methods for 
augmenting blood pressure for clinical effect in stroke may mediate effects via 
collaterals but collaterals have not been specifically measured in these studies 
(237).  
Sphenopalatine ganglion stimulation may increase ipsilateral cerebral blood flow 
via parasympathetic nerve stimulation(238). The safety and efficacy of 
sphenopalatine ganglion stimulation to enhance collateral flow in stroke is the 
subject of current investigation (239). Flow diversion by redirecting flow to the 
brain by performing partial aortic occlusion after stroke has also been 
attempted. Aortic balloon pump occlusion is a safe and potentially efficacious 
means of providing additional blood flow in stroke but requires further 
evaluation (240, 241). other methods of achieving flow diversion includes 
application of external compression devices to enhance venous pressure in the 
setting of carotid occlusion, but this has been evaluated in case reports 
only(242). 
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In summary, several attempts to improve outcome after stroke by enhancing 
collateral flow have been attempted and form part of an expanding therapeutic 
field. However the effects of any of these methods on direct measures of 
collateral flow have yet to be assessed which may be partly due to the lack of an 
agreed method to measure and grade collateral flow extent. In order to target 
collaterals, a reliable means of grading collaterals using imaging may be 
required in order to prove that different interventions mediate an effect via 
collateralisation.  
2.5 Systematic Review of Methods for Assessing 
Leptomeningeal Collateral Flow. 
Studies of leptomeningeal collateral flow in animals have suggested that the 
adequacy of flow via anastomoses could be important in affecting infarct volume 
and outcome after stroke but most of these studies have measured collaterals at 
post mortem, permitting quantitative measurements of vessel diameter or 
qualitative measurements of vessel tortuosity. Early works on collaterals in 
human stroke have also been at post-mortem, but imaging at stroke onset may 
be used to measure collateral flow adequacy for stroke patients in real time. 
Different imaging modalities can be used to evaluate the cerebral circulation 
and collateral flow, including catheter angiography, CT and MR angiography and 
Trans-cranial Doppler, but the modality and grading assessment method which 
can best evaluate the presence and adequacy of collaterals is not clear. 
Numerous studies have evaluated collaterals in acute settings using different 
modalities and grading scales. Poor collaterals when assessed using catheter 
angiography have been associated with haemorrhage after intra-arterial 
thrombolysis (243). Better grades of collateral flow measured with angiography 
and CTA have been associated with lesser amounts of infarct growth and better 
clinical outcomes after stroke (111, 244). These studies, while demonstrating 
the importance of collateral flow adequacy in stroke, have each used different 
scales with which to grade collaterals and there is no consensus on how 
collateral flow should be graded , which limits any potential future research into 
clinical, genetic or blood biomarkers of collaterals flow.  
Part of the purpose in writing this thesis was to evaluate the impact of collateral 
flow on clinical and imaging outcomes after stroke as well as to investigate the 
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presence of biomarkers for adequacy of collateral flow status. In order to 
measure collateral flow adequacy in my dataset later in this thesis, a grading 
scale which could be used to grade collaterals was required. As consensus on 
grading collaterals was lacking from initial review of the literature, a systematic 
literature review was therefore undertaken in order to consider all of the 
currently available methods with which to grade collateral flow, as well as to 
confirm the importance of collateral flow on outcomes in stroke and to 
determine how collaterals could be best classified in order to permit further 
study of collateral flow in this and other future work.   
2.5.1 Methods 
Search Strategy 
The Ovid on-line Portal was used to search Medline and Embase from inception 
to week 32, 2009 for methods to describe leptomeningeal collateral 
assessments. The search strategy is attached in Appendix 1. In addition the 
search was supplemented by review of electronic tables of contents in 
neurological journals and by hand-searching the references and citations of all 
relevant articles identified by the initial literature search. Where full text was 
unavailable (e.g. Conference poster presentations published in abstract form 
only) the relevant authors were contacted directly to obtain copies of the 
grading scale used to grade collateral flow.  
Inclusion criteria 
All publications which were written in English and performed on humans in 
whom collateral flow of any kind was described were initially selected for 
review. Publications which only evaluated primary collateral flow (i.e. through 
the segments of the circle of Willis or via the ophthalmic artery) were 
subsequently excluded from analysis. Terms which were considered to reflect 
leptomeningeal collaterals according to different nomenclature included pial 
collaterals and cortical anastomoses. Studies of collateral flow described using 
these terms were included in the final group of selected publications. A specific 
disease state not included was Moyamoya, as the collateralisation seen in this 
condition, although occurring in the leptomeningeal vessels, was not considered 
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to be reflective of the flow dynamics seen in stroke patients due to presumed 
different pathophysiology of collateral development and recruitment. 
Imaging modalities for inclusion were those that may be employed in acute 
stroke consideration were not pre-specified at the time of literature search, but 
in practice the inference of collateral flow using PET or SPECT in different 
publications did not specifically evaluate collateral flow. Instead PET and SPECT 
measured the responsiveness/capacity of collaterals or inferred the presence of 
collaterals according to flow or metabolic indices and were not ultimately 
included in the final analysis.  
Data extraction 
Information recorded from each relevant publication included imaging modality, 
description of collateral flow grade, number of subjects evaluated, clinical 
setting(i.e. acute stroke, less than 24hrs from symptom onset, or chronic 
cerebrovascular disease states with imaging performed more than 24 hrs after 
initial symptom onset). Inter and intra observer agreement was recorded if it 
was analysed in any publication as was the impact (positive, negative or neutral) 
collateral flow adequacy had on imaging and clinical outcomes. If more than one 
modality or grading scale was evaluated, correlations between methods for 
measuring collateral flow were recorded.  Included publication dates ranged 
from January 1965 to October 2010. 
2.5.2 Results 
Medline and Embase searches yielded 9456 and 6847 publications respectively, 
195 of which were screened as being potentially relevant and had full texts 
reviewed.  After screening, 39 articles were included. A further 42 articles were 
obtained by hand searching bibliographies and review of electronic tables of 
contents from different journals providing a total of 81 different publications for 
inclusion (n=4686 patients, Table 2.1). 
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Modality Different  
assessment 
methods 
Number of 
Publications 
Methods with 
inter/intra observer 
agreement 
assessed 
Angiography 41 58 2(243, 245, 246) 
CT 7 12 5(110, 111, 247-249) 
MRI 9 13 0 
TCD 6 7 0 
Table 2-1 Assessment Methods for Measuring Collateral Flow Using Different Modalities 
Two grading scales had reliability assessed for angiography, but three publications are referenced 
as one had reliability assessed in a second publication by the same author. Five different methods 
using CT tested reliability. 
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Catheter Angiography for Collateral Flow Assessment 
 
The majority of leptomeningeal flow assessments were performed using catheter 
angiography. A total of 3467 patients in 58 publications had leptomeningeal flow 
assessed by a total of 41 different criteria.  36 publications investigated 
collateral flow in acute stroke/TIA, and 18 assessed collaterals in non acute 
patients (191, 250-268). Time from symptomatic event was unclear in 5(160, 
267-270) and a combination of acute and non acute patients was reported once 
(271).  Two publications reviewed collateral flow in the posterior circulation 
alone (267, 272) with the remaining relating to either anterior circulation alone 
or a combination of anterior and posterior circulation (Table 2.2). 
Reliability assessments were available for two of these methods, demonstrating 
good and very good inter/intra observer agreement (n=172) (243, 245, 246). 
Arterial injection sites, when described, included unilateral carotid/MCA 
(n=3)(273-275), bilateral carotid (n=3)(253, 276, 277), minimum of ipsilateral 
carotid and vertebral (n=10)(250, 251, 261, 262, 269, 271, 278-281), and other 
combinations (n=5)(257, 265, 266, 282, 283).  
A simple inspection of the angiogram appearance without use of specifically 
defined grading system (i.e. leptomeningeal collaterals termed as being present 
or not) was identified in 25 publications (160, 191, 251, 253-266, 268-270, 277, 
278, 282-284) . Each of these used a different subjective interpretation of the 
angiographic appearances to assess for leptomeningeal collateral flow presence. 
Inter/intra-observer reliability was not assessed for any of these assessment 
methods. 
One grading method used in three different publications from a single group was 
based on a scale that took into account both the actual site of the arterial 
occlusion as well as the degree of collateral flow around it as determined by the 
adequacy of vessel filling. This method is known as the Qureshi grading scale and 
showed good inter-observer reliability (κ=0.73) for grading among three 
different readers on a sample of 15 patients when it was first used (246). When 
this method was used again, reliability in terms of observer agreement was not 
re-assessed (285, 286). This method had a total of 8 different grades which 
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varied according to the initial occlusion site as well as the collateral flow state, 
and therefore does not solely describe collaterals. 
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The absolute number of individual leptomeningeal vessels visualised at 
angiography was used in 7 publications to grade collateral flow adequacy (271, 
274-276, 280, 281, 287). Other grading scales which were broadly considered to 
be based upon interpretation of the rapidity of vessel filling or anatomic extent 
of leptomeningeal flow were used in 22 publications (40, 234, 243-245, 250, 252, 
267, 271, 272, 275, 276, 279-281, 287-293) . A combination of absolute collateral 
vessel number along with speed and extent of collateral flow was used in 6 
publications (271, 275, 276, 280, 281, 287). An illustration of one of the grading 
methods using catheter angiography is shown in figure 2.2. 
 
Figure 2-2 Illustration of Collateral Scoring Based on Catheter Angiography 
Illustration showing collateral scoring based on extent of retrograde flow from the anterior cerebral 
artery towards a proximal occlusion in the middle cerebral artery scoring corresponds to the 
angiographically visible retrograde reconstitution of the middle cerebral artery segments on the 
delayed venous phase. Each colour depicts the furthest extent of retrograde opacification depicted 
on the anteroposterior cerebral angiograms for each leptomeningeal collateral score. Reproduced 
from Christoforidis et al “Angiographic assessment of pial collaterals as a prognostic indicator 
following intra-arterial thrombolysis for acute ischemic stroke” AJNR Am J Neuroradiol. 2005 
26(7):1789-97 
Impact of Angiographically Defined Collaterals  
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Not all publications described the impact or importance of flow in collateral 
vessels as the purpose of the literature review was primarily to obtain 
information on how collateral flow can be graded. When stated however, the 
presence of adequately developed collaterals appeared to be associated with 
markers for better outcomes when assessed using catheter angiography. 
Christoforidis et al revealed that in addition to known predictors of 
haemorrhagic transformation after intra arterial thrombolysis (Time to 
treatment, diabetes, low platelet count); poorly developed  collaterals were 
associated with haemorrhagic transformation as well as larger size of 
haemorrhage following IA thrombolysis (243). In addition collateral flow grade 
was shown to predict infarct volume and clinical outcome, and may be 
associated with better response to thrombolysis (245). In acute stroke patients 
undergoing angiography <5 hrs from symptom onset, Toni et al found that 
collateral flow was a predictor of early clinical improvement along with arterial 
patency(277). Von Kummer stated that reperfusion and collateral flow were two 
important factors associated with small infarct volume and better clinical 
outcome in patients with MCA/ICA occlusion receiving IV rt-PA(280). Infarct 
volume, clinical outcome, clinical presentation and evolution of ischemic CT 
changes were correlated with collateral status in patients with MCA occlusion in 
the PROACT II trial (273, 279). When compared with other indices using 
Multimodal MRI in acute stroke patients, collateral flow was associated with 
larger volumes of benign oligemia, less infarct growth even without 
recanalisation and was associated with a trend (although not statistically 
significant) towards better grades of recanalisation(244). In the setting of basilar 
occlusions, Arnold et al found that better residual collateral flow was more 
likely to be seen in patients who had good clinical outcomes after therapy(294) 
while Cross et al found that patients with collateral filling of the basilar artery 
tolerated longer symptom duration after basilar artery stroke, although the 
collateral source may have included both primary and secondary flow collateral 
routes(272). Good collateral flow grade was a significant univariate predictor 
and the only multivariate predictor of favourable clinical outcome in a group of 
patients treated with Intra-arterial or intravenous thrombolysis when inspected 
by Kucinski et al (287). No publication assessing collaterals demonstrated a 
negative association between well developed collaterals and clinical or 
radiological outcome, although the effect was neutral or not mentioned in 
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several publications (160, 234, 268, 270, 283). The published articles describing 
collateral flow defined using catheter angiography are summarised in Table 2.2. 
The number of different methods and grading scales published highlights 
heterogeneity in how collateral flow has been quantified. Where numerical 
scales were used, lower numbers reflected poorly developed collaterals while 
higher numbers signified better collateral flow, although these varied between 
publications. 
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Description Grading Author(n) Acute(<24hr 
from 
symptom 
onset)/Non 
acute 
Reliability 
assessed? 
Prognostic 
Significance 
(NS= Not 
Stated) 
Extent of 
antero/ 
retrograde 
vessel filling 
0-3 Brandt(267) 
(20) 
Arnold(294) 
(40) 
Acute No Beneficial (267, 
294)
 
Number and 
rapidity of 
collateral 
vessel filling 
0-2 Von 
Kummer(281) 
(53) 
Acute No Beneficial 
Number and 
rapidity of 
collateral 
vessel filling 
n/a Bozzao(283) 
(36) 
Bozzao(282) 
(36)  
Toni(277) (80) 
Acute No NS (283) 
NS (282) 
Beneficial (277) 
Filling extent 
of main and 
distal vessels 
via collaterals 
0-3 Wu(252) (51) Non acute No n/a 
Vessel filling 
relative to 
occlusion 
1-5 Christoforidis 
(243)
 (104) 
Christoforidis 
(245)
 (53) 
Acute Yes Beneficial (243) 
(245)
 
Table 2-2 Angiographically Defined Collaterals 
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Description Grading Author(n) Acute(<24hr 
from 
symptom 
onset)/Non 
acute 
Reliability 
assessed? 
Prognostic 
Significance 
(NS= Not 
Stated) 
Retrograde 
MCA flow to 
insula 
Present, 
absent, 
indeterminate 
Derdeyn(254) 
(117) 
Non acute No n/a 
Rapidity and 
extent of 
retrograde 
collateral flow 
0- 4 Bang(244)  (44) 
Higashida (289)  
(0)* 
Bang(40) (119) 
Ovbiagele (234) 
(95) 
Sanossian (288) 
(74) 
Liebeskind (293) 
(120) 
Liebeskind (292) 
(120) 
Liebeskind (290) 
(50) 
Liebeskind (291) 
(66) 
Acute No Beneficial(40, 
244, 293) 
n/a(289) 
No effect (234) 
NS (288, 290-292) 
 
Flow  extent 
across cortical 
surface 
n/a Powers(253) 
(19) 
Non acute No n/a 
Visual 
inspection 
n/a Klijn(255) (76) Non acute No n/a 
Delayed 
contrast 
washout 
n/a Essig(256) (30) Non acute No n/a 
Visualisation 
of slow flow 
n/a Kamran(160) (8) Acute No NS 
Visualising  
flow pattern 
Grade 4= 
LMF 
Ozgur(257) (27) Non acute No n/a 
Cortical 
branches from 
contralateral 
ACA/PCA 
n/a Rutgers(258) 
(112) 
Non acute No n/a 
Table 2-2 Angiographically Defined Collaterals (continued) 
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Description Grading Author(n) Acute(<24hr 
from 
symptom 
onset)/Non 
acute 
Reliability 
assessed? 
Prognostic 
Significance 
(NS= Not 
Stated) 
Visualisation 
of Pial vessels 
n/a Zappe(270) (86) Unclear No NS 
Visualising 
flow from 
adjacent 
vascular 
territories 
n/a Noguchi(278)(5) Acute No NS 
Visualising 
arteriogram 
n/a Grubb(259) (81) Non acute No n/a 
Cortical 
arteries from 
PCA 
n/a Fukuyama 
(260) (3) 
Non acute No n/a 
Number and 
rapidity of 
vessel filling 
0-2 Lee(275)(8) Acute No NS 
Distal MCA 
branches 
filling through 
ACA or PCA 
n/a Kim(284)(51) Acute No NS 
Retrograde 
vessel filling 
n/a Kinoshita (269) 
(10) 
Unclear No NS 
Cortical 
branches from 
PCA to MCA 
n/a Van Laar(191) 
(23) 
Non acute No n/a 
 
Retrograde 
filling of MCA 
branches 
n/a Yamauchi  
(261)
 (42) 
Non acute No n/a 
 
Table 2-2 Angiographically Defined Collaterals (continued) 
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Description Grading Author(n) Acute(<24hr 
from 
symptom 
onset)/Non 
acute 
Reliability 
assessed? 
Prognostic 
Significance 
(NS= Not 
Stated) 
Extent and 
number of 
vessels filling 
via collateral 
flow 
Absent, mild, 
or prominent 
Uemura(271)     
(25) 
Combination No NS 
Occlusion site 
and extent of 
collateral flow 
combined 
0-5 Qureshi(246) 
(15) 
Mohammad 
(286)
 (57) 
Mohammad 
(285)
 (55) 
Acute Yes  
k=0.73(246) 
Beneficial (246, 
285, 286)
 
Extent of 
retrograde 
flow in MCA 
Good, poor Kucinski(287) 
(111) 
Gasparotti(295) 
(27) 
Acute No Beneficial 
 
Capillary 
blush in MCA 
territory 
Grade 4= 
leptomeninge
al flow 
Russell(262) 
(14) 
Non acute No n/a 
MCA/PCA 
filling from 
posterior 
circulation 
n/a Bischopps (263) 
(68) 
Non acute No n/a 
Basilar artery 
opacified by 
collaterals 
Distal vs. 
distal & 
proximal 
Cross(272) (24) Acute No Beneficial 
Cortical  
branches 
filling MCA/ 
ACA from 
PCA 
n/a Bokkers(264) 
(17) 
Non acute No n/a 
Pial collateral 
flow from ACA 
and PCA 
n/a Derdeyn(265) 
(10) 
Non acute No n/a 
Table 2-2 Angiographically Defined Collaterals (Continued) 
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Description Grading Author(n) Acute(<24hr 
from 
symptom 
onset)/Non 
acute 
Reliability 
assessed? 
Prognostic 
Significance 
(NS= Not 
Stated) 
Flow via 
channels on 
brain surface 
n/a Smith(266) (18) Non acute No n/a 
Collateral 
flow 
assessment 
based on 
ASPECTS (13 
areas) 
0-3 Chng(250) (18) Non acute No n/a 
Number and 
rapidity of 
vessel filling 
from ACA 
Good or 
scarce 
Von 
Kummer(276) 
(77) 
Acute No No effect 
Number and 
rapidity of 
vessel filling 
from ACA and 
PCA 
0-2 Von 
Kummer(280) 
(32) 
Acute No Beneficial 
Filling extent 
of at risk 
territory 
1-3 Roberts(273)  
(180) 
Acute No Beneficial 
Collateral 
flow 
assessment 
based on 
ASPECTS(15 
areas) 
0-3 Kim(279) (44) Acute No Beneficial 
 
MCA branch 
filling in early 
venous phase 
Good, 
moderate, 
poor 
Ringelstein 
(274) (34) 
Acute No Beneficial 
Table 2-2 Angiographically Defined Collaterals (Continued) 
76 
 
Description Grading Author(n) Acute(<24hr 
from 
symptom 
onset)/Non 
acute 
Reliability 
assessed? 
Prognostic 
Significance 
(NS= Not 
Stated) 
Retrograde 
arterioles 
visualised in 
capillary 
phase 
n/a Weidner(268) 
(4) 
Unclear No NS (268) 
Presence of 
superficial 
PCA/ACA 
cortical 
branches 
n/a Hoffmeijer 
(251) (70) 
Non acute No n/a 
Extent of LMF 
in    occluded 
territory 
Poor, Good Arnold(296) (98) 
Meier(297) 
(311) 
Acute No No effect(296) 
Beneficial(297) 
Presence of 
collaterals in 
affected 
territory 
None/ 
minimal/ 
Moderate/  
maximal 
Gonner(298) 
(43) 
Brekenfeld(299) 
(294) 
Acute No No effect(298) 
Beneficial(299) 
Table 2-2 Angiographically Defined Collaterals (Continued) 
List of publications using catheter angiography to define collateral flow extent are summarised. The 
wide variation in methods and scales limits full explanation in a single table, so a brief summary of 
each is included.
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Computed Tomography for Collateral Flow Assessment 
Studies using CT imaging to investigate collateral flow focussed on qualitative 
interpretation of CTA appearances, either CTA-SI or CTA reconstructions. A total 
of seven grading scales using CTA were identified from nine publications with 
assessments performed on a total of 593 patients suspected of having acute 
ischemic stroke (91, 99, 110, 111, 247-249, 275, 300-303) (Table 2.3). 
Interobserver agreement was assessed for 5/7 CTA methods, ranging from 
moderate to excellent (total patients assessed for reliability of method n=247). 
One grading scale used a combination of CTP and CTA to grade collaterals by 
confirming that collateral flow was truly retrograde using 4-D angiographic 
images obtained from raw CTP data (111). 
Collaterals were scored exclusively in cases of MCA stroke in 3 publications (111, 
300, 301) . Whole anterior circulation strokes were assessed for collaterals in 4 
(91, 99, 247, 248)  while a combination of anterior and posterior circulation 
strokes were included in 1 publication (110). The different processing steps for 
interpretation of CTA included MIP images (301) CTA source images(99, 247, 300) 
and a combination of source images and 3D reconstructions (91, 110, 248, 249). 
Grading scales for collaterals were based upon the extent of peri-lesional vessel 
filling on CTA source images(247),comparison of ipsilateral and contralateral 
filling in the Sylvian fissure(91, 110, 300-302),peri-lesional enhancement on 
source images and reconstructions(99, 303), lesion extent on tri-phasic perfusion 
CT(275) and extent of retrograde flow towards a proximal MCA occlusion(111) 
Impact of CT defined collaterals. 
Extent of collateralisation was shown to correlate with clinical outcome after 
thrombolysis when examined by Wildermuth et al, suggesting that those with 
poor collaterals, alongside subjects with ICA occlusion or with thrombi which had 
auto-lysed may have little benefit when receiving IV thrombolysis (91). When 
source images and MIP reconstructions were blindly compared in the same 
patient group, Tan et al found that CTA source images for collateral assessment 
did not predict infarct volume, but that 3D reconstructions were predictive of 
final infarct volume(249). Maas et al found that neurological deterioration 
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(defined by any subsequent increase in NIHSS after admission measurement) was 
four times more likely in the group with diminished collaterals(301). Rosenthal 
et al compared the predictors of clinical outcome between those patients who 
did and did not show recanalisation of a symptomatic arterial occlusion and 
found that leptomeningeal collaterals only had a positive influence on outcome 
in patients who did not recanalize, and that this impact was proportionally less 
that that of baseline lesion volume and admission NIHSS(300). Schramm et al 
showed that clinical outcomes were significantly better in patients with good 
collateral status and that patients at risk of infarct growth could be identified on 
the basis of poor collateralisation, although baseline lesion volume (defined on 
DWI/ CTA source image) and therapy with IV rt-PA were not corrected for in the 
analysis (99). The independent predictive value of collaterals on clinical 
outcome after stroke in proximal occlusions was confirmed in relatively large 
patient samples by Tan et al and Miteff et al(111, 248) (n=85 and 92 respectively 
) in addition to the association of good collaterals with smaller baseline 
perfusion defects and smaller final infarct volumes. No clear clinical or blood 
biomarkers for collateral flow were found from these studies, although patients 
imaged more than one hour from symptom onset were more likely to have good 
collateral flow than those imaged earlier which suggests that collateral flow 
might improve with time(301). However, serial imaging in individuals to 
determine whether or not collateral flow improved over time was not performed 
meaning an association between collateral flow and time from stroke onset 
remains speculative.
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Modality Method Grading Author (n) Acute   
(<24hr 
from 
symptom 
onset)/ non 
acute 
Reliability 
assessed? 
Prognosis 
(NS= not 
stated) 
Axial CTA-
SI  
 
Extent  of 
peri-lesional 
vessel filling 
None, 
moderate, 
good, 
excellent 
Liebeskind 
(247) (36)   
Acute Yes 
ICC=0.81 
NS 
CTA-SI Sylvian 
LMF 
compared  
with contra-
lateral side 
Absent, 
less, equal 
to, greater 
than contra-
lateral side  
Rosenthal  
(300)(44) 
Maas(301) 
(135) 
Lima(302) 
(196) 
Acute No Beneficial(10
0, 300-302)
 
CTA-SI and 
MPR 
Extent of 
peri-lesional 
filling 
Good, poor Schramm(99)
(20) 
Tan(249) 
(113) 
Acute Yes 
k=0.494 
Beneficial(99
, 249)
 
Table 2-3CT based Collateral Grading Methods 
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Modality Description Grading Author (n) Acute 
(<24hr 
from 
symptom 
onset)/ 
non acute 
Reliability 
assessed? 
Prognosis 
(NS= not 
stated) 
CTA SI 
and MPR 
MCA filling in 
Sylvian 
fissure 
Good, 
moderate, 
absent 
Wildermuth 
(91)
 (40) 
Knauth(110) 
(21) 
Acute Yes 
88% 
agreement 
between 
raters (110) 
Beneficial(9
1, 110)
 
CTA 
MIPS 
Extent of 
filling in 
territory of 
occluded 
vessel 
0-3 Tan(249) 
(113) 
Tan(248)(85) 
Soares(303) 
(22) 
Acute Yes 
k= 
0.669(249) 
ICC 0.87 
Beneficial(2
48, 249, 303)
 
CTA MIP 
& CTP 
Retrograde 
filling of MCA 
Good, 
moderate, 
poor 
Miteff(111) 
(92) 
Acute Yes 
k=0.93 
Beneficial 
Tri- 
phasic 
CTP  
(TPCT) 
Extent  of 
perfusion 
deficit on 
TPCT 
Severe, 
moderate 
Lee (275) 
(8) 
Acute No NS 
Table 2-3 CT based Collateral Grading Methods (Continued) 
A summary of each method for grading collateral flow with CT is included as full methods could not 
be incorporated to a single table. k=Kappa statistic. ICC= Intraclass Correlation Coefficient
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MRI based Collateral Assessments 
A total of 9 different assessment methods determined or inferred the presence 
of leptomeningeal collateral flow using MRI in 13 publications (n=358, 244 acute 
stroke patients, 114 non-acute). 
Detection of vascular hyperintensities on FLAIR imaging was used as a marker of 
delayed arterial transit within leptomeningeal vessels in 5 publications (159, 
160, 278, 288, 304), 4 of which compared findings on FLAIR with an additional 
“gold standard” measurement of collaterals using with catheter angiography 
(160, 278, 288, 304). An example of FLAIR hyperintense vessels is shown in figure 
2.3 
 
Figure 2-3 Hyperintense Vessels on FLAIR. 
Two patients are shown with right MCA occlusion and similar perfusion deficits (PWI-MTT) at 
baseline. The patient with hyperintense vessels on FLAIR (panel B, Arrows) had a smaller 
subacute infarct volume than the patient without (Panel A) demonstrating the effect of good 
collaterals. Reproduced from Lee et al “Distal hyperintense vessels on FLAIR: an MRI marker for 
collateral circulation in acute stroke?” Neurology 2009; 72(13) 1134-9 
Delayed contrast arrival using Perfusion weighted imaging (PWI)(305) Factor 
analysis of Dynamic Studies (FADS)(306), Quantitative MRA (QMRA)(307), Phase 
contrast MRA(308) and arterial spin labelling (ASL) (250, 252, 309) have been 
inferred as markers of leptomeningeal collateral flow markers in a total of 7 
publications. 
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Abnormal visualisation of leptomeningeal vessels (AVLV) on T2* weighted MRI 
was used in one series as a representation of leptomeningeal collateral 
supply(310)  
Although multiple different methods and imaging sequences have inferred the 
presence and adequacy of collateral flow, none of these reported measurements 
compared the presence of collaterals with clinical or radiological outcomes after 
stroke. In addition, no agreement or observer error rates using MRI to grade 
collaterals were performed in any of the included assessment scales. The 
different publications using MRI to define collateral flow extent are summarised 
in Table 2.4. 
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Modality Description Author (n) Acute(<24hr 
from 
symptom 
onset) /non 
acute 
Reliability 
assessed? 
Prognostic 
significance 
of good 
collateral 
flow grade 
in acute 
stroke 
(NS= not 
stated) 
FADS Late FADS 
implies 
collateral flow 
Martel(306)(22) Acute No NS 
QMRA Increased flow 
ipsilateral to 
steno-occlusive 
disease 
Ruland(307)(16) Non Acute No n/a 
Phase 
contrast 
MRA 
Flow from 
posterior to 
anterior 
circulation 
Schomer(308)(29) Non acute No n/a 
FLAIR FLAIR 
hyperintensities 
as a marker of 
collateral flow 
Liebeskind(304)(91) 
Kamran(160)(8) 
Noguchi(278)(5) 
Sanossian(288)(74) 
Lee (159)(52) 
Acute No NS(304) (159, 160, 
278, 288)
 
T2* 
weighted 
MRI 
Abnormal 
visualisation of 
leptomeningeal 
vessels 
Hermier(310)(48) Acute No NS 
PWI Delayed 
perfusion sign 
visualised on 
PWI 
Hermier(305)(29) Acute No NS 
ASL Quantitative  
distal collateral 
flow 
measurement 
 
Wu (252)(51) Non acute No n/a 
TASL Collateral flow 
assessment 
based on 
ASPECTS 
Chng(250)(18) Non acute No n/a 
CASL Collateral flow 
inferred from 
delayed arterial 
flow 
Chalela(309)(15) Acute No NS 
Table 2-4MRI Based Collateral Assessments 
TASL= Territorial Arterial Spin Labelling, CASL= Continuous Arterial Spin Labelling, FADS= Factor 
Analysis of Dynamic Studies, QMRA= Quantitative Magnetic Resonance Angiography, 
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 Transcranial Doppler Measurements of Collateral Flow 
A total of 6 different assessment tools from 7 publications measured 
leptomeningeal collateral flow using transcranial Doppler measurements. At 
least 268 patients were assessed using TCD, although the number examined in 
one publication was unclear(311) . Asymmetry of blood flow measured in 
different arterial segments was used in most TCD based collateral methods, 
either in isolation(215, 312) or in combination with reduced pulsatility of the 
vessel under investigation(284, 313, 314). The degree of asymmetry required to 
define flow via leptomeningeal vessels varied between different publications. 
Additional definitions of collateral flow on TCD included accelerated flow in the 
A1 segment of the ACA feeding flow in the smaller leptomeningeal vessels(315) 
and retrograde flow relative to the TCD probe(311). None of the TCD based 
collateral assessments had measurements of observer agreement/reliability 
assessed, and none of them compared the grade or presence of collaterals with 
any outcome measurement.  
Comparisons between Modalities 
A total of 8 publications compared non-invasive LMF assessments with MRI (n=5) 
CT (n=2) or TCD (n=1) to a reference “gold standard” using catheter 
angiography.  Each time a comparison was made however, a different grading 
scale or definition for measuring collaterals using the gold standard imaging 
modality was performed limiting the potential to compare assessment methods 
between different modalities (160, 250, 252, 269, 275, 278, 284, 288). 
2.5.3 Discussion 
The quality of leptomeningeal collateral flow is reported in several of the 
reviewed publications to be an independent predictor of outcome after acute 
ischemic stroke even after adjustment for other known prognostic factors such 
as age, clinical stroke severity, baseline imaging characteristics, occlusion site, 
treatment and recanalisation/reperfusion, (111, 244, 248, 249, 277, 287, 300)  
which suggests that as a minimum there is a need to account for its influence on 
outcomes after stroke particularly when imaging modalities used at baseline 
assessment in therapeutic trials in stroke have the potential to detect and grade 
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collateral flow . Good collateral flow is assumed to be associated with 
favourable outcome as a consequence of maintaining the ischemic penumbra for 
longer until reperfusion occurs. However the effect of collaterals appears to be 
independent of conventional indices of penumbra such as arterial recanalisation 
or reperfusion as even after correcting for these outcome predictors, collateral 
flow extent has an additional impact on clinical outcome after proximal arterial 
occlusion (111, 300).  
It is unclear whether collateral grade represents an inherent characteristic of 
individual subjects or a potential therapeutic target .Collateral flow grades on 
CTA are reportedly better in patients who undergo imaging later after symptom 
onset, while better collateral flow grades on catheter angiography have been 
reported in patients treated with statins prior to stroke (234), suggesting 
collateral flow is dynamic, develops over time and could potentially be modified 
by medications or other interventions such as partial occlusion of the abdominal 
aorta which increases blood flow proximal to the aortic occlusion, including 
cerebral blood flow, and is used to improve cardiac perfusion following 
myocardial infarction(241). In order to target collaterals in terms of therapy, 
agreement on how collaterals are graded is likely to be needed in order to 
measure response to interventions. At present there is no consensus on 
collateral grading within and between different imaging modalities. 
Collateral flow is not accounted for in most occlusion classification systems 
which may be important in defining arterial occlusion severity at entry to clinical 
trials and adoption of scoring systems from coronary artery disease, notably the 
TIMI(167) system, or minor modification of such systems (e.g. TICI) ignores 
fundamental differences in the acquisition of images and the anatomy of the 
different vascular beds. The original TIMI scale defines the extent of both 
recanalization and reperfusion based on interpretation of dynamic angiography 
appearances, but translation of this scale to a non-dynamic imaging modality 
such as CTA or MRA has some limitations. Patients with complete occlusions but 
good distal collateral flow could be wrongly classified as having a high TIMI 
score, because without dynamic information it is impossible to say whether or 
not the flow into an ischemic territory is anterograde or retrograde in origin. 
Guidelines have been developed for agreed reporting methods in determining 
recanalization/ reperfusion, but have focussed on angiography and have 
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acknowledged that individual CTA/ MRA scales have not been developed, 
requiring adaptation from TIMI/TICI or others. However these have been variably 
applied and therefore have been acknowledged as a possible source of confusion 
(316).  The presence of collaterals as a contribution to the imaging appearances 
seen is seldom considered when defining occlusions at baseline (47). The original 
TIMI and TICI scales are illustrated in Table 2.5 along with subsequent 
adaptations of each(51, 316).The Modified TICI (mTICI) score has recently been 
shown to be a better outcome predictor than TIMI(317). None of these scales 
incorporate collateral flow adequacy which may not be so important when using 
dynamic imaging such as catheter angiography, but this could be seen as a 
limitation when the same scales are applied to non-dynamic imaging methods 
such as CTA or MRA as the source of flow distal to the occlusion (i.e. 
anterograde versus retrograde) is not defined using these imaging methods 
alone. 
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Scale + Grade Description 
TIMI 0 No recanalization/ reperfusion 
TIMI 1 Minimal recanalization/ reperfusion 
TIMI 2 Partial recanalization/ reperfusion 
TIMI 3 Complete recanalization/ reperfusion. 
  
TIMI 0* Complete occlusion 
TIMI 1* Minimal flow 
TIMI 2* Partial flow 
TIMI 3* Normal flow 
  
TICI 0 No Perfusion. 
TICI 1 Penetration With Minimal Perfusion 
TICI 2 Partial Perfusion 
TICI 2a Only partial filling (2⁄3) of the entire vascular territory is 
visualized 
TICI 2b Complete filling of all of the expected vascular territory 
is visualized, but the filling is slower than normal  
TICI 3 Complete Perfusion 
  
mTICI0 No reperfusion 
mTICI1 Flow beyond occlusion without distal branch reperfusion 
mTICI2a Reperfusion of less than half in the downstream target 
arterial territory 
mTICI2b Reperfusion of more than half , yet incomplete, in the 
downstream target arterial territory 
mTICI3 Complete reperfusion of the downstream target arterial 
territory, including distal branches with slow flow 
Table 2-5 Original and Modified TIMI and TICI Scales 
* Adapted TIMI scale describing the occlusive lesion using CTA (reference 51). The original TIMI 
scale was used in coronary angiography. Even with revisions of the scales, they remain somewhat 
subjective particularly in defining the extent of filling in distal territories.  
In order to investigate collaterals in acute stroke, a consistent method for 
assessment and grading is required. This literature review revealed wide 
variation in methods for grading LMF, few of which are supported even by 
measurement of observer agreement. 
Catheter angiography, considered the gold standard for assessing 
cerebrovascular anatomy can reveal retrograde collateral perfusion in a dynamic 
fashion and has been used for LMF assessments in the largest number of 
patients. The most frequently employed scale was proposed by the American 
Society of Interventional and Therapeutic Neuroradiology in an effort to 
homogenise grading with angiography (289) , but an assessment of inter-observer 
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agreement has not yet been reported which may be a limitation. Good 
intraobserver agreement has been demonstrated with angiography when LMF 
was graded according to the anatomical extent of retrograde flow (κ= 0.81) 
(243, 245). The Qureshi scale also demonstrates good interobserver agreement, 
but does not focus on LMF independently as each grade is dependent on the 
index arterial occlusion as well as the collateral flow, which could be a 
limitation when trying to address the impact of collaterals alone. One additional 
grading scale anecdotally used in clinical practice quantifies collateral flow 
according to time taken for contrast to travel from ICA to the M2 segment of the 
MCA via collaterals but this method describes flow through primary collaterals of 
the circle of Willis rather than  specifically through cortical anastomoses(318). 
As there may be specific influences on collateral development (including genetic 
factors as suggested from experimental models) it is important to find a method 
of measuring flow in leptomeningeal vessels alone in order to further understand 
their properties. As LMF is derived from neighbouring arterial territories, its 
quality may only be fully evaluated when the contribution of all potential inflow 
sources is assessed. Descriptions of arterial injection sites are infrequently 
provided for catheter angiography and even when available, the contribution of 
the whole cerebral circulation is seldom evaluated. Catheter angiography is 
invasive and is usually performed when a patient is being considered for IA 
therapy which in general, is reserved for those patients with contraindications to 
IV treatment (e.g. presentation beyond 4.5 hours with favourable appearances 
on CT) meaning that angiographic assessments for collaterals will be 
predominantly restricted to this relatively small patient group. As multimodal CT 
and MRI are increasingly used in clinical practice and prior to entry to clinical 
trials, they offer a larger potential population in which LMF can be assessed non-
invasively.  
Although lacking dynamic information, CTA alone permits visualisation of the 
anatomical extent of collateral flow. The independent predictive value of 
collaterals has been confirmed with different CTA based collateral grading 
methods and interobserver agreement within different grading scales has been 
assessed with good to excellent measures of agreement (110, 247-249). 
Retrograde flow relative to a proximal arterial occlusion provides a 
measurement of LMF adequacy, but grading LMF this way for more distal 
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occlusions may be more difficult due to the specific anatomical landmarks used. 
A collateral scoring system based upon contrast enhancement in defined regions 
of interest provides a scale not dependent on a specific occlusion which could 
potentially be applied in a larger patient population(247). The addition of CT 
perfusion to CTA adds potentially important dynamic information to confirm that 
collateral flow is truly retrograde, and has been shown to have excellent inter-
observer agreement (111). This additional dynamic information obtained with 
CTP requires further imaging, contrast administration and radiation exposure at 
present, although the development of new multidetector scanners which enable 
simultaneous acquisition of both CTA and CTP now allows dynamic collateral 
flow assessment from a single combined CTA/CTP acquisition without the 
current requirement for additional scanning(114). 
LMF assessments with MRI use various imaging characteristics to infer the 
presence of collateral flow. FLAIR Vascular hyperintensities (FVH) due to 
retrograde flow in leptomeningeal vessels have been associated with larger 
mismatch volumes, and smaller subacute infarct volumes, while abnormal 
vessels on T2* imaging may be due to de-oxygenated blood in collaterals and are 
associated with smaller infarct volumes (159, 310).  ASL using different criteria 
has also been used to grade collateral flow with MRI (250, 252, 309). These and 
other LMF assessments with MRI have not been replicated nor had interobserver 
reliability graded and it remains to be seen if they represent robust means of 
assessing collateral flow.  
Relative blood flow velocity and vessel pulsatility have been used as surrogate 
markers for leptomeningeal collateral flow using TCD in a small number of 
studies but the criteria for defining LMF varied among publications . The lack of 
an agreed definition for LMF on TCD, absence of direct collateral visualisation 
and difficulty in finding acoustic windows are limitations for TCD, although these 
are offset by the lack of radiation and contrast requirements.(319). Flow 
diversion on TCD, defined as increased flow velocity in ipsilateral ACA/PCA did 
correlate with angiographic collateral grade when methods were compared, 
suggesting a possible role for TCD to measure LMF (284). 
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Where collaterals were measured using digital subtraction angiography, CTA and 
MRI, CTA compared favourably , but the methods used for grading LMF on CTA 
were not clearly stated so this finding must be interpreted with caution(269). 
2.5.4 Conclusion 
This review of the imaging modalities which can evaluate collateral flow as well 
as the literature regarding historical considerations of collaterals and 
investigations into collateral flow using experimental models of stroke has 
revealed some important findings: 
1: There is little consistency in how flow via leptomeningeal collaterals are 
graded within and between various imaging modalities, 
2: Despite this inconsistency, the positive impact collateral flow can have on 
various markers in stroke seems secure with independent predictive value being 
demonstrated in some studies, 
3:Terms describing severity of arterial occlusions such as TIMI or TICI may 
inadvertently incorporate good and reduced collaterals into different occlusion 
descriptions, but the fact that these scales do not actually describe collateral 
flow which may be a limitation of their use given that collaterals may influence 
outcome, 
4: Experimental and post-mortem studies of collaterals have proven that 
leptomeningeal vessels have many anastomotic connections, with various 
influences on their development, and that anastomotic development are 
associated with markers for improved outcome, 
5: A small number of studies have suggested that collateral flow may be 
influenced by ischemia (increasing in capacity with increasing time from ictus) 
and medications, offering the potential of a new therapeutic target for stroke. 
The influence of well developed collaterals is likely to be positive, in addition to 
other known prognostic indicators but the reasons behind collateral development 
in humans are not understood. No blood or clinical biomarker for collaterals has 
been described: if found, such a biomarker may offer insights into the factors 
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which control the development of collateral circulation. Further confirmation of 
the benefit of collaterals, consensus on grading, and study into biomarkers for 
collateral flow will hopefully improve understanding of the mechanisms behind 
collateral formation and adequacy, and could potentially represent novel targets 
for therapy in stroke. 
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Chapter 3. Materials and Methods 
3.1 Introduction 
The material presented in the different chapters presented in this thesis is 
focussed on multimodal CT imaging in acute stroke, exploration of some of the 
additional information this provides, how thresholds are generated for defining 
core and penumbra with CT perfusion, Collateral flow, and how these tissue 
compartments relate back to standard imaging in acute stroke with non contrast 
CT. Imaging and clinical data presented here were obtained during a research 
fellowship based at the Institute of Neurological Sciences, Southern General 
Hospital, Glasgow and the University of Glasgow from February 2009 to August 
2011. Image analysis for different chapters varied with the specific analysis 
required and will be discussed in the relevant individual chapters but the entire 
cohort of patients and data available will be discussed initially. Recruitment to 
two observational studies into acute stroke took place during the fellowship 
period and elements of each were combined for several of the analyses 
undertaken. Both studies focussed on obtaining imaging data on patients soon 
after stroke onset, and imaging at later time points to use as potential surrogate 
markers for measuring outcome. Several overlapping features of the two studies 
meant that imaging and clinical data from each could be combined for some of 
the analyses within this thesis. The study protocols, procedure and timelines are 
discussed below. 
3.2   The Multicentre Acute Stroke Imaging Study (MASIS) 
MASIS was a study performed at three acute stroke centres in Scotland between 
August 2008 and March 2010. The study was designed to investigate different 
imaging modalities, blood biomarkers and clinical aspects of acute ischemic 
stroke. Funding was provided by the Translational Medicine Research 
collaboration (TMRC), Dundee. The recruitment sites were Aberdeen Royal 
Infirmary, Western General Hospital, Edinburgh and Institute of Neurological 
Sciences, Southern General Hospital, Glasgow.  
Study Objectives 
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1: To define parameter thresholds for tissue damage at presentation with MR 
diffusion/perfusion imaging and CT/CTP imaging 
2: To refine imaging biomarkers for salvageable brain tissue 
3: To define what proportion of patients can be scanned using advanced CT and 
MRI 
4: To define what proportion of acute stroke patients have evidence of 
salvageable tissue at the time of presentation to hospital 
5: To compare the practicality of CT and MRI based imaging techniques 
6: To explore the relationship between imaging findings and blood biomarkers 
for haemostasis and inflammation 
7: To explore the relationship between specific imaging findings and clinical 
progress and blood biomarkers 
8: To use the acquired data to determine the practicality of using additional 
imaging methods in a clinical trial 
As this was a multicentre collaborative study, only some of the overall 
objectives were carried out by me. These included the feasibility of performing 
advanced imaging with CT or MRI, and refining the thresholds for salvageable 
tissue and irreversibly damaged tissue in stroke and will be presented in later 
chapters. 
Study Design 
MASIS was a prospective, observational study of the natural history of acute 
ischemic stroke conducted at three sites specifically relating CT and MRI 
methods, blood biomarkers and follow up imaging with clinical change. No 
therapeutic interventions specific to the study were involved. The aim was for 
equal recruitment with CT and MRI at baseline, and with follow up imaging at 72 
hrs and 30 days with MRI (or CT if MRI contraindicated)  
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Patient Selection-MASIS 
The target for recruitment was 80 acute stroke patients, with baseline imaging 
performed within six hours of symptom onset; 40 patients with admission MRI 
and follow up MRI, 40 patients with admission CT and follow up MRI. No study 
specific procedures could be performed until consent was provided by the 
patients or assent was provided by the next of kin. Screening logs were kept at 
each site to help determine the barriers to patient recruitment. 
If patients were eligible for thrombolysis, as the local imaging practice was to 
obtain CT prior to thrombolysis, all potential thrombolysis patients would have 
CT regardless of subsequent study specific imaging. Eligibility for receiving 
thrombolysis did not influence eligibility for study inclusion. 
Inclusion Criteria: 
1: Clinical Diagnosis of acute ischemic stroke 
2: <6 hours after symptom onset 
Exclusion Criteria: 
1: Known non stroke diagnosis (e.g. Primary intracerebral haemorrhage, tumour, 
subarachnoid haemorrhage, epilepsy) 
2: Inability to lie in a recumbent position for the duration of additional imaging 
(e.g. severe cardiac failure, desaturation on lying flat, high risk of aspiration) 
3: Intercurrent illness likely to limit survival to less than 30 days 
4: Coma 
5: Chronic or acute renal failure 
6:  Known sensitivity to iodinated contrast media (including previous contrast 
reactions or severe asthma) for CT based imaging studies 
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7: Known sensitivity to gadolinium contrast, recently implanted ferromagnetic 
foreign bodies, intracranial aneurysm clip, or dependence on a cardiac 
pacemaker or implantable defibrillator for MRI studies. 
Men and woman from all ethnic groups were considered eligible for the study. 
Children less than 18 years of age were excluded on the grounds that stroke in 
childhood is rare and is likely to have causes that differ significantly from that in 
older populations. All patients with suspected acute ischemic stroke meeting the 
inclusion criteria could therefore be considered for inclusion. 
Patients admitted to the stroke unit of each hospital who were seen by a 
member of the research team at each site could be screened for inclusion. There 
was no specific restriction in terms of time of day or day of week when patients 
could be approached, but in practice the recruitment took place during the 
normal working week when members of the research time were available which 
usually corresponded to the times when MRI scanning was potentially available.  
Patients were able to withdraw from the study at any time for any reason. An 
option to continue with clinical follow up was offered to subjects unwilling to 
undergo further imaging studies. All data collected prior to withdrawal were 
retained. Patient registration was managed at each site independently, and each 
patient was assigned a study number in the form X-XX with the first digit 
representing the site and the second representing the unique patient identifier 
at that site. 
Study protocol and consent forms were reviewed by the Multicentre Research 
Ethics Committee for Scotland and ethical approval for the study was granted in 
October 2007 (reference 07/MRE00/96). Patient and relative information sheets 
along with accompanying consent and assent forms are attached in the 
appendix.  
Baseline imaging  
Imaging on admission was with either CT or with MR (aim was for 50:50 
recruitment with each) with exclusion criteria for each modality considered and 
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documented as appropriate. If both imaging modalities were equally available 
MRI was the preferred option. 
CT imaging at baseline included whole brain non contrast CT, CT perfusion and 
CT angiography from aortic arch to vertex. Multimodal CT examination was 
obtained using a Multidetector Scanner (Philips Brilliance 64 Slice). Whole brain 
NCCT was acquired first (5 mm slice thickness FOV 218 x 218 mm,120kv, 171 mA 
or 0.9 mm slice thickness, FOV 250x250mm, 120 kV, 404 mA) followed by CTP 
with 40mm slab coverage (8x5mm slices, FOV 25cm, 80kVp, 476 mAs, 2 second 
cycle time, 30 cycles) using a 50 ml contrast bolus administered at 5mls/second 
(350 Xenetix) via a large-gauge venous cannula, usually placed in the antecubital 
fossa. CTP was followed by CTA from aortic arch to the top of the lateral 
ventricles (0.67 mm slice thickness, 120 kV, 475 mA) using bolus tracking to 
enable correct timing of image acquisition.  
MRI on admission included DWI, PWI, T2, FLAIR post contrast, gradient echo, 
Circle of Willis Time-Of-Flight MR angiography. MRI acquisition parameters are 
included in Appendix 2. 
Clinical Assessment 
All patients had full clinical assessment on admission to hospital using validated 
scales including NIHSS and OCSP classification. Additional clinical information 
included blood pressure, capillary blood glucose, body temperature, 
concomitant medications, ECG, social history (e.g. smoking) and family history. 
NIHSS was repeated at 24hr, 72hr, day 7 and day 30, Blood pressure and glucose 
were recorded at 4 hourly intervals for the first 48 hours, and thereafter at the 
same intervals as NIHSS. Pre-morbid modified Rankin scale was recorded at 
baseline and was repeated using structured questionnaire at day 30 and 90 after 
stroke onset. Blood samples for biomarkers were taken at baseline, 2hrs post 
lysis administration (only if given lysis), 24, 48,72hrs, 7 days and 30 days post 
stroke. Other bloods taken as part of routine clinical care included baseline full 
blood count, urea and electrolytes, and coagulation profile, the results of which 
were recorded . 
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Follow up imaging 
All MRI compatible patients were scheduled to have followed up MRI at 72hrs and 
day 30 irrespective of the choice of baseline imaging modality. For those 
patients who were unable to undergo follow up MRI at 72hrs, non-contrast CT 
and CT angiography were performed instead. Day 30 imaging was not performed 
using CT. 
72 hr MRI included DWI, PWI, T2, FLAIR post contrast, gradient echo and Circle 
of Willis MRA. Day 30 MRI included DWI, PWI, T2, FLAIR post contrast and 
Gradient Echo. 
Follow up CT imaging if MRI was unavailable or contraindicated was with whole 
brain NCCT followed by intracranial CTA from base of skull to the top of the 
lateral ventricles. If the initial occlusion was extracranial, the subacute CTA was 
extended using the same protocol as the admission CTA. The MASIS study 
calendar is shown in table 3.1 
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Table 3-1 MASIS Study Calendar 
MASIS study calendar with procedures at different time points.   denotes study-specific procedure 
† denotes clinically routine procedure, data captured for study, * denotes procedure clinically 
routine in some patients 
 
3.2.1 Data Recording and Transfer 
All study specific data were recorded on a paper case record form for each 
patient kept at the site of recruitment. The data were subsequently transferred 
to a web based electronic database (http://tmrc-
openclinica.lifesci.dundee.ac.uk) for centralised data checks and statistical 
analysis by research fellows at each site. Image analysis for all patients was 
recorded on pre-specified data collection sheets and transferred centrally. The 
image analysis undertaken for the overall study is not covered in this thesis, 
although specific subgroup analysis will be included in due course. 
Raw imaging data were transferred between the recruiting centres via the 
national Picture Archiving and Communication System for Scotland. Scans were 
downloaded from there onto radiology workstations locally for anonymization of 
data prior to study specific image analysis. Anonymization of imaging data from 
each study will be discussed later in this chapter.  
Procedure Baseline 24h 48h 72h Day7 Day30 Day90 
Informed 
consent/Assent        
Non contrast CT 
brain † *      
CT Perfusion 
*       
CT Angiography 
*       
MRI brain 
*       
NIHSS †  *     
Blood Samples  
      
 
Modified Rankin 
Scale        
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Although all image data were collected, the only data that will be discussed 
within this thesis relate to those patients imaged with multimodal CT on 
admission as these patients could be combined with patients from an additional 
study using multimodal CT on admission. 
3.3 POSH- POst Stroke Hyperglycaemia 
The second observational study into acute stroke which took place during my 
research fellowship was the POSH study (Pathophysiology of acute post-stroke 
hyperglycaemia in relation to brain perfusion and arterial patency). The purpose 
of POSH was to define the interaction of early and delayed hyperglycaemia with 
arterial patency and brain perfusion in acute stroke patients, which was a single 
centre, prospective, observational study in with an aim to recruit approximately 
100 acute stroke patients. Much of the imaging and clinical data for the POSH 
study overlapped with the MASIS study allowing elements of each to be 
combined for the work presented. 
Funding for the POSH study was from an award from the Stroke Association 
(awarded July 2006) 
Study Objectives-POSH 
The primary research question was whether there is a difference in the growth 
of irreversibly damaged tissue after stroke between patients in whom blood 
glucose remains normal throughout, in whom blood glucose is increased early 
(within 6 hours of onset), and in whom blood glucose is initially normal but 
increases later (>6 hours after onset). Additional secondary outcomes included: 
1:  Interaction between blood glucose and recanalisation 
2: Interaction between recanalisation and infarct growth 
3: Penumbral salvage according to recanalisation and glucose status 
4: Clinical progression and glucose status 
5: Influence of glucose on death and dependency at day 30 after stroke 
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Patient Selection-POSH 
Acute Stroke patients presenting to the Institute of Neurological Sciences, 
Southern General Hospital, Glasgow within 6 hrs of symptom onset were 
considered for study entry. No study specific procedures were performed 
without written consent was obtained from the patient (or assent from a relative 
if appropriate). All imaging protocols for the POSH study used CT, both at 
baseline and at follow up. If CT CTP and CTA were obtained for clinical reasons 
(meaning at the discretion of the stroke physician dealing with the patient on 
admission), patients were offered participation in the study in retrospect as the 
other information obtained during the first 24hrs of study participation was the 
same as that obtained during routine care for acute stroke and would not have 
altered the information obtained for study purposes. 
Inclusion Criteria: 
1: Clinical diagnosis of acute ischemic stroke 
2: <6 hours after symptom onset 
Exclusion Criteria: 
1. Known non-ischemic stroke diagnosis prior to consent )(e.g. primary 
intracerebral haemorrhage, tumour, subarachnoid haemorrhage, epilepsy) 
2. Known sensitivity to iodinated contrast media (including previous contrast 
reactions or severe asthma) 
3. Inability to lie in a recumbent position for the duration of additional imaging 
(e.g. severe cardiac failure, desaturation on lying flat, high risk of aspiration) 
4. Intercurrent illness likely to limit survival to less than 30 days 
Again only patients seen by a member of the research team on admission (or 
soon after if additional imaging was performed for clinical reasons) were able to 
be entered into the study. Informed written consent was obtained from the 
patient where possible, while assent from the next of kin was obtained if the 
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patient was unable to provide consent (e.g. aphasia). Patients could withdraw 
from the study at any time for any reason and all data collected prior to 
withdrawal was retained. 
Ethical approval for the study was granted by the Scotland A research ethics 
committee on 22nd Feb 2007. Patient and relative information sheets and 
consent/assent forms are attached in the appendix. 
Imaging 
Initial imaging for POSH comprised whole brain non-contrast CT, CT perfusion, 
and CT angiography from the aortic arch to the vertex. Parameters for CT were 
identical to those for MASIS. Follow up imaging was scheduled for 24-48 hrs and 
comprised whole brain non-contrast CT and CT angiography of the intracranial 
vessels only. If no occlusion was seen on the admission CTA and there was no 
clinical suspicion of a new/repeat occlusion, CTA was not performed at 24-48 
hrs. Where the treating clinician requested MRI for follow up imaging for clinical 
reasons (typically performed if minor clinical deficit and normal admission 
imaging), CT/CTA was not routinely requested for study purposes as it was 
considered that MRI would be more likely to reveal the final infarct extent and 
that additional CT imaging in this setting would not necessarily be required.  
Clinical assessment 
Clinical assessment at baseline included NIHSS, OCSP classification and pre-
morbid Modified Rankin Scale. NIHSS was repeated at 24hrs, 72hrs and day 7 
after stroke onset. Clinical outcome following stroke was assessed at day 30 
using the Modified Rankin scale according to a structured questionnaire, along 
with Barthel Index. Clinical measurements of blood pressure, capillary blood 
glucose and temperature were assessed at 4 hourly intervals for 48 hours and 
thereafter at 72hrs and 7 days.   
Concomitant medications including thrombolysis were recorded, but no study 
specific therapeutic interventions were performed for the study.  Blood samples 
specific to the study included HbA1C and a single serum sample frozen and 
stored for future analysis, although other blood samples were taken on most 
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patients as part of routine clinical practice such as blood count, urea and 
electrolyte profile and coagulation profile.   
Data were recorded on a paper case record for each patient which was stored 
locally. Once completed, data from the paper CRFs were transferred to a master 
database in SPSS format locally for analysis. Study procedures are summarised in 
table 3.2 
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Procedure Baseline 
(<6h) 
6-24h 24-
48h 
72h Day 
7 
Day 
30 
Informed consent or 
assent from next of kin 
 
     
Non-contrast CT brain   *    
CT Perfusion       
CT Angiography       
NIHSS   *    
Blood Sample - 
biomarkers 
 
     
Blood sample – HbA1c, 
glucose 
 
     
Blood sample – U&Es   *    
Capillary Blood Glucose       
TCD *      
Modified Rankin Scale       
Table 3-2 POSH Study Calendar 
 Denotes study-specific procedure 
 Denotes clinically routine procedure, data captured for study 
* denotes procedure clinically routine in some patients 
 
3.4 Combined Studies Image Analysis 
Imaging data from each study were used for this thesis as the inclusion criteria, 
baseline CT imaging protocol and clinical follow up showed overlap and 
therefore permitted amalgamation of both datasets relatively easily. Follow-up 
imaging from each study was similar in terms of assessing infarct volume and 
recanalisation at subacute time points (24-72hrs) and as a proportion from MASIS 
had contraindications to MRI, the same imaging modality at follow up was used 
for many patients was used (non-contrast CT and CTA).  All image analysis on the 
combined datasets was performed blinded to clinical information, and therefore 
required anonymization of imaging data prior to analysis. 
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As the focus of the thesis is on CT based imaging in acute stroke, a combined 
database from both studies with CT imaging on admission was compiled, forming 
the bulk of the data presented. 
3.4.1 Image Transfer, Anonymization and Storage 
After imaging data were acquired locally, the raw images in DICOM format were 
transferred to a workstation where interpretation of images was undertaken for 
clinical purposes. A copy of the raw image data were made on the same 
workstation for study purposes, which included a DICOM header specific to that 
patient and imaging time-point so that the images could be identified for future 
use. Patient identifiers from the initial raw data were removed (including name, 
age, date of birth, physician) and were replaced with study specific DICOM 
headers. The programme used for this purpose was Philips Brilliance Workstation 
package. The same procedure was followed for both CT and MRI data after initial 
transfer to the workstation. Imaging data from remote sites for the MASIS study 
was anonymized using the same technique after the raw data were downloaded 
to the workstation from the National radiology archive for Scotland. 
After initial anonymization, a CD copy of each study scan was made which were 
subsequently archived on an external hard drive for storage. The hard drive was 
password protected for security purposes. In addition, all other remaining DICOM 
headers were removed using an additional anonymization tool (Neologica Dicom 
Anonymizer Pro version 1.1.19, www.neologica.it) ensuring that all imaging data 
stored externally had no DICOM headers which could be used to identify the 
patient apart from a study specific DICOM header and date of acquisition. 
3.4.2 Image Analysis  
Different methods used for image analysis will require detailed descriptions 
specific to the relevant chapters, but all scans were processed and interpreted 
by me according to the same method initially in order to classify study recruits 
into different groups according to different characteristics (e.g. perfusion 
deficit, occlusion status, recanalisation, intracerebral haemorrhage). This 
interpretation was performed blinded to treatment and clinical outcome. 
Admission imaging 
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Initial imaging was evaluated beginning with Non contrast CT for the hemisphere 
affected (if any), presence/absence of a hyper-intense vessel sign indicating 
arterial occlusion and for ASPECTS(320). 
CTP was processed next on the proprietary software present in the Philips 
Brilliance brain perfusion module obtained for clinical use in the Neuroradiology 
department of the Institute of Neurological Sciences, Glasgow. Raw data were 
loaded and underwent an automated motion correction. The arterial input 
function was selected manually by placing a region of interest within the 
anterior cerebral artery contralateral to the ischemic lesion, and the venous 
output function was selected after placing a region of interest in the superior 
saggital sinus. Perfusion maps including CBF, CBV, MTT and TTP were 
automatically generated and were interpreted for presence/ absence of 
ischemic lesion on each of the ASPECTS regions (79). After initial qualitative 
analysis of the CTP, thresholds for core and penumbra were applied and 
displayed in a final summary map “penumbragram”. Penumbral pixels were 
defined by those pixels ipsilateral to the stroke lesion with prolonged MTT ≥ 
145% of the normal contralateral hemisphere with normal cerebral blood 
volume. Core pixels were defined as those with prolonged MTT (≥145% of 
normal) but with reduced cerebral blood volume below 2.0ml/100g (131)). As 
core and penumbra were presented visually on each perfusion scan slice, an 
overall qualitative measurement of mismatch was taken (mismatch defined as 
perfusion lesion >20% larger than the core lesion). Volume of core and penumbra 
were also calculated using the total area of core and penumbra according to the 
thresholds mentioned (area measured in mm2) multiplied by the slice thickness 
(5mm). If the processed CTP parameter maps had no obvious perfusion deficit 
present visually (e.g. lacunar stroke, brainstem stroke missed by perfusion slab) 
thresholds were not applied for core and penumbra as this was likely to have 
resulted in false positive volumes for each. 
CT angiography for each patient was evaluated for presence / absence of 
arterial occlusion and if occlusion was present, the arterial segment occluded 
was recorded. CTA source images were reviewed initially from the aortic arch to 
the vertex and each arterial segment was followed proximally to elucidate any 
segments which did not fill with contrast. 3D MIP reformats in saggital, coronal 
and axial planes were reviewed for occlusion site and collateral status. An 
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occlusion was defined as absence of contrast in a vessel which separated the 
proximal portion of the vessel from the distal portion(111), and occlusions were 
classified as extracranial ICA, intracranial ICA, M1 segment MCA, M2 segment, 
M3, ACA and PCA. Circle of Willis anatomy was also recorded. 
Follow-up Imaging 
Presence or absence of a visualised infarct was recorded after assessment of the 
non contrast CT or MRI FLAIR sequence of the subacute imaging scans (usually 
obtained at 24-72hrs). Final infarct ASPECTS was recorded using the same 
method as for the admission scan ASPECTS grading, while presence or absence of 
haemorrhage was recorded , and classified as HI1 (Small patchier along margins 
of infarct) ,HI2 (more confluent patchier within the infarcted area), PH1( blood 
clot not exceeding 30 percent of the infarcted area with some mild space 
occupying effect) and PH2(dense blood clot/clots exceeding 30 percent of the 
infarcted area with significant space occupying effect)(44). 
Follow up CTA or MRA were evaluated for change in the appearance of the 
baseline occlusive lesion. Again, source angiographic data were viewed initially 
followed by MIP images in 3 planes as before. Recanalisation was determined by 
comparing the initial and follow up angiographic appearances which were 
measured using an adaptation of the TIMI score; TIMI 1=no recanalisation, 2= 
minimal recanalisation, 3=partial recanalisation, 4=complete recanalisation.  
Additional Imaging Platform: MIStar 
In addition to the baseline characterisation of each patient described above, 
further imaging analyses were undertaken which required an alternative imaging 
platform which permitted image co-registration, evaluation of a variety of 
different perfusion thresholds, volumetric measurement of infarct volumes, and 
dynamic interpretation of raw CTP data to confirm the direction of collateral 
blood flow distal to arterial occlusions. A licence for the imaging platform was 
obtained in April 2010, after I received initial training in its use during a 6 week 
visiting fellowship to the John Hunter Hospital, Newcastle, New South Wales 
Australia under the Supervision of Dr Mark Parsons in November/December 2009. 
MIStar is a software package that provides manipulation, visualization and 
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processing of medical images in a diagnostic imaging setting, and was used for 
the majority of image analysis covered in this thesis. A number of different 
modules were available for use including a stroke module designed for CTP 
processing using a fully deconvolved methodology and a fusion tool permitting 
accurate co-registration of subacute imaging with CT/MRI to CTP raw data and 
interpolating the follow up images to match the orientation of the CTP scan.  An 
ROI tool was also available which permitted manual drawing or semi-automated 
generation of ROIs to map out areas of interest such as infarct extent with an 
automated calculation of lesion volume as needed. These ROIs could be copied, 
saved for future use, and transposed to images different to those on which they 
were originally obtained. Exact descriptions are provided in later chapters. The 
MIStar interface screen is shown for descriptive purposes in figure 3.1 
 
Figure 3-1 MIStar Interface 
MIStar stored imaging files for analysis in the format shown above. Anonymized scans could be 
highlighted and examined in a variety of image processing modules accessed from the icons on the 
top right of the screen. Data characteristics from each slice are shown in the bottom third of the 
screen 
3.5 Conclusion 
Data included in this work were obtained from two observational studies into 
acute stroke which were undertaken at the Institute of Neurological Sciences 
during my research fellowship based there and at the University of Glasgow from 
February 2009 to August 2011. As a member of the stroke research team, I was 
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involved in many different aspects of each study, including patient screening, 
obtaining informed consent/assent, performing clinical assessments, requesting 
imaging procedures, maintenance of paper and electronic case record forms and 
imaging data transfer, anonymization and storage prior to analysis. All image 
analysis was performed by me after appropriate training both locally and 
abroad. Other members of the research team locally and in other centres made 
major contributions to each study, the end result of which resulted in a 
relatively large population of acute stroke patients with imaging data available 
for examination in the upcoming chapters of this thesis. The two studies used 
had several similar characteristics such as inclusion and exclusion criteria, 
baseline imaging protocols for multimodal CT, clinical information and follow up 
permitting the amalgamation of much of the data from the two studies for 
analysis. 
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Chapter 4. Feasibility of Imaging Based Study 
Recruitment 
4.1 Introduction 
Advanced brain imaging with either MRI or multimodal computed tomography CT 
offers the potential to select specific treatment strategies for individual patients 
based on the volumes of irreversibly damaged core tissue and tissue with 
characteristics of the ischemic penumbra (131, 143). Although further validation 
of the imaging based targets for therapy is required, a number of stroke trials 
and open label studies have used advanced imaging techniques, predominantly 
using MRI in order to identify patients with specific imaging patterns prior to 
therapy or to measure imaging findings such as reperfusion, recanalisation or 
infarct growth as potential surrogate markers for outcome(47, 48, 51, 154). Most 
of these studies have focussed on acquiring, but not necessarily interpreting MR 
imaging prior to trial entry and have shown several findings supportive of the use 
of additional imaging for trials in acute stroke. The DEFUSE Study showed that 
early reperfusion was associated with clinical benefit in those with 
perfusion/diffusion mismatch, but that reperfusion was not beneficial in those 
without mismatch (153). The DIAS I trial showed that dose dependant 
reperfusion after desmoteplase was correlated with clinical outcome in patients 
selected on the basis of pre-defined perfusion/diffusion mismatch while the 
DEDAS trial suggested efficacy of Desmoteplase at a dose of 125micrograms/litre 
in stroke patients with perfusion and diffusion mismatch(48, 321). EPITHET 
suggested that alteplase was associated increased reperfusion in patients with 
PWI/DWI mismatch between 3 and 6 hrs after stroke onset compared with 
placebo and that reperfusion was correlated with improved clinical outcome, 
although no clear effect on infarct growth was seen (154).   
These studies confirm that MRI measures such as mismatch between infarct core 
and potentially salvageable penumbral tissue are attractive (if not yet uniformly 
defined) therapeutic targets which can be visualised using MRI, and that imaging 
findings before and after therapy may correlate with response to therapy. 
However some limitations of these studies should be considered; MRI was not 
reviewed prior to entry to the EPITHET study partly due to slow post processing 
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which would have caused unacceptable delays in treatment even after the 
additional imaging was performed. Recruitment to most MRI based trials in acute 
stroke has been restricted to a relatively small number of expert centres with 
sufficient resources to perform such studies. Despite adequate resources in 
terms of imaging availability and staff, rates of patient recruitment to these 
trials have been slow in comparison to earlier trials of rt-PA which required only 
non contrast brain CT at entry, although time window and entry criteria varied 
between different trials and observational studies which could also influence 
recruitment rate. A recent study using multimodal CT based selection criteria 
prior to randomisation to IV tenecteplase or alteplase has demonstrated the 
excellent potential for CT based trial recruitment with high recruitment rates 
even with a very specific imaging target(52) .Importantly, this study required 
interpretation of imaging prior to randomization and mean time from symptom 
onset to treatment administration was rapid, demonstrating that time taken for 
multimodal CT acquisition and interpretation is not a barrier to rapid treatment 
or to trial participation. However the centres recruiting to this study were large 
centres with extensive experience in use of multimodal CT, and still the 
proportion of patients recruited was just 3% of those screened, reflecting 
inherent barriers to recruitment including the pre-specified imaging criteria. 
This finding highlights the importance of centres with high volumes of stroke 
admissions as well as experience in advanced imaging interpretation when 
designing such trials. Recruitment rates for trials and observational studies of IV 
thrombolysis and their different imaging requirements are shown in figure 4.1
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Study Modality Time 
Window  
(h) 
Duration 
(years) 
Participati
ng 
Centres 
Number 
recruited 
Crude 
Rate per 
centre per 
year 
Mean Age 
 
Median 
NIHSS 
 
EPITHET MRI 3-6 7 15 101 1.0 71.6 13 
DEFUSE MRI 3-6 4 7 74 2.6 70.9 11.5 
DEDAS MRI 3-9 2.6 25 37 0.6 73* 11 
DIAS MRI 3-9 2.7 44 104 0.9 68* 12 
DIAS II CT/MRI 3-9 1.7 52 186 2.1 71 9 
NINDS CT 0-3 3.7 43 624 3.9 67-69† 14-15† 
ECASS CT 0-6 1.5 75 620 5.5 65-66† 12-11† 
ECASS II CT 0-6 1.3 108 800 3.2 68† 11† 
ECASS III CT 3-4.5 4.3 130 821 1.5 65-66† 9-10† 
TNK- 
NEJM 
CT/ CTP/ 
CTA 
0-6 3 3 75 8.3 68-72 14.4Ώ 
Table 4-1 Recruitment Rates of Trials and Observational Studies of Thrombolysis using CT or MRI 
Key characteristics of randomised trials and observational studies of IV thrombolysis and imaging modality are demonstrated, including crude recruitment rates. Trials 
using imaging selection for Intra-arterial therapy are not included as additional factors such as restricted access to IA therapy are additional barriers to recruitment to 
these studies.* Median age, † Placebo and treatment groups, Ώ Mean NIHSS, 
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Designing clinical trials which select patients with specific occlusion subtypes or 
perfusion patterns are likely to result in a more homogenous study population 
which will have the advantage of reduced sample size requirements in order to 
prove a beneficial effect of the agent being investigated(20). This benefit could 
be offset by higher numbers of screening failures due to more stringent inclusion 
or exclusion criteria, while the practical difficulties of obtaining and processing 
additional imaging before deciding on eligibility represents another potential 
recruitment barrier. An additional consideration for trial design is that the 
choice of imaging modality may also affect the ability to recruit patients. This 
may be the case as those with contraindications to undergo MRI may differ from 
those without, while the centres recruiting may also be different depending on 
the availability of different imaging modalities. 
Multimodal CT is generally more widely accessible than MRI, is better tolerated 
with shorter acquisition times, and has fewer contraindications although renal 
impairment and hypersensitivity to contrast material may preclude additional 
imaging with CT and excessive radiation dose is a concern(116). The limited 
brain coverage offered by most CTP protocols is also a limitation compared to 
MRI, although whole brain coverage may eventually become available (114). 
While multimodal CT imaging may provide information similar to that obtained 
with MRI in acute stroke, it has been less frequently studied as an entry 
selection criterion (47). 
 Better understanding of the impact of imaging biomarker selection on key 
factors such as recruitment rates and study population characteristics is needed 
to aid the design of future therapeutic trials. These issues were therefore 
investigated prospectively as part of the MASIS study comparing acute CT and 
MRI as initial imaging modalities in acute stroke. 
Some of the content of later chapters will be focussed on the validation of CT 
thresholds for core and penumbra which would be important for trial selection 
criteria. Initially however the question of whether there is a need for 
multimodal CT imaging for trial purposes was examined using data from the 
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MASIS study, which was designed in part to compare advanced MR and CT-based 
techniques for imaging in acute stroke. This chapter will examine the feasibility 
of performing each modality in the acute time window after stroke, as well as 
the difficulties encountered in obtaining imaging based outcomes a at different 
time points after stroke and will argue that imaging with multimodal CT could be 
used to expand the number of patients potentially entered into imaging based 
stroke trials. 
4.2 Methods 
Feasibility of imaging with CT and MRI at different time-points was examined as 
part of the MASIS study. Recruitment, study protocol, ethical approval and data 
collection was described in chapter 3. In summary, acute stroke patients 
admitted to the three participating stroke centres between August 2008 and 
March 2010 were prospectively screened for recruitment to MASIS, an 
observational study examining clinical, imaging and blood biomarkers of 
salvageable tissue and outcome after ischemic stroke. Each site had access to 
MRI scanners with the ability to perform stroke imaging including DWI, PWI, 
FLAIR, GRE and MRA, and multimodal CT including non contrast brain CT, CT CTA 
and CTP (CTP/CTA was unavailable in Aberdeen for the first 18 months of the 
study meaning MRI was the exclusive imaging modality at this site for the 
majority of the recruitment period). Acute imaging was performed within 6 
hours of symptom onset, and thereafter was scheduled for 72 hrs and 30 days. 
Acute imaging could be with either CT or MRI, whichever was available, while 
follow-up imaging was with MRI unless there were contraindications or MRI was 
not available.  
Screening logs were maintained at each study centre in order to document 
reasons for inclusion or exclusion of patients from study participation after 
initial screening. As the aim was to recruit equally with CT and MRI after 
admission, the reasons for choosing one modality over the other were recorded 
prospectively. If both CT and MRI were equally available, MRI was the default 
imaging choice. As scans were obtained for research purposes, they were not 
routinely evaluated to aid decision making on acute management including 
thrombolysis unless specifically requested by the treating physician 
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All clinical and imaging data from the three sites were examined together after 
the last patient follow up was completed and data were entered into the online 
database. Imaging modality used per time point (CT or MRI) and the reasons for 
each were documented. Clinical characteristics examined included age, sex, 
smoking status, alcohol intake, stroke risk factors, pre-morbid modified Rankin 
scale, medication history, NIHSS, OCSP, blood pressure, body temperature and 
hemisphere affected.  Clinical characteristics of those imaged using CT or MRI on 
admission were compared using the t-test and Mann-Whitney test for normally 
and non-normally distributed variables respectively. Associations between 
categorical variables were assessed using the chi-squared test.  
4.3 Results 
Patient screening commenced on 21/04/2008 and completed on 31/03/2010, 
with the last patient follow-up performed in June 2010. 360 patients were 
screened as potential study recruits within the time period, and informed 
written consent or assent for study participation was obtained from 93.  Reasons 
for non study participation were: 
1: Refusal of consent (n=17) 
2: Recruitment to other study (n=52) 
3: Unknown (n=5) 
4: Non ischemic stroke diagnosis (n=69) 
5: >6hrs from symptom onset (n=36) 
6: Renal failure (n=7) 
7: Medical co-morbidities (n=3)  
8: MRI incompatible (n=16) 
9: MRI unavailable (n=9) 
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10: Research staff unavailable (n=50) 
11: Comatose (n=4) 
12: Onset time unclear (n=8) 
13: Incorrect diagnosis on admission (n=1) 
Study recruitment is summarised in Figure 4.1, with screening log data from 
each site summarised in table 4.2. 
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Figure 4-1 Flowchart for Recruitment to MASIS Study 
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 Aberdeen 
 
Edinburgh Glasgow 
 
All 
Screened 45 185 130 360 
Consented to 
study  
12 42 39 93 
Completed 
Study 
8 37 38 83 
Refused 
consent 
3 3 11 17 
Other Study 0 5 47 52 
Unknown 1 3 1 5 
Non ischemic 
stroke 
4 37 28 69 
>6hrs 0 34 2 36 
Renal Failure 0 6 1 7 
Co 
morbidities 
0 2 1 3 
MRI 
incompatible 
9 6 1 16 
MRI 
unavailable 
9 0 0 9 
Staff not 
available 
10 40 0 50 
Coma 0 4 0 4 
Onset time 
unclear 
0 8 0 8 
Incorrect non-
stroke 
diagnosis on 
admission 
0 1 0 1 
Table 4-2 Screening Failures for Study Participation in MASIS 
Reasons for failure to recruit after screening in each site are shown. The reasons varied 
considerably between sites which likely reflects differences in imaging availability at each site, but 
also different practices for screening and recruiting patients which limits what conclusions can be 
drawn from the study on feasibility of imaging based study recruitment 
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As consent was obtained prior to performing study-specific imaging, some 
patients who had provided written consent in fact had a non-ischemic stroke 
diagnosis. These included:  
1: Primary intra-cerebral haemorrhage (n=4)  
2: Migraine with focal neurological deficit (n=2) 
These 6 patients were recruited but withdrawn from study participation 
thereafter when the correct clinical diagnosis was confirmed. One patient 
recruited locally in Glasgow became claustrophobic prior to acquisition of study 
imaging with MRI acutely and chose to withdraw from study participation 
immediately. 3 patients consented to the study in Aberdeen but could not 
tolerate MR imaging due to: 
1: Claustrophobia (n=1)  
2: Body habitus (n=1) 
3: Inability to tolerate MRI scanner noise (n=1)  
After removal of these 10 patients unable to participate despite providing 
written consent, a total of 83 eligible patients remained in the study for the 
final analysis.  
There were 50 males and 33 females recruited to the study, with a mean age of 
70 years (SD 14). 18 (22%) had a previous diagnosis of stroke, 54 (65%) had 
hypertension, 23 (28%) had atrial fibrillation and 28 (33%) had previous ischemic 
heart disease. Median NIHSS on admission was 7 (Range 1-30) with a mean NIHSS 
of 9.8 (SD 7.52). In terms of OCSP classification, 20 (24%) had TACS, 42(51%) 
were PACS, 6(7%) were POCS and 15 (18%) were LACS. 31 (41%) received IV rt-PA 
with a further 2 randomized to the control arm of the IST3 study(322). 
4.3.1 Acute Imaging 
Baseline imaging was with CT for 63 (76%) and with MRI for 20 (24%) patients, 
rather than the target of equal distribution between both modalities. For those 
119 
imaged using CT at baseline, MRI was unavailable (38, 60.3%) was 
contraindicated (9, 14.3%) or an exact reason was not documented (16, 25.4%). 
Patients imaged with CT or MRI on admission did not differ in most baseline 
characteristics including stroke risk factors, medications, and blood pressure. 
However, those who were imaged acutely with MRI differed from those imaged 
with CT in respect of some characteristics: 
1: Younger age.  Mean age for MRI group = 65 years (SD 15) Mean age for CT 
group =72 years (SD 11), p=0.024 
2: Pre-morbid disability. Pre-morbid mRS was 0 for 19/20(95%) of MRI group and 
35/63 (56%) of CT group, p=0.0013)  
3: Non dominant hemisphere stroke location. Right hemisphere strokes 
accounted for 13 (72%) of the MRI group and 15 (33%) of the CT group, p=0.0041) 
Differences in groups depending on admission imaging modality are summarised 
in table 4.3. 
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Parameter 
 
Baseline MRI Baseline CT P 
Age, years,  
mean (SD) 
64.7 (14.9) 71.9 (11.4) 0.024 
Male Sex 14 (70.0%) 36 (57.1%) 0.31 
Smoking Status  
Never 8 (40.0%) 24 (38.1%) 0.57 
Ex-smoker 5 (25.0%) 23 (36.5%)  
Current  7 (35.0%) 16 (25.4%)  
History  of 
Previous Stroke 
5 (25.0%) 13 (20.6%) 0.58 
Hypertension 13 (65.0%) 41 (65.1%) 0.99 
Diabetes 1 (5.0%) 8 (12.7%) 0.52 
Atrial Fibrillation 4 (20.0%) 19 (30.2%) 0.38 
Ischemic Heart 
Disease 
5 (25.0%) 23 (36.5%) 0.48 
Pre-morbid Modified Rankin Scale  
0 19 (95.0%) 35 (55.6%) 0.0013 
1 1 (5.0%) 10 (15.9%)  
2 0 (0%) 11 (17.5%)  
3 0 (0%) 6 (9.5%)  
4 0 (0%) 1 (1.6%)  
NIHSS on 
admission, mean 
(SD) 
8.0 (6.0) 10.3 (7.9) 0.22 
Right 
Hemisphere 
Affected 
13 (72.2%) 15 (32.6%) 0.0041 
Table 4-3 Comparison of Clinical Characteristics Between Patients Imaged Using CT or MRI 
on Admission for MASIS 
MASIS patients imaged at baseline with MRI were more likely to have non dominant strokes, had 
lower pre-morbid Rankin scales and were younger than those imaged with CT. The Students t test 
and Mann Whitney U test were used for testing differences between continuous and categorical 
variables, respectively. 
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4.3.2 Subacute Imaging 
At 72hrs most patients (n=60, 72.3%) were able to undergo imaging with MRI as 
planned in the study protocol. A subset of patients (n=16, 19.3%) had imaging 
with CT rather than MRI and 7 patients (8.4%) had no imaging performed at this 
time-point. Reasons for MRI not being performed at 72hrs included: 
1: MRI contraindicated n=10 (12%)  
2: MRI scan unavailable n=5 (6.3%) (e.g. due to administrative reasons or scanner 
malfunction) 
3: Death n=3 (3.6%) 
4: Transfer to another hospital for rehabilitation n=2 (2.4%) 
5: Patient refusal of MRI scanning n=3 (3.6%) 
4.3.3 Day 30 Imaging 
Day 30 imaging with MRI was performed in just over half of the eligible patients 
recruited to the study (n=44, 53%). Reasons for study imaging not being 
performed included: 
1: Patient refusal of further imaging n=10 (12%) 
2: Transfer to another hospital for rehabilitation n=11 (13.4%),  
3: Death n=8 (9.6%) 
4: MRI incompatibility /contraindications n=10 (12%) 
Study imaging at each time point is summarised in Figure 4.2 
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Figure 4-2 Imaging Acquired at Each Study Time point 
Most patients at study entry had CT based imaging, with the majority being imaged with MRI at 72 
hours. A high proportion did not have day 30 imaging. 
 
4.4 Discussion 
This analysis highlights some important issues regarding the practicality and 
feasibility of performing multimodal imaging with CT and MRI for research or 
trial purposes. Trials or open label studies of thrombolysis in the later time 
window after stroke which predominantly used MRI for case selection at baseline 
have had low overall recruitment rates from a smaller number of centres when 
compared to trials that used only non-contrast CT. This suggests that choice of 
imaging modality and acquisition of additional information beyond what is 
obtained with plain CT alone may be at the expense of the ease with which trials 
in acute stroke can be conducted. While other factors such as service changes 
over time and differing inclusion and exclusion criteria will also affect study 
recruitment, complexity of image acquisition can have a major influence on 
recruitment rate as evident in the recruitment rates of EPITHET and ECASS III 
which both studied alteplase in the extended time window but with different 
imaging protocols. Acute stroke trials and studies inevitably involve patients who 
are potentially clinically unstable and therefore additional imaging must be both 
safe and acceptable for the patients involved. 
The present results confirm that limited access to MRI may be a major barrier to 
stroke trial recruitment. This is despite specific research funding and research 
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dedicated MRI scan time at each of the participating sites. Limited MRI access 
may be seen solely as an administrative barrier which reflects local 
circumstances and resources, but the limited number of sites capable of 
recruiting to other trials that select on the basis of complex imaging suggests 
that this is actually a widespread issue for acute stroke trials employing MRI as 
the imaging method of choice. Many patients remain unable to undergo MRI 
scanning due to relatively common contraindications such as metallic heart 
valves, pacemakers and claustrophobia. Even if MRI access was equal to that of 
CT, clinical instability and presence of hypoxia in acute stroke patients 
represent additional limiting factors for MRI given the longer time required for 
image acquisition(172). The MASIS study confirms that contraindications to MRI 
alone prevent imaging in a proportion of patients, similar to that reported 
previously (14%)(323). This finding has implications for trial design as a sizeable 
portion of otherwise eligible patients would be excluded from trials selecting on 
the basis of MRI findings alone(323). By comparing patients recruited with CT 
and MRI, this study has shown that the imaging modality chosen to select 
patients for research studies may directly influence the population recruited, 
with those imaged with MRI on admission being younger, more likely to have a 
non-dominant hemisphere stroke, and having less pre-morbid disability than 
those able to undergo multimodal CT examination using the same inclusion 
/exclusion criteria and time window. Although these results could just reflect 
investigator bias in selection of imaging modality, it is also consistent with 
reduced tolerability of longer examination times for MRI by older and more 
disabled patients, and, if representative of wider clinical practice, would 
restrict the generalisability of the results of randomised trials of treatments 
based on MR selection criteria to a younger and less disabled population than 
what would be representative of most stroke patients. No previous clinical study 
has compared imaging modality in a randomised manner and most insisted on 
either CT or MR but did not allow both freely. Indirect comparisons of trial 
reports do not identify any consistent difference in age or clinical stroke severity 
where MRI rather than CT selection has been used (Table 4.1). However DIAS II, 
the only trial that allowed recruitment based on either multimodal CT or 
multimodal MRI found significantly greater stroke severity in terms of NIHSS 
among CT-selected patients compared to MRI-selected patients, among other 
differences such as mismatch volume (47). Patients recruited to DIAS II with MRI 
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also had a trend towards younger age also but no statistically significant 
difference was detected.  It is therefore possible that, in addition to restricting 
generalisability of overall trial results, imaging modality for patient selection 
will in itself systematically influence trial population characteristics and in turn 
potentially impact upon key parameters such as rates of favourable clinical 
outcome. These outcome measures are used to prove therapeutic effect and are 
determinants of sample size calculations. These results suggest that a greater 
proportion of patients, with a wider range of stroke severities and greater pre-
morbid disabilities, more reflective of the complete range of patients that 
experience a stroke, are able to undergo multimodal CT compared to MRI within 
6 hours of symptom onset. Based on these results, the recruitment rate for a 
trial with multimodal CT selection might be as high as 3-fold greater than for 
one based on MRI alone. 
However, while minimising barriers to trial participation is important in order to 
maximise study participation, recruitment rates are not the only parameters of 
relevance in trial design and other important issues require discussion when 
considering multimodal CT as part of research and clinical imaging protocols. 
Limited brain coverage by the majority of CTP scans relative to that covered by 
MRI means that the volume of tissue covered per scan must be chosen manually 
at the time of scanning and even if the perfusion scan is appropriately located, 
volumes of core and penumbra or mismatch tissue which are present outside the 
reaches of the perfusion slab will inevitably be missed with a possible influence 
on penumbra volume or mismatch ratio for that patient. The definitions for core 
and penumbra on CT as well as the acquisition parameters used to obtain and 
process CTP scan are not yet agreed and there has been heterogeneous image 
acquisition in many CTP studies (168). Imaging with CTP and CTA requires 
exposure to ionizing radiation when screening patients for a trial based on 
utilising multimodal CT, requiring consent /assent for this exposure prior to 
scanning. Reports of excessive radiation dose with CTP with disfiguring 
consequences could conceivably influence patient choice, emphasising the need 
to standardise how scans are obtained (324). The requirement for administration 
of iodinated contrast materials restricted in patients with renal impairment, 
known contrast hypersensitivity, or diabetes are other important considerations 
(325).  
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These findings are consistent with previously published results where the use of 
late imaging time-points for determining infarct volume was associated with 
patient drop-out (157). The reasons for patient drop-out were diverse and some 
(death, transfer to remote rehabilitation facilities) will affect trials regardless of 
imaging modality used. Patient refusal however, accounted for a high proportion 
of the numbers lost to follow-up in the MASIS study, and it appears that this is 
more commonly a problem with MRI for reasons such as claustrophobia and 
scanner noise. The high proportion able to be imaged at 72h supports the benefit 
for trials of using a subacute time-point for determining imaging outcome 
biomarkers since delaying until day 30 (or later) would require larger sample 
sizes to compensate for losses to follow-up which may in turn bias results as 
larger infarcts may be more likely to result in death prior to imaging at late time 
points. Using subacute imaging as an imaging outcome has some limitations; for 
example lesion swelling may result in overestimation of infarct volume in the 
first week in some patients(326), and some trials have used even later imaging 
time points to measure infarct volume(154).  Use of an earlier imaging outcome 
this is likely to represent a reasonable compromise between accuracy of infarct 
volume measurement and ability to obtain useful study imaging because of 
patient drop out. This approach is supported by recent research suggesting that 
earlier time points for measuring infarct volume correlate well with later time 
points and therefore could represent an appropriate end point for trials 
measuring infarct volume. Therefore subacute imaging (i.e. 3-6 days) post stroke 
appears to be a time point which could be used for measuring infarct volume 
after stroke (156). Even earlier endpoints could potentially be used, as acute 
and subacute DWI lesions have been shown to be similar in patients with major 
reperfusion, but comparison of these to an accepted gold standard has yet to be 
performed (134).  
Where imaging selection or analyses have been used in acute stroke studies, a 
single imaging modality has generally been used both on admission and at follow 
up. The data presented indicate that a flexible approach using acute CT on 
admission with follow up MRI is perhaps the most feasible approach. A 
combination of acute CT and follow-up MRI for study design could permit 
penumbral imaging rapidly and safely, but also allow infarct volumes to be 
measured accurately on FLAIR (156). When Multimodal CT was used to select 
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patients for trial entry for patients recruited to DIAS II, CT was also used for day 
30 imaging outcome on this patient group (47). CT can be used to measure 
infarct volumes (327), although MRI if available has some advantages over CT 
including infarct delineation (328).  
Using the same image modality throughout has advantages for image analysis in 
terms of calculating changes in lesion extent over time. Measurement of infarct 
growth from baseline to the final outcome measurement can be determined by a 
simple calculation of the difference between two volumes at different time 
points (e.g. final infarct volume on FLAIR – acute DWI volume = infarct growth 
(154)). As CTP has only limited brain coverage, simple measurements of the 
differences in CTP defined core and final infarct volume may reflect changes in 
brain coverage between scans rather than true evolution of infarct volume, 
meaning such simple calculations could be misleading.  CT and MRI can however 
be combined in a relatively straightforward fashion by co-registration, placing 
acute and follow up imaging pixels into the same anatomical space for accurate 
measurement of outcome in tissue covered by the CTP slab. With imaging 
software this step can be performed easily permitting the combining of different 
modalities for trial purposes. Image co-registration may be required even when 
using MRI alone at each time point as has been highlighted in a reanalysis of the 
EPITHET trial results suggesting this image processing step is likely to be 
required regardless of image modality chosen at baseline and follow up (329). 
This fact implies that additional image post-processing is needed in determining 
tissue outcome and therefore combining imaging modalities is not necessarily a 
barrier to using a combination of image modalities. Other studies have 
demonstrated that Acute CT and follow up MRI can be relatively easily combined 
for these purposes (51).  
Some limitations of this study do however limit the conclusions which can be 
drawn. Lack of success in recruiting using MRI acutely is likely to have been 
affected by treatments received by the patients acutely. Institutional protocols 
at each site required CT prior to thrombolysis, meaning any potential study 
recruit would have had CT rather than MRI acutely. This suggests that each site 
could have a bias towards obtaining CT initially despite each site having 
dedicated research slots and staff for MRI. Furthermore, the number of patients 
screened per site, as well as the different recruitment patterns suggests that 
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study recruits were not identified in the same way at each site. This also limits 
conclusions based on the overall cohort. In particular the clinical differences 
observed between MRI and CT based study recruits may reflect this bias, 
although the fact that the findings replicate previous work make it worthy of 
ongoing evaluation. Accessing MRI was more problematic for later time points 
with a high degree of drop out for late imaging, suggesting MRI at late time 
points as a measure of radiological outcome has clear limitations.    
4.4.1 Conclusion 
One of the purposes of the MASIS study was to explore the feasibility of 
obtaining advanced imaging for research purposes by adopting a flexible 
approach to image acquisition on admission and at follow up. The results suggest 
that acute stroke imaging with perfusion and angiography is generally more 
feasible using CT rather than MRI, but that follow up MRI can generally be 
obtained, particularly in the subacute time window after stroke. MRI was 
contraindicated in a proportion but limited availability was also an important 
factor which has implications when planning imaging based trials . 
These results, along with DIAS II (47) which used both CT and MRI suggest that 
patients recruited on the basis of MRI alone may not be reflective of the wider 
stroke populations and this could limit the applicability of results from these 
studies on wider clinical practice. A number of patients were unable to have MRI 
follow-up at later time points which included a proportion of patients who 
refused MRI because of tolerability issues, although some loss to follow up would 
have occurred regardless of imaging modality. Subacute MRI, which was more 
feasible than day 30 imaging, may therefore have important advantages for 
trials that employ an imaging outcome marker.  
As acute multimodal CT imaging is likely to be more feasible than MRI for acute 
stroke trials, further study of CT CTP and CTA will help validate its use for trials 
and for clinical practice. 
128 
Chapter 5. Quantifying Collateral Flow Extent in 
Acute Ischemic Stroke 
5.1 Introduction 
Chapter one reviewed the evidence for therapeutic interventions in acute 
ischemic stroke which, considering the burden of disease and research activity 
remain relatively limited, focussing on techniques to recanalize occluded vessels 
with intravenous or intra-arterial rt-PA, or with mechanical clot removal. 
Additional therapeutic options focussing on neuroprotection have not shown 
benefit in clinical trials despite promising experimental data (20). The reasons 
proposed for the failure of neuroprotective agents are numerous, with trial 
design being a consistent reported explanation, as the heterogeneity of patients 
recruited in trials may mask a subgroup(s) who may have benefited. 
Identification of these specific patient subgroups with the use of additional 
imaging may be one way to improve trial design. Poor collateral blood flow has 
been suggested as an additional explanation for failure of neuroprotectants due 
to limited delivery to the site of action. While this is likely to be an overly 
simplistic view due to the fact that neuroprotectants should eventually reach a 
site of action if any residual flow is present, it has been one of the reasons 
suggested for considering collateral flow adequacy in trial design. In addition, 
collateral flow to the area served by an occluded vessel via a developed 
collateral circulation may also be associated with reduced severity of ischemia in 
that area.  Residual perfusion distal to an occluded vessel varies between stoke 
patients, which may explain to a degree why successful recanalisation does not 
result in the same outcomes despite being treated in a similar time 
window(330).Recanalisation may be futile if parenchymal tissue distal to an 
occlusion has insufficient flow to prevent tissue infarction, therefore strategies 
which could augment collateral flow are of potential clinical relevance.. 
Improved understanding of the factors which determine collateral flow adequacy 
is likely to be needed in order to use collaterals as a therapeutic target. The 
importance of collateral flow is shown by the fact that despite a variety of 
imaging modalities and techniques used to grade collaterals, the presence of 
good collateral flow corresponds to direct or indirect markers of good outcome 
as discussed in Chapter 2. Most of these methods have been qualitative 
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assessments of collateral flow extent in the ischemic territory or hemisphere, 
only some of which had inter-observer agreement documented. In addition the 
factors which govern collateral flow recruitment have been less well evaluated.  
Efforts to augment collateral flow are already the focus of clinical trials 
focussing on partial occlusion of the abdominal aorta in an effort to enhance 
cerebral blood flow although a benefit has yet to be clearly demonstrated(240, 
331). Additional potential interventions to augment collaterals include 
vasodilation and induced hypertension although the evidence that these 
interventions have a meaningful impact on collaterals or clinical outcome is 
limited (332, 333). Factors which could negatively affect collateral flow extent 
have been suggested such as congenital anatomy variation, dehydration, 
hyperthermia, hyperglycemia, increased blood viscosity, systemic infections, 
pulmonary compromise, cardiac failure, renal dysfunction, antihypertensive 
agents , and widespread intracranial atherosclerosis, but there is no direct 
evidence thus far to support the interaction between these and collateral 
adequacy and they remain therefore speculative associations (237).  
Before collateral flow can be targeted for therapeutic effect in stroke, improved 
understanding of the mechanisms which govern collateral recruitment is needed. 
Research up to this point has sought to evaluate the impact of collateral flow 
using multiple different imaging modalities and suggests collateral flow confers a 
benefit although uncertainties remain regarding the methods for grading 
collaterals and their absolute impact. Markers for collaterals have not been 
previously studied in detail. Some factors have been associated with collateral 
flow extent, including pre-morbid medication with statins (234) and with time 
taken from symptom onset(301). These potential influences have not previously 
been evaluated for impact on collateral flow in independent populations which 
may limit the emphasis that can be placed up on them at present. Further 
understanding of the potential influences on collateral flow and agreement on 
how it should be measured are likely to be needed to further any therapy aimed 
at improving collateralisation, or even to incorporate collateral adequacy into 
decision making processes such as therapy in the extended time window. The 
aims of this chapter therefore are as follows: 
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1: To derive a novel grading scale for measuring collateral flow extent in acute 
hemispheric stroke. 
2: To demonstrate intra-observer reliability of the grading scale. 
3: To use the grading scale to demonstrate the impact of collateral flow on 
clinical and imaging markers of outcome after stroke 
4: To examine baseline clinical characteristics and blood biomarkers of patients 
with good and reduced collateral flow to evaluate which, if any, are associated 
with collateral flow extent. 
Blood biomarkers for collateral flow have yet to be identified. Although serum, 
plasma and DNA were obtained from recruits to MASIS, only serum was obtained 
and stored for patients recruited to POSH, therefore a specific blood biomarker 
applicable to the combined study recruit cohort was not analysed for association 
with collateral flow. All patients did however have blood testing for clinical 
purposes on admission to hospital which included fibrinogen as part of a 
coagulation blood assay. Blood fibrinogen has been suggested as a potential 
marker for collateral flow in a single publication by Lee et al where lower 
fibrinogen measurements were associated with presence of a dominant posterior 
cerebral artery ipsilateral to an occluded middle cerebral artery (334). This sign 
has been suggested by the authors as a marker of flow from posterior to anterior 
circulation via leptomeningeal collaterals. Blood fibrinogen levels have also been 
associated with poorer outcomes following stroke and methods to reduce 
fibrinogen have been studied in a number of randomized clinical trials, although 
these have not examined collateral flow specifically (335, 336).  In the absence 
of other candidate biomarkers and with the suggestion of an association between 
fibrinogen and collaterals, blood fibrinogen was examined for any association 
with collateral flow extent. 
5.2 Quantifying Collateral Flow Using Multimodal CT 
Imaging. 
Although catheter angiography is often considered the gold standard for 
assessing vascular anatomy and therefore collateral flow extent (40), its use is 
131 
generally restricted to a smaller number of adequately resourced institutions 
while the patients undergoing angiography may have contraindications to IV rt-
PA, meaning collaterals measured by angiography may not be generalisable to 
other patient populations. CT is more widely available and non-invasive and 
although lack of dynamic information with CTA is a potential limitation(113), the 
use of raw CTP data to confirm the retrograde direction of collateral flow is 
complementary to the anatomical detail of CTA(111). Not all patients who have 
previously had collaterals graded using CTA had a documented arterial occlusion 
meaning that the extent to which flow in ischemic territory was truly collateral 
or not is debatable. Using anatomical grading scales of collaterals in the setting 
of lacunar stroke for example may be misleading and conclusions derived from 
collateral measurements without visualised occlusions need to be viewed with 
caution. All previous methods using CTA graded collateral flow extent 
qualitatively. 
Given the lack of consensus regarding collateral flow grading, the opportunity to 
explore a novel method for collateral measurement was taken. 
5.3 Inclusion Criteria 
The combined databases from MASIS and POSH studies comprising patients who 
underwent multimodal CT imaging on admission to hospital were used to 
evaluate collateral flow. For consistency in methodology, only those patients 
imaged with CT at study entry to MASIS were considered for inclusion. Overall 
study inclusion criteria, recruitment, consent, imaging protocols, anonymization 
and clinical assessments for POSH and MASIS are described in Chapter 3.  
Patients selected for collateral flow evaluation met the following conditions: 
1: Diagnosis of acute ischemic stroke. 
2: Written consent and imaging obtained as part of participation in either POSH 
or MASIS studies. 
3: Baseline CTA confirmed an acute symptomatic arterial occlusion in ICA or 
proximal MCA vessels. 
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4: Retrograde direction of collateral flow demonstrated using 4-D Angiogram 
from baseline CTP raw data. 
5.3.1 Clinical Data 
The clinical evaluations performed were discussed in detail previously. In brief, 
baseline and follow-up clinical assessments included NIHSS(337), mRS(338), OCSP 
classification (339), routine physiological monitoring including blood pressure 
and blood glucose, age, sex, time of symptom onset and therapy given. Risk 
factors for stroke and medication history were recorded. Good clinical outcome 
was defined as mRS ≤2 at 1 month following stroke. Presence and degree of 
carotid stenosis was determined on admission CTA. Degree of stenosis was 
graded for clinical purposes by consultant radiologists who were not involved in 
subsequent research-specific analyses. Presence of Atrial fibrillation was 
determined from ECG on admission to hospital or if paroxysmal, from previous 
medical notes. Blood fibrinogen measurement was determined from coagulation 
samples obtained on admission to hospital as part of routine clinical practice. 
5.3.2 Image Analysis 
CT imaging on admission, comprising CT, CTP and CTA, was analysed after 
DICOM anonymization.  Evaluation was performed blind to treatment received 
and clinical outcome. A single reader performed all analyses (FMV). 
Baseline non-contrast CT was evaluated qualitatively for ASPECTS (79). 
Presence and location of arterial occlusions were determined from CTA. An 
occlusion visualised using CTA source images and 3-D MIP reconstructions was 
defined as the absence of contrast filling in a vessel which separated the 
proximal and distal portions of the vessel(111). 
After post-processing, CTP scans were examined qualitatively for ASPECTS on 
MTT, CBF and CBV summary maps. Core volume, penumbra volume and total 
perfusion lesion volume were recorded. Core volume was defined as tissue with 
reduced CBV (Absolute CBV≤2.0ml/100g). Penumbra was defined as tissue with 
prolonged MTT (Relative MTT ≥145% that of contralateral hemisphere) but with 
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normal CBV (131). Total perfusion lesion volume was calculated as the volume of 
core and penumbra combined.  
Severity of hypoperfusion in the affected ischemic territory was measured using 
a newer perfusion measure, Delay time (DT),(340) according to four thresholds 
of hypo perfusion severity; DT≥2 seconds, DT≥4 seconds, DT ≥6seconds and DT ≥8 
seconds. To calculate DT as part of the deconvolution algorithm, a series of 
delay time values, DTi ranging from 0 to Tmax were applied and for each delay 
time value a modelled arterial transport function was convolved with the 
measured global AIF to produce AIFi which is used for SVD deconvolution of the 
tissue curve to produce an impulse residue function IRFi with its maximum 
appearing at Tmax (i). Delay time (DT) was determined as the minimal DTi value 
which produces Tmax (i) =0(341).  
DT value in any given pixel is a measurement of hypo perfusion severity. A series 
of thresholds was applied to the DT perfusion maps according to the principle 
used by Bang et al to grade severity of hypo perfusion according to time taken 
for contrast arrival (40). A masking ROI was manually drawn over the affected 
hemisphere.  Non parenchymal pixels were excluded. A further ROI seed was 
placed in the hemispheric ROI which was then grown according to a series of 
pre-specified thresholds: DT ≥2 seconds, DT≥4 seconds, DT≥ 6 seconds and DT≥ 8 
seconds. Volume of hypoperfused tissue within each threshold group was 
automatically calculated. The process was repeated for each perfusion scan slice 
and added together to provide a volume of tissue within the different DT 
thresholds for each patient evaluated (Figure 5.1)
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Figure 5-1 DT Summary Map with ROI Measuring Pixels with DT>2 Seconds (Units = seconds 
x 100) 
Colour coded map displaying region of interest over pixels with DT>2 seconds. Key on left shows 
perfusion deficit severity depending on colour. Most severe perfusion deficit shown in red (>9 
seconds) 
 
Recanalisation was determined on subacute imaging using an adapted 
Thrombolysis in Myocardial infarction (TIMI) scale where recanalisation was 
defined as none (TIMI 0), minimal recanalisation/ persistent severe stenosis (TIMI 
1) partial (TIMI 2) and complete (TIMI 3)(167).  Recanalisation was further 
dichotomised; TIMI 0-1 was considered non-recanalisation, TIMI 2-3 represented 
recanalisation. 
Subacute structural imaging with CT or FLAIR was evaluated for presence / 
absence of intracerebral haemorrhage. Infarct Volume was determined from 
follow up structural imaging after co-registration with the baseline perfusion 
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scan. Follow up CT or FLAIR was loaded along with CTP into a fusion tool 
function using MIStar. A rigid body 3-D transformation was used to register the 
follow up structural imaging to the perfusion scan. Structural CT/ MRI-FLAIR 
sequences were subjected to a series reformatting procedures in the axial, 
saggital, coronal and oblique planes to obtain an orientation which matched that 
of the original CTP scan. The co registration process is shown in figure 5.2. 
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Figure 5-2 Fusion Tool Before and After Co-registration 
Baseline CTP and follow up CT from one patient are shown before (top panel) and after ( lower 
panel) coregistration.In each panel, the follow-up CT is shown in the middle row, CTP  is shown in 
the lower row, and the fusion overlay of each is shown in the top row. After co registration, the 
fusion overlay images show a close fit (top row from lower image screen save) 
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Figure 5-3 Reformatted Structural Image After Co-Registration 
Screen save showing imaging output after using the MIStar co registration tool. Processed CTP scan (Bottom left panel) and follow up structural CT (bottom right 
panel) have been co registered as shown in figure 5.2. The fusion overlay is shown on the top right panel, and the reformatted structural CT, which now matches the 
3D orientation of the original CTP scan, is shown on the top left. This reformatted CT scan is used to measure infarct volume in the same pixels covered by the original 
CTP acquisition, 
138 
 
After co-registration, the reformatted follow-up images were used to measure 
final infarct volume. A ROI seed was placed within the visualised area of final 
infarction. This ROI was subsequently adjusted by HU threshold semi-
automatically to match the extent of visualised infarct. Manual correction was 
used if needed to map the infarct extent precisely. ROI seed placement and 
growth/adjustment was repeated for each scan slice and combined to obtain a 
total infarct volume for each patient. 
As the CTP scan did not provide complete brain coverage, infarct volume was 
measured separately for those pixels which were covered by the perfusion scan 
and additionally for all parenchymal pixels which went on to become infarcted 
but which were not necessarily covered by the perfusion scan at baseline. Two 
separate measurements for infarct volume were therefore obtained; a total final 
infarct volume and a co-registered infarct volume which was used to determine 
the fate of tissue pixels covered by the perfusion scan.  
Measurements for core and penumbra volumes on CTP and co-registered infarct 
volume were used to determine tissue outcome according to a number of 
calculations; 
•Infarct Growth=Co-registered infarct volume-Core volume 
•Penumbra salvage= Penumbra Volume – Penumbra volume which infarcted 
•Proportion Penumbra Salvage= (Penumbra salvage/Penumbra Volume) x100  
•Relative Growth= Co-registered infarct Volume/ Core Volume 
5.3.3 Collateral Flow Grade 
A novel, semi-quantitative method based on CTA and CTP for measuring 
collateral flow extent was devised. Patients with arterial occlusion in the ICA or 
proximal MCA vessels had perfusion scans evaluated to determine the direction 
of blood flow distal to the vessel occlusion. 4-D angiographic appearances of the 
4 cm perfusion slab were displayed as a MIP image and evaluated in cine mode. 
139 
The 4D angiographic appearances permitted visualisation of arterial filling in 
normal and ischemic tissue beds in real time or at faster rates if needed, 
adjusted by the operator. This effect permitted the presence of contrast 
enhancement in distal portions of an arterial distribution to be seen prior to 
filling of the proximal portions and thereby confirming that flow in the relevant 
territory is truly collateral in nature. Without being able to confirm the 
retrograde direction of flow it would be impossible to say if CTA appearances 
were due to collateral filling and not simply due to delayed antegrade flow due 
to an incomplete arterial occlusion/ stenosis. The use of perfusion data to 
confirm flow direction has been previously demonstrated using the same 
software package(111). The effect is best appreciated when viewed in the cine 
mode, but can be appreciated using a series of screen shots taken at 2 second 
intervals as seen in figure 5.4 
 
Figure 5-4 4D Angiography Demonstrating Retrograde Collateral Flow 
Right MCA occlusion with perfusion scan MIP shown at 2 second intervals. The right MCA 
demonstrates delayed contrast filling, but the distal portion fills prior to proximal portion confirming 
that flow in ischemic area is retrograde and collateral in origin. 
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CTA was evaluated for collateral flow in those with retrograde flow on CTP. The 
intracranial CTA portion was viewed and if necessary underwent a 3-D 
Mulitplanar reconstruction to ensure the orientation for each hemisphere was 
symmetrical when viewed in the axial plane when centred over the level of the 
basal ganglia (lower ASPECTS level)(79). Images were then converted to maximal 
intensity projections with a slice thickness of 40mm in order to include most of 
the MCA territory in a single image.  
A ROI was drawn over the vessel portions in the unaffected MCA territory. The 
MCA origin was defined as the confluence of ICA MCA and ACA vessels. The most 
distal portion covered by the ROI was the most distal portion of the vessel seen 
which had continuity with the proximal MCA portion. Use of the unaffected 
hemisphere with full contrast enhancement was in order to remove any bias 
when drawing ROIs according to the visualised extent of collateral vessel filling. 
A mirror ROI was then generated in symptomatic hemisphere, each ROI 
containing the same absolute number of pixels. A high-low HU threshold was 
applied to the ROIs to permit inclusion of pixels measuring between 90 and 350 
HU. This threshold range included pixels which contained contrast within vessels 
and excluded pixels representing brain parenchyma, ventricles and bone. The 
range chosen is also the HU threshold range for vascular pixels used on CTA post-
processing packages used in clinical practice (e.g. Philips Brilliance) and 
therefore was considered to represent a reasonable attempt at visualising 
vascular pixels alone. ROI appearances after applying the HU thresholds is shown 
in figure 5.5. 
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Figure 5-5 CTA After Application of High-Low HU Threshold 
An ROI was generated over the right MCA territory (blue) and mirrored to the symptomatic left 
MCA territory (yellow). Applying the high-low HU threshold permitted calculation of the absolute 
number of vascular pixels within each ROI. 
 
The importance of quantifying vascular filling in both hemispheres was due to 
the fact that CTA acquisition and appearances vary between individuals. 
Differences such as timing of image acquisition after contrast bolus injection, 
cardiac output, atrial fibrillation and blood pressure variability result in large 
variation in the absolute number of vascular pixels measured within a vascular 
territory between different individuals. This inter-patient variability was seen 
during the present analysis with large differences in the absolute number of 
vascular pixels measured in vascular territories which appeared similar on 
inspection, thus preventing the use of absolute numbers of vascular pixels as a 
measure of collateralisation. These factors are constant however for a given 
individual meaning that contrast enhancement in each hemisphere should be 
symmetrical in the absence of an occlusive lesion. This principle was employed 
to compare affected and unaffected hemispheres for vascular filling and a ratio 
was determined as; 
Collateral ratio (%) = (Ipsilateral pixels/ Contralateral pixels) x100 
using only the number of vascular pixels measured within the ROIs over the 
affected and unaffected hemispheres. 
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Collateral ratio was generated as a continuous variable and then dichotomised 
into two groups, good (collateral ratio ≥75%) and reduced collaterals (collateral 
ratio <75%) for analysis. This cut point was chosen based on interpretation of the 
best available qualitative scales.  
To determine agreement for collateral grading, all anonymized CTA scans were 
re-evaluated for collateral flow grade one month after initial assessments were 
made. 
5.3.4 Statistical Analysis 
Statistical analysis was performed using PASW statistics 18 (www.SPSS.com). 
Analysis was performed for collateral flow grade as the outcome measure in 
order to investigate factors which may impact collateral flow, as well as clinical 
outcome to assess the contribution of different factors including collateralisation 
to final clinical outcome after stroke. Group comparisons were performed using 
the student’s T test and Mann-Whitney test for continuous and ordinal data, or 
the Pearson Chi Squared test for categorical data. Binary logistic regression was 
performed for predictors of collateral grade and clinical outcome using 
univariate analysis. Those univariate predictors with p values <0.1 were included 
in multivariate analysis. Intra-observer agreement for collateral grade was 
assessed using an un-weighted kappa score 
5.4  Results 
From the combined MASIS and POSH databases, 151 subjects were available for 
analysis. Of those, 62 had no visual occlusion on CTA and a further 11 had 
arterial occlusions in the posterior circulation. Of the 78 patients with CTA-
defined anterior circulation occlusion, 45 patients had evidence of retrograde 
flow on CTP while 33 patients did not, 3 of whom had chronic extracranial ICA 
occlusions which were not responsible for the individuals’ presentation. The 
remaining 42 subjects had ICA /proximal MCA occlusions with retrograde flow on 
CTP demonstrated and were included in the final analysis (Figure 5.6).
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Figure 5-6 Flowchart for Inclusion in Collateral Flow Evaluation 
 
Collateral flow was reduced in 29 (69%) and good in 13 (31%) subjects. Both 
groups were well matched in terms of age, sex, blood pressure and blood 
glucose. There were no significant differences in frequency of occlusion subtypes 
between collateral subgroups but those with good collateral flow had lower 
NIHSS measurements on admission. Stroke risk factors and previous medical 
conditions were generally similar between groups but atrial fibrillation was 
detected significantly more frequently in those with reduced collateral flow (n= 
15 vs. n=2, p=0.013). Pre-morbid medications including statins were not 
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significantly different. Time taken from symptom onset to image acquisition was 
similar in both groups. Plasma fibrinogen level was lower in those patients with 
good collateral flow (p=0.012). Carotid stenosis was not more frequently seen 
with good collateral flow.  Baseline clinical characteristics of both groups are 
summarised in table 5.1 and figures 5.7 to 5.9. Intra-observer agreement for 
collateral flow grade was excellent (k=0.86). 
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Variable All (n=42) Good 
Collaterals 
(n=13) 
Reduced 
Collaterals 
(n=29) 
p 
Age(SD) 73.1(11.8) 69.1(11.3) 74.9(11.7) 0.138 
Male sex (% of 
group)  
16(38%) 9(21.4%) 7(16.7%) 0.159 
NIHSS (Range) 18 (6-33) 13(6-21) 19(9-33) <0.001 
Systolic BP (SD) 
(mmHg) 
146.7(21.2) 139.2(13.5) 150.5(23.4) 0.119 
Diastolic BP (SD) 
(mmHg) 
75.4(20.5) 68.8(17.6) 78.8(21.4) 0.154 
Blood Glucose 
(Range (mmol/L) 
6.7(3.8-9.0) 
 
6.4(3.8-9.0) 
 
7.0(5.0-9.0) 
 
0.157 
 
ICA occlusion (% 
of group) 
13(31%) 2(4.8) 11(26.2) 0.144 
MCA occlusion 
(% of group) 
29(69%) 11(26.2) 18(42.9) 0.144 
Pre-morbid 
Statin use (% of 
group) 
22(52.4%) 7(16.7%) 15(35.7%) 0.899 
Carotid stenosis 
>70% (% of 
group) 
5(11.9%) 
 
2(4.8%) 
 
3(7.1%) 
 
0.641 
 
Atrial Fibrillation 
*(% of group) 
17(40.5%) 2(4.8%) 15(35.7%) 0.013 
Hypertension 
(% of group) 
26(61.9%) 7(16.7%) 19(45.2%) 0.471 
Diabetes (% of 
group) 
7(16.7%) 2(4.8%) 5(12.0%) 0.941 
Never smoked 
(% of group) 
14(33%) 4(9.5%) 10(23.8%) 0.807 
Previous stroke  
(%of group) 
7(16.7%) 1(2.4%) 6(14.3%) 0.296 
Fibrinogen (SD) 
(g/L) 
3.6(0.8) 
 
3.0(0.8) 
 
3.8(0.8) 
 
0.012 
 
Onset to Imaging 
Obtained (Mins) 
(Range) 
147.5(57-355) 
 
126(57-220) 
 
154(82-355) 
 
0.105 
 
Table 5-1 Baseline Clinical Characteristics of Subjects with Good and Reduced Collaterals 
T test and Mann-Whitney test used for normal and non-normal continuous variables. Chi Square 
test used for categorical variables. * No data on atrial fibrillation for 3 subjects
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Figure 5-7 Collateral Status and NIHSS (Median +IQR +Range) 
Mann Whitney U test p<0.001 
 
Figure 5-8 Collateral Grade and Fibrinogen Level (Mean +SD + Range +Outlier) 
T test p=0.012 
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Figure 5-9 Collateral Grade and Atrial Fibrillation 
Good collateral flow was less frequently seen in patients with atrial fibrillation. Data on atrial 
fibrillation status on 3 subjects are missing. Chi-Squared Test p=0.012
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Collateral flow extent was studied for association with other baseline imaging 
characteristics. Qualitative assessment of NCCT and processed CTP maps were 
similar in both groups apart from CBV-ASPECTS score which was significantly 
lower in the group with reduced collaterals (Median scores 8.0 and 6.5 p=0.006). 
Core volume, penumbra volume and thresholded perfusion lesion volume were 
similar in each group. The volume of hypoperfused tissue on DT ≥2 second maps 
was significantly greater in those with reduced collateral flow compared to good 
collateral flow (p=0.031). Volumes were also significantly larger for DT≥6 and DT 
≥8 second thresholds in the reduced collateral groups suggesting larger volumes 
of severely hypoperfused tissue in association with reduced collateral flow, 
although proportion of tissue with severe hypo perfusion (DT≥8/DT/2≥) was not 
significantly different between groups. Imaging features and collateral status are 
summarised in Table 5.2 and figures 5.10 to 5.15 
149 
 
Measurement All (n=42) Good 
Collaterals 
(n=13) 
Reduced 
Collaterals 
(n=29) 
p 
NCCT 
ASPECTS 
(Range) 
6.0 (1-10) 7.0 (2-10) 5.5 (0-10) 0.336 
CBV ASPECTS 
(Range) 
8.0 (1-10) 8.0 (5-10) 6.5 (1-10) 0.006 
CBF ASPECTS 
(Range) 
4.0 (0-10) 5.0 (1-9) 4.0 (0-10) 0.295 
MTT ASPECTS 
(Range) 
3.0 (0-9) 3.0 (1-9) 3.0 (0-9) 0.585 
Core Volume 
(ml) (Range) 
25.6 (4.8-131.0) 
 
20.5 (4.8-92.9) 
 
30.0 (6.4-131.0) 
 
0.117 
 
Penumbra 
Volume 
(ml)(Range) 
31.7 (5.1-76.9) 
 
22.7 (5.1-69.6) 
 
33.5 (12.1-76.9) 0.256 
 
Perfusion lesion 
volume (ml) 
(Range) 
68.8 (19.5-
194.7) 
 
45.2 (19.5-
148.4) 
 
82.1 (27.8-
194.7) 
 
0.053 
 
DT ≥2 Seconds 
Volume 
(ml)(Range) 
77.3 (13.0-
185.0) 
 
43.6 (17.5-
139.0) 
 
94.5 (13.0-
185.0) 
 
0.031 
 
DT ≥ 4 Seconds 
Volume (ml) 
(Range) 
39.4 (3.5-161.0) 
 
23.2(3.5-100.2) 
 
44.7 (5.9-161.0) 
 
0.056 
 
DT ≥6 Seconds 
Volume 
(ml)(Range) 
22.5 (0.0-121.0) 
 
10.0 (0.0-66.3)  
 
27.5 (0.7-121.0) 
 
0.037 
 
DT ≥8 Seconds 
Volume (ml) 
(Range) 
11.1 (0.0-96.0) 
 
5.3 (0.0-25.5) 
 
15.2 (0.0-96.0) 
 
0.05 
 
DT ≥8/DT≥2 
ratio (Range) 
0.19 (0.0-0.52) 0.14 (0.0-0.25) 0.23 (0.0-0.52.) 0.116 
Table 5-2 Collateral Status and Associated Imaging Findings on Admission 
Groups were compared using the Mann Whitney U test 
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Figure 5-10 Collateral grade and Volume with DT ≥ 2 Seconds (Median +IQR, +Range) 
Mann Whitney U test p=0.031 
 
Figure 5-11 Collateral grade and Volume with DT≥ 4 seconds (Median +IQR, +Range+ Outlier) 
Mann Whitney U test p=0.056 
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Figure 5-12 Collateral grade and DT≥ 6 seconds (Median +IQR +Range +Outliers)  
Mann Whitney U test p=0.037 
 
 
Figure 5-13 Collateral grade and DT≥ 8 Seconds (Median +IQR+ Range + Outlier) 
Mann Whitney U test p=0.05 
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Figure 5-14 Collateral grade and Infarct Core Volume (Median +IQR +Range + Outlier) 
Mann Whitney U test p=0.117 
 
 
Figure 5-15 Collateral Grade and Penumbra Volume (Median +IQR +Range) 
Mann Whitney U test p=0.256 
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Variables with significant association with good collateral grade from a 
univariate logistic regression analysis included NIHSS, CBV ASPECTS, atrial 
Fibrillation, plasma fibrinogen and DT≥ 2 seconds volume. 
 
Predictor OR (CI) p 
NIHSS 0.763 (0.637-0.914) 0.03 
CBV ASPECTS 1.762 (1.116-2.781) 0.02 
Atrial Fibrillation 0.133 (0.024-0.727) 0.02 
Fibrinogen 0.227 (0.062-0.833) 0.03 
DT >2 seconds 0.980 (0.960-0.999) 0.04 
Table 5-3 Univariate Logistic Regression Summary 
 
These elements were entered to a multiple logistic regression model but none 
achieved statistical significance. 
5.4.1 Collateral Flow and Outcome 
Recanalisation on subacute angiography appeared to occur more often in those 
with poor collaterals although the result was not statistically significant for both 
groups with no statistical difference seen. Intracerebral haemorrhage was 
present for 7 subjects all of whom had reduced collaterals. No ICH was detected 
in the good collateral flow group. Of the 7 with ICH at follow up, recanalisation 
was assessed in 5. 4/5(80%) had evidence of recanalisation on follow up, 
although the result was not statistically significant (Chi Square p=0.523). 
Collateral flow was associated with smaller infarct volume, less absolute and 
relative infarct growth from baseline and larger proportions of penumbra 
salvage.  
Good clinical outcomes were more likely in the good collateral flow group who 
also had significantly lower NIHSS measurements at 24 hrs. Absolute NIHSS 
reduction from admission to 24 hrs was not statistically different between 
groups. Proportional NIHSS reduction at 24hrs appeared higher in those with 
good collaterals, although statistical significance was not seen. Two subjects 
were lost to clinical follow up meaning final outcome measurement was 
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available for 40 of 42 subjects. Results are summarised in table 5.4 and figures 
5.16 and 5.17. 
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Outcome All (n=42) Good 
Collaterals 
(n=13) 
Poor 
Collaterals 
(n=29) 
p 
ICH (% of total) 7 (16.7%) 
 
0 (0) 
 
7 (16.7 %) 
 
0.039 
 
Recanalisation 
(% of total) 
23 (54.7%) 
 
7 (16.7%) 
 
16 (38.1%) 
 
0.73 
 
Infarct Volume 
(ml) (Range)  
39.3 (0.0-364.8) 
 
21.6 (0.0-151.0) 
 
60.9 (1.1-364.8) 0.006 
 
Infarct Growth 
(ml) (Range) 
13.9 (0-79.5) 
 
10.2 (0-43.4) 
 
22.7 (0-79.5) 
 
0.017 
 
Penumbra 
Salvage 
(ml)(Range) 
 
14.9 (3.1-76.8) 
 
17.2 (3.1-68.1) 
 
14.7 (4.9-76.8) 
 
0.861 
 
Proportion 
Penumbra 
salvaged 
(%)(Range) 
74.0(16.0-
100.0) 
 
89.0(50.0-
100.0) 
 
71.5 (16.0-
100.0) 
 
0.034 
 
Relative Growth 
(Range) 
1.4(0.0-8.5) 
 
0.9(0.0-1.9) 
 
1.6(0.1-8.5) 
 
0.005 
 
NIHSS 24hrs 
(Range) 
14 (0-30) 
 
6 (0-20) 
 
15 (1-30) 
 
0.013 
 
24hr NIHSS 
reduction 
(Range) 
4(-11.0-32.0) 
 
6(-9.0-16.0) 
 
3 (-11.0-32.0) 
 
0.643 
 
Proportional 
NIHSS reduction 
24hrs (%) 
(Range) 
12.9 (-88.9-
100.0) 
38.9 (-81.8-
100.0) 
10.5 (-88.9-
97.0) 
0.110 
Good Clinical 
Outcome(% of 
total) 
8(19.0%) 
 
3 (7.1%) 
 
5(11.9%) 
 
0.043 
 
Table 5-4 Collateral Flow and Clinical Outcome 
Categorical variables compared using the Chi-Squared test. Continuous variables compared using 
the Mann Whitney U test.
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Figure 5-16 Collateral Grade and Infarct Volume (Median +IQR +Range +Outliers) 
Mann Whitney U test p=0.006 
 
 
Figure 5-17 Collateral Grade and Infarct Growth (Median +IQR +Range +Outlier) 
Mann Whitney U test p=0.017 
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 Additional measurements significantly associated with clinical outcomes 
included baseline NIHSS measurement, NCCT-ASPECTS and CBV-ASPECTS on 
admission, infarct volume, and proportion of penumbra salvaged. Collateral 
grade expressed as a continuous measurement was significantly greater in those 
who achieved good outcomes. Lower NIHSS measurements at 24 hrs were seen in 
those with good outcome. Recanalisation, administration of alteplase, occlusion 
site, atrial fibrillation, blood fibrinogen and volumetric measurements of core 
and penumbra were not associated with clinical outcome. Results are 
summarised in table 5.5 and figures 5.18 to 5.24. 
NIHSS, ASPECTS on CBV and NCCT, Collateral flow grade and infarct volume were 
significant univariate predictors of good outcome after logistic regression 
analysis (Table 5.6). Statistical significance for each was lost after entry to a 
multivariate logistic regression analysis. 
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Good Clinical Outcome? 
(mRS ≤2) 
Variable 
 
No (n=32) Yes (n=8) 
P 
Age (SD) 73.8 (11.5) 68.6 (13.7) 0.276 
Admission NIHSS 
(Median)(Range) 
18.0 (6.0-30.0) 15.5(8.0-19.0) 0.050 
Blood Glucose mmol/l 
(SD) 
8.9 (5.5) 6.7 (1.2) 0.403 
Carotid occlusion 10 (25%) 2 (5%) 0.730 
M1 Occlusion 17 (42.5%) 5 (12.5%) 0.634 
M2 Occlusion 7 (17.5%) 3 (7.5%) 0.361 
Good Collaterals? 8 (20%) 5 (12.5%) 0.043 
Alteplase 22 (55%) 6 (15%) 0.768 
Recanalisation?(n=32) 15 (46.8%) 6 (18.8%) 0.519 
Atrial Fibrillation? 15 (46.8%) 1 (2.5) 0.086 
ASPECTS NCCT 
(Range) 
5 (0-10) 8 (5-10) 0.042 
ASPECTS CBV 
(Range)  
7 (1-10) 9 (7-10) 0.017 
ASPECTS CBF 
(Range)  
4 (0-9) 4 (1-10) 0.860 
ASPECTS MTT 
(Range) 
4 (0-9) 3 (1-6) 0.433 
Core Volume (ml) 
(Range) 
34.6 (4.8-121.2) 25.5 (10.8-37.0) 0.279 
Penumbra Volume 
(ml) (Range) 
24.1 (5.1-68.7) 35.2 (15.2-19.6) 0.772 
Hypoperfused Volume 
(ml) (Range) 
72.0(19.5-148.4) 61.0 (35.1-
106.6) 
0.382 
Proportion Core (%) 
(Range) 
57.6(18.5-58.2) 34.7(18.5-58.2) 0.196 
Infarct Volume (ml) 
(Range) 
70.2(0-264.8) 29.0(9.7064.4 0.034 
Absolute Infarct 
Growth (ml) (Range) 
23.2 (0.0-79.5) 10.2 (7.5-37.9) 0.128 
Relative Infarct 
Growth (Range) 
1.5(0.0-8.6) 0.9 (0.2-2.0) 0.122 
Volume Penumbra 
Salvaged (ml) 
(Range) 
12.7 (3.1-62.5) 32.3 (11.5-68.1) 0.166 
Proportion penumbra 
salvaged (%) (Range) 
65.0(16.0-100.0) 91.0(42.0-98.0) 0.041 
24 hr NIHSS 15.5 (0.0-30.0) 7.0(5.0-15.0) 0.016 
24hr NIHSS reduction 3.0(-11.0-16.0) 7.0(2.0-10.0) 0.295 
Fibrinogen (mg/L) 
(SD) 
3.7(3.3-4.3) 3.2(2.7-3.5) 0.167 
Table 5-5 Clinical and Imaging Factors Associated with Clinical Outcome 
Admission /24hr NIHSS, ASPECTS on NCCT and CBV, proportion of penumbra salvaged and final 
infarct volume were all associated with clinical outcome status. Categorical variables compared 
using the Chi Squared test. Normal and non-normal continuous variables compared using the t test 
and Mann Whitney U test, respectively.
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Figure 5-18 Admission NIHSS and Outcome (Median +IQR +Range) 
Mann Whitney U test p=0.05 
 
 
Figure 5-19 24hr NIHSS and Outcome (Median +IQR +Range) 
Mann Whitney U test p=0.016 
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Figure 5-20  Infarct Volume and Clinical Outcome (Median +IQR +Range +Outlier) 
Mann Whitney U test p=0.034 
 
Figure 5-21 Proportion Penumbra Salvage and Clinical Outcome (Median +IQR +Range + 
Outlier) 
Mann Whitney U test p=0.041
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Figure 5-22 ASPECTS Score on CBV Maps and Clinical Outcome (Median +IQR +Range) 
Mann Whitney U test p=0.017 
 
 
Figure 5-23 ASPECTS Score on NCCT and Clinical Outcome (Median +IQR +Range+ Outliers) 
Mann Whitney U test p=0.042 
162 
 
Figure 5-24 Collateral Flow and Clinical Outcome (Median +IQR +Range) 
Collateral ratio, when measured as a continuous variable was associated with better clinical 
outcomes. Median 77.5 %( Range 63-91%) and 53.5 %( range 2-91%) for good and poor clinical 
outcome groups, respectively .Mann Whitney U test p=0.017 
 
Predictor OR (CI) P 
ASPECTS NCCT 1.426(0.990-2.055) 0.057 
ASPECTS CBV 1.856 (1.023-3.366) 0.042 
Infarct Volume 0.974 (0.946-1.003) 0.080 
Collateral flow 1.006 (1.004-1.119) 0.037 
NIHSS 0.852 (0.727-0.998) 0.047 
24hr NIHSS 0.850 (0.733-0.987) 0.033 
Table 5-6 Univariate Logistic Regression Analysis Summaries for Clinical Outcome 
Prediction (Modified Rankin Scale ≤2 at one month 
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5.5 Discussion 
This study evaluated collateral flow extent using a novel semi-quantitative 
measurement based on quantifying the extent of vessel filling in a region 
affected by stroke relative to the normal contralateral region. The method was 
devised after considering the merits of other available grading scales 
summarised in chapter 2. All previous methods using CTA to measure collaterals 
were based on qualitative interpretation of images with only some studies 
reporting inter/intra observer agreement. This method design attempted to 
avoid subjective interpretations of what may appear as good or poor vessel 
filling and risk of bias by drawing a ROI over the normal hemisphere and 
quantifying the number of vascular pixels in the mirror region. This assumes that 
vascular territories are relatively symmetrical which in practice they usually are, 
although this may not be true for all subjects (e.g. previous stroke with 
established infarction, previous intracranial steno-occlusive disease, presence of 
arteriovenous malformation). Similar to previous studies, only proximal anterior 
circulation strokes were evaluated. The use of CTP to determine the direction of 
flow was considered an important additional feature in order to evaluate 
features associated with different collateral flow and has been used in a 
previous study(111). This may have resulted in a smaller final patient cohort but 
is likely to have made the population more homogenous. If subjects with residual 
antegrade (e.g. high grade stenosis/incomplete occlusion) rather than 
retrograde flow were included, patient characteristics specifically relating to 
collateralisation may not have been evident. Intra-observer agreement was 
excellent although inter-observer reliability was not assessed. Measuring 
collaterals in a quantitative fashion is not something likely to be possible in 
clinical practice but as a way of studying collateral flow influences and 
minimising subjective interpretation, a quantitative assessment appears useful 
and promising for further work.    
Patients with well developed collateral flow had some differences from those 
with poor collateral flow although the two groups were generally well matched 
at baseline. Collateral flow extent was not associated with increased time 
between symptom onset and scan acquisition as had been previously suggested, 
and pre-morbid statin therapy did not appear to affect collateral flow grade in 
this population (234, 301). Although the occlusion subtypes, core, penumbra and 
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perfusion lesion volumes were not significantly different in this cohort those 
with good collateral flow had significantly lower admission NIHSS values. Right 
and left hemisphere strokes may be represented differently by the NIHSS but this 
is not likely to account for this difference alone. The volumes of hypoperfused 
tissue on DT maps at 2, 6 and 8 second thresholds were significantly larger in 
those with poor collateral flow, although the ratio of severe to mild levels of 
hypo perfusion was not significantly different. The difference in absolute DT 
volumes appears at odds with the core and penumbra measurements, but these 
are based on perfusion thresholds which are not yet validated and therefore 
using combined core/penumbra volume as the only measure of hypoperfused 
tissue on CTP should be interpreted with some caution. Although use of DT 
thresholds also has limited validation the observed trend could suggest that 
collateral flow may result in smaller volumes of severely hypoperfused tissue. A 
reduction in volume of severely hypo perfused tissue could potentially result in 
less tissue being at risk of infarction, and as ischemic penumbra is by definition 
associated with a clinical deficit, a reduced penumbra volume could result in 
less clinically severe strokes measured using the NIHSS. However, although 
groups were not significantly different at baseline, the higher proportion of 
proximal occlusions ( particularly ICA occlusions ) seen with reduced collaterals 
means an effect from occlusion site as a confounder cannot be excluded. 
The similarity in the qualitative measurements of hypoperfusion (ASPECTS on 
MTT or TTP) between patient groups suggests that the overall volume of tissue 
which is experiencing any hypoperfusion is not significantly different between 
groups with good and reduced collaterals. This visualised area of perfusion 
disturbance on ASPECTS does not measure the severity of hypoperfusion, but 
just its overall extent and therefore could include mildly hypoperfused tissue or 
“benign oligemia” which is not at risk of infarction and unlikely to contribute to 
the clinical deficit(342). The reduced collateral group did however have 
significantly lower ASPECTS scores measured on CBV, an indicator of tissue which 
is likely to be irreversibly damaged(130) . Viewed in combination these findings 
suggest that volumes of hypoperfusion are broadly similar in those with good and 
reduced collaterals, but those with good collateral flow have smaller volumes of 
core. If this is a true effect it is suggestive of a beneficial effect of well 
developed collateral flow, resulting in larger volumes of ischemic tissue being in 
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a potentially viable state compared to those with reduced collaterals. However 
as previously stated, the potential for differences based on baseline occlusion to 
be a confounding variable needs to be considered.   
Collateral flow grade was associated with beneficial outcome on imaging 
markers. No patient with good collaterals underwent haemorrhagic 
transformation post thrombolysis. Recanalization after IV thrombolysis was not 
influenced by collateral flow extent in this study as had been previously 
suggested due to enhanced drug delivery to the site of action(343) but final 
infarct volume and volume of infarct growth from baseline core measurement 
were significantly less in the group with good collaterals. Proportional penumbra 
volume salvaged and relative lesion growth from baseline were significantly 
different between groups with good and reduced collaterals. These findings are 
supportive evidence of the beneficial effect of collaterals by maintaining 
residual flow to the ischemic zone despite the presence of a proximal occlusion. 
Recanalisation is an important predictor of outcome and is used as a surrogate 
marker for outcome, but collateral flow has also been shown to impact imaging 
and clinical outcomes (53, 111, 244). Prompt recanalisation even with poor 
collaterals can have good outcomes, while collateral status is also predictive of 
outcome, suggesting that good collaterals and recanalisation are likely to result 
in the best outcomes(245).The effect on imaging outcomes measured support 
the protective effect of collateral flow in reducing severity of hypo perfusion, 
limiting the progression of ischemic tissue to infarction before and after the 
time of initial image acquisition and importantly the overall infarct volume, a 
surrogate marker for clinical outcome (47, 321). 
Baseline characteristics associated with collateral flow included NIHSS, atrial 
fibrillation and blood fibrinogen. The association with less clinical severity may 
reflect milder strokes and consequently a confounding measurement when 
determining predictors of outcome. The similar volumes of hypoperfused tissue 
measured could point towards collaterals maintaining tissue in a state of benign 
oligemia and therefore less symptomatic penumbra/ core tissue for the reasons 
outlined above, as truly penumbral tissue should be associated with a clinical 
deficit(26).  
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Patients with good collateral flow were less likely to have a history of atrial 
fibrillation. This has not been previously reported. Cardio-embolic stroke may be 
associated with a different response to ischemia than large artery athero-
thrombotic stroke as animal models have suggested that previous reduction in 
blood flow may serve a protective role by pre-conditioning the cerebrum to the 
effects of ischemia(344). Mechanisms for induction of ischemic tolerance are 
unclear with neuronal gene expression and protein synthesis being suggested as 
potential methods (344, 345). Reduction in cerebral perfusion pressure prior to a 
stroke has been shown to be associated with preserved cerebral blood flow 
mediated via leptomeningeal collaterals in rat models suggesting ischemic 
preconditioning may be mediated via an enhanced collateral flow network(346).  
Sudden onset of brain ischemia without previous warning, such as in cardio-
embolic stroke could possibly be associated with reduced ability to compensate 
compared to those with extracranial / intracranial atherosclerotic disease but 
the association is unclear. This study did not find a relationship with the 
presence or degree of carotid stenosis and collateral flow, although large artery 
/non cardio-embolic related strokes are not necessarily associated with carotid 
stenosis. As this association has not been previously reported it should be viewed 
with caution but given the proposed mechanism of collateral development by 
previous transient ischemia in animal models, additional studies to investigate 
whether the response to stroke medicated via collaterals may be influenced by 
stroke mechanism should be considered. 
Baseline fibrinogen level was significantly lower in patients with good collateral 
flow which is intriguing given the association of fibrinogen with stroke risk but 
also stroke outcome. The fibrinogen studies collaboration have shown in a 
metanalysis of 31 studies that higher fibrinogen levels influences risk of stroke, 
cardiovascular death and all vascular mortality implicating fibrinogen as a 
marker for cardiovascular risk(347). In addition, fibrinogen has been identified 
as a marker for outcome after stroke by Tanne et al who found higher baseline 
fibrinogen levels in those with a poor clinical outcome in subjects recruited to 
the original NINDS study (348). Reducing fibrinogen in a rodent stroke model by 
plasma exchange has been shown to reduce blood viscosity , improve CBF and 
reduce ischemic injury potentially via enhanced collateralisation(349). 
Fibrinogen reduction has therefore been studied in a number of randomised 
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clinical trials for a potential treatment effect, although the results are 
conflicting. Ancrod is a purified extract from Malayan Pit Viper Agkistro 
donrhodostoma which rapidly induces defibrinogenation in humans (350). The 
STAT study suggested that using Ancrod to reduce fibrinogen within 3 hrs of 
stroke onset was associated with better clinical outcomes (351). The European 
ESTAT study did not show any beneficial effect when Ancrod was administered in 
subjects recruited within 6 hours of symptom onset(335). A recently updated 
Cochrane review of defibrinogenation for ischemic stroke did not support the 
routine use of fibrinogen-lowering agents but suggested some patients could 
possibly benefit and further study was required in order to identify subgroups 
appropriately(352). Those trials included in the Cochrane review did not report 
use of additional imaging which may have provided insights into subgroups that 
may have benefited from lowering fibrinogen levels. As fibrinogen is a marker 
for blood viscosity and micro vascular occlusion, the association with collateral 
flow grade demonstrates a potential mechanism for the possible benefit seen 
with lower fibrinogen level(349). There is a single previous study which 
investigated fibrinogen and collateral flow, although only an indirect imaging 
marker for collaterals was used. Lee et al found an association between low 
fibrinogen and the presence of a dominant posterior cerebral artery ipsilateral 
to an occluded Middle cerebral artery. The enlarged posterior cerebral artery in 
this study was considered a sign of collateral recruitment to the ischemic site 
from the adjacent arterial network and flow was suggested to be enhanced in 
those with lower fibrinogen levels(334). Imaging characteristics of those with 
elevated and reduced fibrinogen have not otherwise been reported previously. 
Fibrinogen level may have a number of effects, but if collateral flow is 
influenced by fibrinogen, it may be that some patient subgroups would have 
little to benefit from lowering fibrinogen acutely. Lenticulostriate arteries which 
are affected in lacunar stroke are anatomically end arteries which do not benefit 
from collateral supply, while patients with very distal occlusions may not benefit 
from reduced viscosity/ improved collaterals compared to more proximal 
occlusions with larger volumes at risk but also more potential for collateral flow 
derivation. These mechanisms remain speculative but point towards 
heterogeneous stroke subtypes in whom increasing collateral flow (and lowering 
fibrinogen) could potentially have a meaningful effect depending on the site of 
arterial occlusion. This study cannot prove a direct relationship between 
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collaterals and fibrinogen, but if this relationship was evident it could mean that 
some subgroups have potential benefit by reducing fibrinogen level acutely such 
as those with vessel occlusion and poor collaterals, while others would have 
little to benefit from enhanced collaterals, such as lacunar strokes. Improved 
characterisation of subgroups using imaging will be needed to see if fibrinogen 
depletion can be of benefit in some groups, but this study suggests that 
collateral flow and fibrinogen may have a relationship which could potentially be 
targeted for effect. 
Good clinical outcome was seen significantly more often in those with good 
collaterals, although overall numbers with good clinical outcome were low 
overall. Other univariate predictors of good outcome were also associated with 
collateral flow grade when good and reduced groups were compared. None had a 
significant impact on outcome in a multivariate analysis, and therefore an 
independent effect for any of the variables, including collateral grade, on 
outcome was not demonstrated. Although the effect of collaterals may be 
confounded by other variables, in particular admission NIHSS, the results suggest 
that collateral flow extent is variable among patients with similar baseline 
occlusions, that hypoperfused volume is similar overall but less severe in those 
with good collaterals, that core and infarct volume are smaller when collaterals 
are developed, and that both fibrinogen and stroke mechanism could influence 
the degree of collateral recruitment.    
Strengths of this study include the precise identification of collateral flow using 
both CTA and CTP, the objective semi-quantitative measurement used and the 
excellent intra-observer reliability. Limitations include that the population is 
highly selected and therefore the results may not apply to other stroke subtypes, 
although even after selection based on occlusion and flow direction on CTP, the 
different occlusion subtypes could be seen as a limitation as more proximal 
occlusions are associated with markers for poor clinical outcome. The study 
population was small, which limits the ability to draw firm conclusions on the 
reported findings associated with good and reduced collateral flow which have 
not been previously reported. These findings should therefore be evaluated in 
larger independent populations. Outcome imaging was early which may result in 
overestimation of lesion volume due to swelling in the first days after stroke. 
Given the extent of image post processing involved, the method is not one which 
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can be used in “real time” limiting use in clinical practice, but it is important to 
study collateral flow characteristics first as the degree to which collateral 
development could /should influence clinical decision making remains unclear. 
CTA appearances can however be rapidly evaluated meaning that other 
qualitative scales could potentially be used in acute stroke decision making 
without major delays in treatment. Should the case for considering collaterals in 
treatment decisions be proven, a more pragmatic scoring system would need to 
be employed. In the meantime, this novel grading scale has shown the beneficial 
effects of collateral flow on imaging and clinical measurements of outcome after 
ischemic stroke and has suggested additional areas for research.  In particular 
the possibility of fibrinogen being a blood biomarker for collaterals is of 
potential significance with the possibility of exploring collateral therapeutics 
with agents to reduce fibrinogen such as Ancrod in selected populations. As 
collaterals seem to be associated with less severe blood flow reduction and 
smaller infarct volumes, methods to enhance collateral flow could be of real 
clinical importance to acute stroke patients. 
5.6 Conclusion 
The application of a novel and semi quantitative method for grading collaterals 
in proximal arterial occlusions has demonstrated good intra-observer reliability 
and could represent a robust method in which to study characteristics of 
collaterals. No previous study has evaluated collaterals with blood biomarkers, 
and although the results require confirmation, the possibility of fibrinogen being 
associated with collateral adequacy is supported by other studies which 
suggested collaterals and fibrinogen may be interrelated and is an interesting 
finding worthy of further study, particularly as fibrinogen lowering has been 
linked with positive effects in stroke. Good and poor collaterals were associated 
with similar volumes of perfusion disturbance, but better collaterals seemed to 
have less severe degrees of hypo perfusion suggesting a beneficial effect in real 
time. Smaller infarct volumes also support the concept of collaterals being 
beneficial for stroke outcome. Small numbers are a limitation and this study did 
not show that collaterals were independently predictive of outcome but overall 
the results are strongly supportive of the positive impact of collaterals and 
suggest further evaluation of clinical and blood biomarkers should be undertaken 
to understand collaterals as a potential future therapeutic target. 
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Chapter 6. Derivation and Evaluation of Thresholds 
for Core and Tissue at Risk of Infarction Using CT 
Perfusion 
6.1 Introduction 
The limited overall sensitivity for NCCT to detect acute ischaemia in the first 
hours after stroke onset has led to the use of alternative or complementary 
imaging modalities to provide additional information in acute stroke assessment 
(74, 151).  Physiological imaging identifies distinct groups of patients that are 
clinically indistinguishable but have different brain imaging profiles with respect 
to blood flow and metabolic activity, and potentially divergent outcomes based 
on the presence or absence of viable tissue(29).  Brain perfusion imaging with CT 
or MRI offers a practical means of identifying brain tissue viability in individual 
patients, with the potential to improve patient selection for reperfusion 
therapies such as IV thrombolysis. While MRI based perfusion imaging has been 
extensively used to operationally define core and penumbra, and to demonstrate 
the impact of thrombolysis on stroke lesion evolution (143, 170), multiple other 
factors impact on the feasibility of performing MRI based penumbra and core 
imaging highlighted previously. Multislice CT scanners are widely available 
resulting in the potential for acquiring CTP in addition to CT and CTA in 
hyperacute stroke with only a few additional minutes required to complete 
imaging(353). CTP offers potentially quantifiable assessment of perfusion 
parameters that can be acquired rapidly and predict volumes of potentially 
salvageable tissue(113) 
Thresholds to define irreversibly damaged core and tissue at risk of infarction/ 
penumbra have been proposed for CTP, equivalent to the MRI diffusion-perfusion 
mismatch concept (131). These proposed thresholds have been used as selection 
criteria for entry to clinical trials of novel thrombolytic agents and appear in 
post-processing packages on CT workstations for use in clinical practice  
(47, 52). However, CTP thresholds for core and penumbra have been derived 
from only a limited number of subjects and scanners, and no study has validated 
the proposed thresholds in an independent dataset to assess the accuracy of 
each threshold in practice. Moreover, different studies have reached differing 
conclusions regarding optimal indices and thresholds for core or penumbra based 
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on CTP suggesting that further validation of thresholds is needed before their 
routine application in clinical practice (104, 131, 133, 134, 354, 355). 
Methods for core measurement have used concurrently acquired DWI volume as a 
gold standard measurement of infarct core against which to test CTP parameters 
(131). Comparison between acute and 24 hr DWI volumes in patients who showed 
major reperfusion demonstrated similar results however, suggesting lesion 
evolution after initial image acquisition may be negligible if early reperfusion 
occurs (134). 
Tissue at risk of infarction on CTP has been measured using final infarct volume 
as the gold standard reference in patients who did not show recanalisation of a 
baseline arterial occlusion. The differences between the thresholds for core and 
tissue at risk have been used as a measurement of penumbra (131). 
Post-processing algorithms vary among different manufacturers with the result 
that generated perfusion maps can be different despite use of the same raw 
imaging data (117). An important feature of post-processing packages 
highlighted more recently is the algorithmic correction for tracer bolus delay in 
order to avoid pseudo-reversibility of some perfusion lesions (127).  Delay 
correction may not have been performed for all previous CTP threshold 
derivations which could produce unreliable results if applied on a scan processed 
using a delay corrected algorithm. 
Given the uncertainty over which thresholds best represent core and penumbra, 
possible unreliable map generation without correction for tracer delay, and lack 
of validation in independent cohorts, I sought to derive the perfusion thresholds 
which best represent core and penumbra on CTP and evaluate the accuracy of 
the derived thresholds along with those from the literature to determine which 
thresholds perform best in independent validation. 
6.2 Materials and methods 
6.2.1 Patient selection 
Patients included in the present analysis were selected from those recruited to 
the POSH or MASIS studies between August 2008 and September 2010 at the 
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Institute of Neurological Sciences, Southern General Hospital, Glasgow. Entry 
criteria to the studies, imaging protocols, and clinical assessments are described 
in more detail in Chapter 3. For the present analysis patients were selected from 
the combined dataset based on specific imaging characteristics. As stated in 
chapter 3, some patients recruited to MASIS underwent MRI imaging at baseline 
instead of CT, but only those imaged with CT were considered for this analysis as 
MRI perfusion thresholds would require separate evaluation which is beyond the 
scope of this work. After recruitment to each study imaging characteristics 
including occlusion status, recanalisation status clinical severity at baseline and 
24 hrs were recorded. From the combined dataset, 2 sets of selection criteria 
were used to identify patient and imaging data on which threshold analysis could 
be performed. 
Tissue at risk was evaluated in patients with the following imaging 
characteristics: 
1) Arterial occlusion on admission CTA 
2) Non recanalization of baseline occlusion at subacute CTA/ MRA at 24-72 
hrs (TIMI 0) 
3) Follow-up structural brain imaging at 24-72 hrs obtained to enable 
quantification of final infarct volume 
These inclusion criteria are similar to those used in previous threshold derivation 
work (131). The presence of an arterial occlusion which does not recanalize on 
follow up scanning permits the assumption that all hypoperfused tissue which 
was at risk of infarction at baseline will have infarcted at follow up. In this 
assumption even small degrees of recanalisation could potentially result in 
reperfusion to some of the ischemic zone and subsequently influence the derived 
threshold. For this reason only those with no recanalisation of any degree were 
selected for inclusion.  Hypoperfused tissue which does not infarct despite the 
lack of recanalization or reperfusion may be considered to be benign oligemia, 
hypoperfused but not actually at risk of infarction (356). 
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Patient data were selected for inclusion in the core threshold dataset based on 
the following characteristics: 
1) Arterial occlusion on admission CTA 
2) Evidence of recanalisation on subacute CTA/MRA at 24-72 hrs 
3) Clinical evidence suggestive of major reperfusion – Improvement in NIHSS 
by ≥4 points at 24 hrs 
4) Follow-up structural brain imaging at 24-72 hrs obtained to enable 
quantification of final infarct volume 
A concurrently acquired DWI was not available as a measure of infarct core but 
as infarct volume at 24 hrs in patients who undergo major reperfusion have been 
shown to be similar to baseline DWI volume subacute imaging characteristics can 
serve as a reference for core lesion volume in selected patients(134). Imaging 
evidence of reperfusion was not available for all patients due to the imaging 
protocols within the POSH study so patients with recanalisation combined with 
major early clinical improvement were chosen as this is likely to represent a 
group with salvaged penumbra and minimal infarct growth between baseline and 
subacute imaging time-points. Final lesion volume in this cohort was used as the 
reference for measuring infarct core extent. 
Patients who met entry criteria for core or tissue at risk analysis were then 
further divided into subgroups. Within the tissue at risk group, patients were 
divided randomly into a threshold derivation group used to test a large range of 
absolute and relative thresholds and a validation group in which to test the best 
performing thresholds from the derivation dataset and a selection of those from 
the literature. The same sub-group division was performed for those meeting 
core group entry criteria, where patients were randomly divided to derivation 
and validation cohorts in which to derive and then test the best performing 
thresholds along with a selection from the literature. Cases were listed within 
the core and tissue at risk groups in Microsoft excel and a randomisation formula 
was used to select patients for inclusion in either threshold derivation or 
threshold validation subgroups separately for core and tissue at risk. 
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6.2.2 Image Acquisition 
Multimodal CT examination was obtained using a Multidetector Scanner (Philips 
Brilliance 64 Slice) comprising non contrast CT, CT perfusion and CTA from aortic 
arch to the Circle of Willis. Imaging parameters are describe in detail in chapter 
3. 
Follow up CT imaging for was with whole brain NCCT followed by intracranial 
CTA from base of skull to the top of the lateral ventricles as described in 
chapter 3. 
Follow up MRI, where applicable was performed on a 3T MRI using post –contrast 
FLAIR to demarcate the final infarct volume (GE, 3.0T Signa Excite, TR 10000 
ms, TE 144.4 ms, slice thickness 5mm matrix 284x286). 
6.2.3 Image analysis 
CTA interpretation 
Initial image analysis is described in chapter 3. In summary, patent identifiers 
were removed and each scan was given a unique study Identification header. 
Presence of arterial occlusion was determined from the acute CTA processed on 
a Philips Brilliance workstation (Advanced Vessel Analysis tool) using source 
images and MIP reconstructions in axial, coronal and saggital planes. An 
occlusion was defined as an absence of contrast material in the vessel which 
completely separated the proximal portion of the vessel from the distal 
portion(111). Recanalisation was determined using an adapted Thrombolysis in 
Myocardial infarction (TIMI) scale where recanalisation was defined as none (TIMI 
0), minimal (TIMI 1) partial (TIMI 2) and complete (TIMI 3)(167) 
 CTP processing 
CTP post-processing was performed using MIStar.  This provided 4 perfusion 
parameters for analysis, CBF, CBV, MTT and DT. Motion correction was 
automatically applied by the programme after loading the raw CTP dataset. AIF 
and VOF were selected semi-automatically after placing a ROI in the anterior 
cerebral artery and superior saggital sinus respectively. 
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Deconvolution of the tissue enhancement curve and the AIF was performed using 
a modified singular value decomposition (SVD) method. A tissue impulse residue 
function (IRF) was derived, where the maximum of the IRF appears at certain 
time point known as Tmax. Usually where Tmax=0 this reflects normal blood 
supply in normal tissue without delay. In contrast, Tmax>0 is considered to be   
associated with arterial delay and dispersion effect due to the presence of an 
ischemic lesion. While the physiological meaning of Tmax is unclear, its value 
could be dependent on various factors including arterial delay and dispersion, 
tissue transit time and dispersion, as well as the cut-off threshold for the SVD 
deconvolution algorithm. In order to properly compensate for the effect of 
arterial delay and dispersion, a vascular transport model involving an arterial 
transport function with a delay time and a relative dispersion was used(341). 
The effect of the arterial transport function is to shift and broaden the AIF 
profile, more reflective of true physiology in acute stroke. A delay-corrected 
SVD deconvolution approach applied a series of delay time values, DTi, ranging 
from 0 to Tmax. For each delay time, a modelled arterial transport function was 
convolved with the measured global AIF to produce an AIF (i), which is used for 
SVD deconvolution of the tissue curve to generate an IRF (i) with its maximum 
appearing at Tmax (i). The actual delay time, DT, was determined as the 
minimum DTi value which produces Tmax (i) =0.  
Subsequently, CBF and CBV were determined from the deconvolved tissue 
concentration-time curve. CBV was measured as the area under the deconvolved 
curve while CBF was measured as the peak height of the deconvolved curve. 
Knowledge of these values for each pixel measured in turn permitted the 
calculation of MTT according to the following: 
                                            MTT=CBV/CBF 
 A constant relative dispersion value of 0.35 was used in this study, 
automatically incorporated by the processing software. This figure is based upon 
the best fit from internal validation of the MIStar software performed by the 
software designers. While this figure has been used in CTP validation in other 
cohorts, the accuracy of the dispersion correction alone has not been subject to 
external validation (134, 340, 341, 357). 
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Follow up imaging was co-registered to the baseline CTP frames as previously 
described. 
 
6.2.4 Derivation dataset image analysis 
Final infarct ROIs were delineated semi-automatically from co-registered images 
by growth of a ROI seed placed within the infarct according to threshold with 
subsequent manual correction as required for each slice to ensure the ROI 
matched the visualised region of infarction (Figure 6.1)   
 
Figure 6-1 ROI Surrounding Final Infarct Volume 
Subacute NCCT showing left MCA territory infarction with ROI superimposed on the visualised 
area of hypodensity. 
ROIs were transposed onto the corresponding perfusion map slices which could 
be altered according to perfusion threshold so as to test the predictive value of 
several different perfusion parameters and thresholds. Seven different perfusion 
parameters were tested: Absolute CBV, Relative CBV, Absolute CBF, Relative 
CBF, Absolute MTT, Relative MTT and DT in core and penumbra groups, with 66 
and 65 different thresholds assessed for core and penumbra in total respectively. 
The thresholds tested were chosen to reflect the range of those previously 
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tested in the literature. The range of thresholds evaluated are shown in Tables 
6.1 and 6.2 
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Perfusion Parameter Threshold Range Increment 
Relative MTT 100-250% 25% 
Absolute MTT 4-14 seconds 1 second 
Relative CBF 40-90% 5% 
Absolute CBF 5-45ml/100g/min 4ml/100g/min 
Relative CBV 40-90% 5% 
Absolute CBV 0.5-3.5ml/100g 0.3ml/100g 
Delay(DT) 0-10 seconds+ baseline 2 seconds 
Table 6-1 Perfusion Parameter Ranges and Increments Evaluated for Tissue at Risk 
Relative measures are percentages relative to the mean value in the contralateral hemisphere 
 
Perfusion Parameter Threshold Range Increment 
Relative MTT 125-300% 25% 
Absolute MTT 4-14 seconds 1second 
Relative CBF 10-60% 5% 
Absolute CBF 3-17 ml/100g/min 2ml/100g/min 
Relative CBV 10-70% 5% 
Absolute CBV 1-2.5ml/100g 0.25 ml/100g 
Delay (DT) 0-10seconds + baseline 2seconds 
Table 6-2 Perfusion Parameter Range and Increments Evaluated for Core 
 
The ranges of thresholds were evaluated for each slice after placing the infarct 
ROI onto the Penumbragram which could be manipulated according to a chosen 
perfusion threshold. All pixels within the Penumbragram could be dichotomised 
as either within or out-with a certain pre specified threshold. In order to test a 
single threshold at a time, all pixels within the threshold were defined as core 
within the programme and all others defined as penumbra. This meant that the 
absolute number of pixels within and out-with a certain threshold could be 
quantified based on the pixel being represented by one of two possible colours. 
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“Positive” pixels which were within a given threshold appeared as red and those 
outside that threshold appeared as green “negative” pixels (Figure 6.2). 
 
 
Figure 6-2 Penumbragram with Infarct ROI 
Red pixels represent pixels within a given threshold; green pixels represent all other parenchymal 
pixels. Final Infarct ROI is superimposed in yellow. 
 
Pixels within a chosen CTP threshold which appeared within the final infarct 
volume were defined as “true positives” (TP), while pixels which were within 
the chosen threshold but were not within in the final infarct volume were 
classified as “false positives” (FP). Pixels which were within the final infarct but 
were not predicted by the chosen threshold were “false negatives” (FN) and 
non-infarcted pixels not within the thresholded perfusion lesion were “true 
negatives” (TN) (Figure 6.3). Only pixels in the affected cerebral hemisphere 
were considered for this analysis as inclusion of whole brain pixels would result 
in an over-representation of “true negative” pixels which correctly predict that 
pixels in the hemisphere contralateral to the ischemic lesion would not undergo 
infarction and result in an overestimation of the true specificity of the threshold 
tested(134) 
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Figure 6-3 True & False Positive/Negative Pixels 
Positive pixels appear red, negative pixels appear in green. Their relation to the final infarct ROI 
defines whether or not each is a true or false positive/ negative. 
 
6.2.5 Validation datasets image analysis 
A total of 4 perfusion parameter thresholds were evaluated in the independent 
validation datasets for both core and penumbra. After the optimum parameter 
thresholds were derived from each the derivation datasets, the best performing 
thresholds from the ROC curve analysis were tested along with selected 
thresholds from the literature for accuracy in predicting core and tissue at risk 
volume. For core analysis, absolute CBV ≤2.0ml/100g and relative CBF ≤45% of 
normal were evaluated with the best derived thresholds, while for penumbra 
relative MTT ≥145% of normal was evaluated in addition to the best thresholds 
from derivation dataset. AIF and VOF selection and co-registration were 
performed as previously described for the derivation group image analysis. 
Volume of tissue defined according to each chosen parameter threshold was 
measured. Final infarct volume in the corresponding slices on follow up imaging 
was determined from ROI analyses using semi-automated ROI growth with 
subsequent manual correction in the same way as previously described. 
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Infarct volume for the validation datasets were evaluated on two occasions 
separated by approximately 2 months blind to the results of the first reading in 
order to determine intra-observer agreement for infarct volume determination. 
 
6.2.6 Statistical analysis 
Derivation Datasets 
Sensitivity for each threshold was calculated as TP/ (TP+FN), while specificity 
was defined as TN/ (TN+FP). The combination of sensitivity and specificity were 
plotted for each threshold on a ROC curve of sensitivity (Y-Axis) against 1-
specifity (X-axis) for all pixels evaluated. AUC for each perfusion parameter and 
Youden’s index for each threshold tested were derived from the ROC curve for 
each perfusion parameter [Youden’s index Y= (sensitivity + specificity) -1](358). 
The parameters with highest Youden’s index values, reflecting the best overall 
combination of sensitivity and specificity, were examined in more detail to 
determine the optimum threshold within the perfusion parameter tested for 
each patient within the derivation datasets.  The thresholds which corresponded 
to the best sensitivity and specificity combination per perfusion parameter per 
patient were plotted using a histogram, with the most frequently occurring 
threshold(s) chosen for testing in the validation datasets. The comparison of 
thresholds with different sensitivity and specificity illustrated in figure 6.4 
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Figure 6-4 Effect of Varying Perfusion Threshold on Sensitivity and Specificity 
The effect of varying the perfusion threshold on the number of true and false positive pixels 
measured. Relative MTT of 100%, 150% 200% and 250% of normal are shown. Large numbers of 
false positive pixels reflect sensitivity but poor specificity of the MTT threshold 100 % (on left). The 
converse is seen with a higher threshold of 250%, with fewer false positives but also fewer true 
positives – seen on right. 
Validation Datasets 
Volume of predicted infarct volume from CTP according to the selected 
thresholds were compared to the actual final infarct volume using a Bland 
Altman plot comparing means and differences in predicted and actual infarct 
volume for core and penumbra groups . 
Baseline clinical characteristics of each group were compared using the Mann-
Whitney test. Statistical analysis was performed using Graphpad Prism 
(www.graphpad.com) 
 
6.3 Results 
Tissue at Risk Group 
 
Of 118 patients recruited to the combined studies for the present analysis, 44 
had no visualised occlusion, 6 did not have recanalisation assessed, 42 had 
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evidence of some recanalisation on subacute CTA/MRA, 4 had chronic ICA 
occlusions which were not responsible for the acute presentation, 1 CTP was 
acquired with jog mode, 1 stroke lesion was outside the CTP coverage (Superior 
Cerebellar Artery occlusion) leaving 20 patients with persistent symptomatic 
arterial occlusions for analysis. One was later excluded from analysis because of 
massive and ultimately fatal space occupying oedema on follow up imaging as 
the range of perfusion thresholds tested would inevitably underestimate the 
apparent infarct volume in this setting.  
Of those included, eleven were male and 8 were female. Median age was 72 
years (IQR 63-81) and median NIHSS on admission was 18 (IQR 11-19). Occluded 
vessels included internal carotid artery (ICA) (n=6), M1 segment Middle Cerebral 
Artery (MCA) (n=6), M2 segment (n=5), M3 segment (n= 1) and Posterior Cerebral 
Artery (PCA) (n=2). Median time from symptom onset to imaging with CTP was 
164 minutes (IQR 136-196) and hemisphere affected was the left side in 13/19 
cases. 17/19 had follow up brain imaging with CT with a median time from onset 
to follow up scan of 26 hours (IQR 24-31). There were no significant differences 
in age, NIHSS or imaging times between validation and derivation datasets 
(Table 6.3). 
 All 
(n=19) 
Derivation 
Dataset 
(n=12) 
Validation 
Dataset 
(n=7) 
P 
Age (Mean 
+SD) 
71(11) 69 (11) 
 
74(11) 
 
0.35 
 
NIHSS (IQR) 18(11-19) 
 
17(11-19.8) 
 
19(8-19) 
 
0.93 
 
Onset to CTP 
(Mins)(IQR) 
164 (136-196) 
 
156 (138-196) 
 
169(130-247) 
 
0.47 
 
Time to follow 
up imaging       
(Hours)(IQR) 
26(24-31) 
 
27(24-30) 
 
25(24-48) 
 
0.77 
 
Table 6-3 Characteristics of Tissue at Risk Evaluation Group 
Groups were compared using the t test or the Mann Whitney U test for normal and non-normally 
distributed data, respectively. 
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Over 3.8 million pixels were analysed in total. ROC curves and Youden’s index 
for each perfusion parameter showed that the best overall predictors for tissue 
at risk were relative MTT, absolute MTT and delay time.  (Figure 6.5) 
The best combination of sensitivity and specificity for these perfusion 
parameters were determined for each patient showed clustering around DT ≥2 
seconds, absolute MTT  ≥7 seconds and relative MTT of 125% for the three 
parameters evaluated suggesting that these thresholds had the best predictive 
value of infarct volume in this setting (Figure 6.6). 
In the validation dataset, Bland-Altman plots to assess the accuracy of each 
chosen threshold (Relative MTT ≥125%, Absolute MTT ≥7seconds , DT ≥ 2 
seconds) and one from the literature (relative MTT≥ 145%) revealed that the cut 
point with most accuracy in predicting final infarct volume was DT ≥ 2 seconds 
(95% limits of agreement -44 to +30, Bias -6.89) followed by relative MTT≥145% 
(95% limits of agreement -75.1 to +96.8 Bias +10.8), relative MTT ≥125% (95 % 
limits of agreement -70.1 to +108.5 Bias 19.2) and Absolute MTT 7≥ seconds (95% 
limits of agreement -65.7 to +112.2  Bias 23.3)(Figure6.7). 
 
 
 
Figure 6-5 Youden’s Index for Each Perfusion Threshold Evaluated for Tissue at Risk 
186 
 
Figure 6-6 Frequency Distribution for Optimum DT, Relative MTT and Absolute MTT 
Thresholds for Tissue at Risk 
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Figure 6-7 Bland Altman Plot for DT >2 Seconds, Relative MTT 145 %, Relative MTT 125 % 
and Absolute MTT 7 Seconds for Detecting Tissue at Risk 
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Core Group 
16 patients were included in the core threshold analysis, 7 were male and 9 
were female. Median age was 75 (IQR 65-83), Median NIHSS on admission was 15 
(IQR 7-15) and median time to subacute imaging with CT/MRI was 29 hrs (IQR 27-
63), with subacute CT being performed for 15/17 cases. Left hemisphere was 
affected in 6/17 occasions. Vessel occlusions at baseline included M1 MCA (8) M2 
(5) PCA (2) and ACA (1). 
There were no significant differences in clinical characteristics at baseline 
between derivation and validation groups (Table 6.4). Over 2.9 million pixels 
were analysed. 
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 All Derivation 
Dataset 
Validation 
Dataset 
p 
Age 
(Mean + SD) 
72(14) 73(13) 
 
70(15) 
 
0.62 
 
NIHSS  
(Median + IQR) 
15(7-18) 
 
8(7-16) 
 
18(12-22) 
 
0.08 
 
Onset to CTP 
(Mins) 
(Median + IQR) 
196 (149-233) 
 
219 (154-284) 
 
188(143-227) 
 
0.35 
 
Time to follow 
up imaging       
(Hours) 
(Median +IQR) 
29(27-63) 
 
28(25-52) 
 
30(27-123) 
 
0.63 
 
Table 6-4 Clinical Characteristics of Infarct Core Groups 
Groups were compared using the t test or the Mann Whitney U test for normal and non-normally 
distributed data respectively. 
Cut points derived from the ROC curves for each perfusion measurement showed 
that absolute and relative MTT were the best predictors of final infarct volume 
in the trial dataset (Figure 6.8) and histograms of the most frequently occurring 
thresholds for each parameter demonstrated clustering at absolute MTT of 8 
seconds and relative MTT of 125% of normal (Figure 6.9) 
Bland-Altman plots for these two derived thresholds and two from the literature 
(Absolute CBV ≤2.0 ml/100g and relative CBF≤ 45%) revealed that the best 
performing threshold was relative CBF ≤ 45% (bias -3.9ml, 95% limits of 
agreement -51.6 to +43.6) followed by absolute CBV ≤2.0 ml/100g (bias 6.4ml 
95% limits of agreement -49.3 to +62.3),  absolute MTT of 8 seconds (bias 
24.4ml, 95% limits of agreement -38.8 to + 87.6) and relative MTT of 125% (bias 
39.2ml 95% limits of agreement -47.4 to +127.8 ) (Figure 6.10). 
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Figure 6-8 Youden’s Index for Each Perfusion Threshold Evaluated for Core 
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Figure 6-9 Frequency Distribution for Optimum Relative (A) and Absolute (B) MTT 
Thresholds for Core 
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Figure 6-10 Bland Altman Plot for Relative CBF ≤45%, Absolute CBV 2ml/100g, Absolute 
MTT> 8 Seconds, and Relative MTT125%, for Detecting Infarct Core 
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6.4 Discussion 
The previous studies that sought to establish thresholds for core and penumbra 
with CTP have proposed different perfusion parameters and values for viability 
thresholds. The differing results highlight the need to find agreement on which 
perfusion measures are best for measuring core and tissue at risk using CTP. 
Validation of any derived thresholds in an independent dataset has not been 
previously performed but some of the proposed thresholds have been used in 
selection criteria for clinical trials (47). The importance of validation is 
highlighted in the variation in performance of some thresholds within the 
validation studies. 
The results show that time based perfusion measures are best for defining 
hypoperfused tissue which is at risk of infarction in the setting of persistent 
arterial occlusion.  Relative MTT, Absolute MTT and DT all performed similarly in 
the derivation group as shown in figure 6.5 implying the best available 
combinations of sensitivity and specificity for detecting tissue at risk. MTT has 
been used as a marker for tissue at risk with CTP previously, and both relative 
and absolute measurements had similar values for AUC in ROC curve analysis. DT 
is a more recently used measurement for hypo perfusion and has been recently 
reported as a marker for tissue at risk in another study (357). Although these 
perfusion indices performed similarly in the derivation group, the performance 
in the validation group showed variation in predictive value of each , with the 
best measurement being DT≥2 seconds which performed best in the Bland 
Altman plot comparison between predicted and final infarct volumes (figure 
6.7). This measurement was close to final infarct volume in the validation 
dataset over a range of infarct volumes, but had a tendency to underestimate 
the final infarct volume. The MTT measurements tended to overestimate the 
infarct volume, but relative measurements performed better than absolute 
measurements of MTT in keeping with previous work on threshold derivation for 
tissue at risk (131). MTT of 145% performed best of the three MTT measures 
tested in the validation dataset, but was not predicted by the derivation 
dataset. This shows that relative MTT is a good measurement of tissue at risk but 
emphasises the importance of validating the performance of any proposed 
threshold as ROC curve derivation alone does not give a measure of how closely 
a chosen threshold will perform in practice. MTT of 145% was tested because it 
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is widely used in practice and a comparison with the best derived thresholds 
could help compare accuracy in practice. As DT provided closer measurements of 
infarct volume it appears to be a superior predictor of infarct volume to relative 
MTT which has been reported elsewhere(134). 
The predictive value of the perfusion measures tested in the derivation dataset 
seems less in comparison to previous studies(131). Important methodological 
differences may account for the apparent difference. When determining 
threshold sensitivity and specificity using a ROC curve Wintermark et al included 
pixels in the contralateral hemisphere as true negatives, meaning a chosen 
threshold under evaluation correctly did not predict infarction in those pixels 
which were contralateral to the stroke lesion(131). This would inevitably result 
in a much larger number of true negative pixels being measured for each scan 
evaluated relative to the number of false positive pixels. As specificity is 
determined as TN/(TN +FP), the inclusion of contralateral negative pixels would 
result in larger values for specificity at all points increasing the AUC for the ROC 
curve.  By including only pixels ipsilateral to the stroke lesion, this study 
included fewer true negative pixels for each scan slice resulting in lower 
apparent specificity but a result which is likely to be more reflective of the true 
measurement. Not all pixels ipsilateral to the stroke lesion will be at risk of 
infarction such as distal MCA occlusions. Even in this setting specificity may be 
overestimated by including all hemispheric pixels but for consistency in 
methodology this was performed as the territory of any given arterial occlusion 
could not be accurately demarcated. The variability in what pixels may be 
considered as potentially at risk and counted for in ROC curves underscore the 
importance of performing a subsequent validation of chosen thresholds. 
The perfusion threshold which most accurately measured core in the validation 
dataset was relative CBF of ≤45%, which was the closest measurement of infarct 
core when compared using Bland Altman plots (figure 6.10).  This tended to 
underestimate the core lesion volume but all other thresholds tested in the 
validation group overestimated lesion volume. As two thresholds from the 
literature were available for testing, I chose only the best 2 from the validation 
datasets for comparison. Again the importance of threshold validation was 
underscored as the best threshold from the validation dataset was not actually 
predicted by the derivation dataset. MTT measures had the best Youden’s index 
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values from the derivation dataset. As stated, this is usually considered a marker 
for tissue at risk but not for core, although recent work has demonstrated that 
MTT can have a predictive value in defining core within the DWI lesion on MRI 
suggesting it may be helpful in detecting core(359). As core tissue is usually 
located within a volume of hypoperfused tissue and MTT can be used to measure 
hypoperfusion it is not surprising that MTT is sensitive for infarct core and 
therefore can have relatively high AUC and Youden’s index values for core 
detection. Its specificity is not likely to be as good because MTT would be 
expected to include penumbra as well as core. In the model used for this study, 
the measurement of core was performed on subacute images in a selected 
patient group with clinical evidence suggestive of major reperfusion. Infarct 
growth even to a small degree after the timing of initial scanning could result in 
infarct core expansion into the space occupied by penumbra which may account 
for the apparent predictive value of MTT in this setting.  The large 
overestimation of infarct volume by MTT measures in the validation dataset 
suggest that the choice of recanalisation and clinical improvement is likely to 
represent a model of minimal infarct growth overall. The overestimation of 
infarct volume by absolute CBV in the validation dataset is of importance given 
its widespread use as a marker for core on CTP post-processing packages in 
practice. CBV may not be accurately determined in situations of severe 
hypoperfusion, and this may explain differing values proposed in the literature 
to define core tissue (including≤2.0ml/100g and <2.3ml/100g(131) and CBV/CBF 
interaction (133).The results suggest absolute CBV may not be a reliable marker 
for infarct core as it still overestimates lesion volume in a model were some 
lesion growth cannot be excluded. Relative measurements of CBF have been 
suggested as superior markers for infarct core in a number of studies and the 
present results support this finding(104, 355, 357).  Stroke severity, although not 
statistically different between groups, did appear to be greater in the validation 
dataset. As this stroke severity is likely to increase with increasing lesion 
volumes, a confounding effect on threshold accuracy cannot be excluded.  
The CTP processing algorithm is different to previous studies examining 
thresholds for determining tissue at risk. Delay insensitive deconvolution has 
been shown to be important when examining reversibility of perfusion lesions 
after recanalisation(127). Delay insensitive algorithms produce perfusion maps 
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that are less sensitive to tracer delay, a problem that may result in an 
overestimation of the volume of tissue at risk particularly in cases of 
extracranial stenosis. The post processing package in this study used a delay-
insensitive deconvolution algorithm which also took into account the effect of 
bolus dispersion.   
This study has some strengths and also limitations. The small sample size in each 
group places a limit on the generalisability of the results to all patients, and 
differences in stroke severity seen between groups could have a confounding 
effect, despite the lack of statistically significant differences, due to the small 
sample size. A large number of pixels were included for analysis despite the 
sample size. Inclusion of patients with different arterial occlusions at baseline 
reflects clinical practice, although different thresholds may exist for different 
arterial territories. Although a minimal sample size calculation has not been 
done, larger cohorts could have produced different results. The results are 
consistent with other work on threshold derivation suggesting that future studies 
could focus on validation of existing perfusion thresholds. The choice of imaging 
modality at follow up is a potential limitation. Other studies have used MRI at 
24- 120 hours for final infarct volume determination while the majority in this 
analysis had volumes measured on CT which may be more difficult (131, 134). 
The clinical severity and proximal occlusions included however were typically 
associated with large infarct volumes which were readily demonstrated on CT. 
Early swelling may mask the true final infarct volume. Although the timing for a 
“gold standard” infarct volume has been suggested as 90 days, changes after the 
subacute period may be negligible (156). Furthermore as illustrated in chapter 4, 
imaging at later time points is less feasible than early time points. A pragmatic 
approach to study design for POSH and MASIS, along with the amalgamation of 
the datasets to identify suitable recruits necessitated the use of early imaging 
outcomes. All data were acquired from a single institution with the same 
scanner specifications and imaging protocols. Therefore the results may not 
necessarily be applicable to other centres with different image acquisition 
protocols. The need to harmonise CTP acquisition protocols has been emphasised 
elsewhere and threshold validation on different scanner types is needed (168). 
Image analysis was performed by a single reader with the potential for error. 
Differences in lesion volume measurements were small when intra observer 
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agreement was assessed but co-registration errors, if present may also have had 
an influence on the outcome.   
The fully deconvolved processing algorithm with correction for bolus 
delay/dispersion is strength of the study as delay correction is being increasingly 
recognised as an important feature of CTP post processing (127). The large 
perfusion slab permitted coverage of a large portion of the ischemic area, 
although some hypoperfused tissue may have been beyond the CTP coverage. A 
large range of perfusion parameters and thresholds were tested comprising 
absolute and relative measures. Dividing groups into derivation and validation 
datasets had not previously been done which is a strength of the study because 
no assessment of how precisely perfusion thresholds predicted core or tissue at 
risk was previously available. Previous publications derived thresholds for tissue 
at risk in 46 patients and core in 25, 57 and 48 patients but did not evaluate the 
performance of chosen thresholds in independent datasets (134, 355). Different 
perfusion parameters and thresholds may underestimate or overestimate core 
and tissue at risk, but the closest matches are likely to indicate reasonable 
markers for each tissue compartment. There was little difference in measured 
volumes at different time points highlighting consistency in ROI analysis 
performed for determining infarct volume. 
6.5 Conclusion 
This study demonstrated that the ability to predict tissue at risk of infarction 
with CTP is best using DT≥ 2 seconds which is a superior measure to the 
previously used relative MTT of 145% of the contralateral normal hemisphere. 
Irreversibly damaged core tissue is best predicted using relative CBF of 45%. As 
optimum thresholds may depend on processing software and scanner type, 
evaluation of these thresholds in different populations and scanner types is 
required. 
In order to realise the promise of CTP for patient treatment selection in clinical 
trials or routine management, standard definitions of core and penumbra 
thresholds are required. Clinical, imaging and scanner specific differences exist 
between different studies which have evaluated perfusion based definitions for 
core and penumbra which may limit their use as in acute stroke assessment and 
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as outcome markers in trials. These results should be tested in a wider setting 
using different scanner protocols and manufacturers. Prospective evaluation of 
these and other thresholds in independent cohorts is needed to examine how 
they perform in wider clinical practice. 
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Chapter 7. Pixel Based Identification of Infarct Core 
on Non-Contrast CT 
7.1 Introduction 
Early ischemic changes including hypodensity and brain swelling may be 
visualised in most MCA territory strokes within 3 hours of symptom onset when 
viewed by expert readers although hypoattenuation and brain swelling are likely 
to represent distinct stages of the ischemic cascade (71, 360-362).Water uptake 
into cells results in visualised hypoattenuation(78). Hypo attenuated regions on 
CT correspond to regions of DWI abnormality(320). Reduced CBV and CBF are 
seen in regions with hypoattenuation while focal swelling is associated with 
increased CBV(363). Areas of hypoattenuation within 6 hours of stroke onset 
almost always progress to infarction on follow up MRI whether reperfusion occurs 
or not, and larger volumes of hypoattenuation are associated with larger infarct 
volumes and less favourable outcomes(74, 363). The presence of 
hypoattenuation on CT indicates core with high specificity, but sensitivity for 
detection is low and interobserver agreement can be low even using methodical 
grading tools such as ASPECTS (71, 79). It has been suggested that a normal CT 
may not imply solely a lack of sensitivity, but instead represents a favourable 
situation where ischemic oedema has not yet developed (99). However the 
presence of infarct core markers on CTP acquired concurrently to CT suggests 
that sensitivity is a genuine limitation of CT and core may be present at a 
cellular level but not necessarily visible on CT(130). CTP acquired after CT can 
measure core according to thresholds with CBF being suggested as the most 
appropriate marker for core from earlier chapters and other work (104, 134, 
355). Given that interobserver agreement for detecting hypodensity can be poor 
while expert readers may report better sensitivity when interpreting CT scans, a 
less subjective interpretation of CT for the presence of infarct core could be of 
interest in demonstrating the sensitivity of CT alone or in outlining the 
importance of additional imaging for measuring infarct core(74). For example, if 
absolute values for HU attenuation could be shown to be sensitive and specific 
for core, an analysis of CT based on absolute HU thresholds could potentially add 
helpful information beyond what is obtained by a standard visual interpretation 
of a CT scan. Grey and white matter have different attenuation on CT, with loss 
of distinction between compartments a sign of early ischemic change(364). The 
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definition of hypodensity for each may be different given the variation in 
baseline appearances so accounting for differences in HU attenuation in grey and 
white matter separately would be important. I sought to measure the absolute 
HU values of pixels on CT which were considered infarct core on CTP in order to 
determine the sensitivity and specificity for infarct core detection on non-
contrast CT for both grey and white matter.    
7.2 Materials and methods 
Patient selection 
Consecutive patients who participated in the POSH study between January 2009 
and January 2011 were considered for inclusion. From this dataset, scans were 
selected for analysis according to the following criteria: 
1: Confirmed diagnosis of ischemic stroke 
2: Baseline occlusion visualised in ICA or MCA territory 
3: Core lesion volume >5ml on baseline CTP scan 
Clinical characteristics and measurements are described in the materials and 
methods chapter. 
Image analysis 
Anonymized scans were processed using the MIStar image processing platform as 
previously described. Admission CT scans were first co-registered to the baseline 
frames of the CTP using a rigid body 3-D transformation as previously described. 
Slices reformatted to match the CTP orientation were used for core 
quantification. Two 5 mm slices corresponding to the lower and upper ASPECTS 
reading areas were chosen to give a representative sample of both grey and 
white matter for each patient included. 
Grey and white matter segmentation was performed using the time-averaged 
mean arterial phase sequences at each ASPECTS level which produced maximal 
contrast between grey and white matter in normal tissue(355). Normal grey and 
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white matter were segmented according to HU threshold in the hemisphere 
contralateral to the stroke region by placing ROI seeds within each on the time 
averaged maps and adjusted according to threshold with manual correction if 
necessary. Normal grey and white matter ROIs were then transposed onto the 
reformatted CT scan and then mirrored to the contralateral (symptomatic) 
hemisphere in order to give a map of the territories comprising grey and white 
matter. The unaffected hemisphere was used to delineate normal grey and 
white matter as the presence of a stroke lesion would be likely to obscure the 
normal boundaries between each.  
CTP data were then processed as previously described according to a delay 
corrected deconvolution algorithm with AIF and VOF selected from the Anterior 
Cerebral Artery and Superior Saggital Sinus respectively.  Given the results of 
the thresholds derivation and evaluation chapter, along with developments in 
the literature suggesting CBF is the optimum marker for core rather than CBV 
core pixels were defined by relative cerebral blood flow of ≤ 45% of normal(104, 
134).  
ROIs were drawn semi-automatically around areas of core tissue on the final 
“Penumbragram” map on the upper and lower ASPECTS slices and saved. These 
ROIS were transposed to the appropriate slices on the reformatted CT along with 
the grey and white matter ROIs (Figure 7.1).  
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Figure 7-1 Core Grey & White Matter Segmentation 
Grey and white matter are segmented in the right hemisphere on time averaged CTP, transposed 
to CT and mirrored to the affected hemisphere. ROI for core pixels are also transposed (only 1 core 
ROI shown). Penumbragram revealing extent of core and penumbra is shown at bottom for 
reference . Core pixels shown in red, penumbral pixels shown in green. 
Pixels within each ROI in the stroke hemisphere had a Hounsfield unit value and 
a spatial location given by an x and y coordinate which were combined for each 
patient and saved as a text file. The HU values for Grey, white matter and 
overlapping core were therefore recorded. The saved ROI data comprising 
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spatial and HU value information for each pixel in text format was exported to 
Microsoft Excel and manipulated in a series of steps that permitted separation of 
normal and core tissue for both grey and white matter: 
1) The core ROI and Grey matter ROI data were combined in an excel file 
with separate columns for pixel number, x coordinate, Y coordinate and 
HU value. Duplicate rows in this composite of 2 saved ROIS reflected 
pixels identical spatial positions. These were selected from the overall list 
using an excel formula and saved. The saved pixels corresponded to those 
grey matter pixels which were defined as core on the CTP (Termed A).  
2) The remaining “non duplicate” pixels were a combination of both normal 
grey matter and core pixels which were spatially within the white matter. 
This composite  was also selected and saved(Termed B) 
3) White matter ROI pixels were combined with the same core ROI pixels in 
Excel as above (see step 1) and duplicate pixels were again highlighted 
and saved. Duplicate pixels corresponded to white matter pixels that 
were defined as core on CTP (Termed C) 
4) The remaining pixels after removing the duplicates were a combination of 
normal white matter pixels and core pixels which occupied white matter 
space (Termed D) 
5) D and A were combined in single document and duplicate pixels were 
selected and deleted. This removed any grey matter core pixels from the 
combined list (D and A). The remainder represented all normal white 
matter pixels for that scan slice (Termed E) 
6) C and B were combined in a single document and duplicate pixels were 
selected and deleted in order to remove any white matter core pixels 
from the combined list (C and B). The remaining list represented all 
normal grey matter pixels for that scan slice (Termed F). 
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In summary: 
A= Grey Matter core 
B= Normal Grey matter along with some White Matter core pixels 
C= White Matter core 
D= Normal White Matter along with some Grey Matter core pixels 
E= (A+D) minus any duplicates = normal White Matter pixels 
F= (C+B) minus any duplicates= normal Grey Matter 
 
By subjecting the raw numerical data to the series of steps described, the HU 
values for normal and infarcted grey and white matter were listed for each slice 
examined and combined for individual patients. Core pixels were assigned a 
value of 1 and normal parenchyma was assigned a value of 0 for subsequent 
statistical analysis. 
Statistical analysis 
SPSS version 18 was used for all statistical analysis undertaken. For each patient 
sensitivity and specificity for quantifying core pixels was assessed using ROC 
curve generation, with the area under the curve indicating the overall diagnostic 
performance of CT compared to the chosen gold standard. Optimum cut-points 
per patient were derived from the ROC curve to determine the HU threshold 
with best sensitivity/specificity combination for detecting core pixels. Youden’s 
index was used to quantify the combination of sensitivity & specificity for each 
threshold tested. Histograms were generated to identify which HU cut-points 
with highest Youden’s Index value occurred most frequently.  HU values of pixels 
for all patients were additionally combined to produce a ROC curve for overall 
performance of CT in detecting CBF defined core. Sensitivity and specificity 
measurements for each threshold were interpolated from the ROC curve and 
overall sensitivity and specificity for the most frequently occurring HU cut-point 
for grey and white matter was calculated from the ROC curve.  
205 
7.3 Results 
89 subjects were considered for inclusion. 32 had no occlusion on CTA, 2 had 
problems with AIF selection due to movement rendering perfusion maps 
unusable, 2 had Anterior Cerebral Artery  occlusions, 7 had posterior circulation 
occlusions, 12 had no core on CTP despite having an arterial occlusion, and 1 
patients admission CT scan was not available leaving 33 in the final analysis 
cohort. Clinical and imaging characteristics are shown in table 7.1 
Variable Result 
Age (Mean +SD) 72 (12) 
NIHSS( Median +IQR) 16 (11-20) 
Carotid occlusion (n) 9 
M1 occlusion (n) 11 
M2 occlusion (n) 13 
ASPECTS- NCCT   
(Median +IQR) 
6.0 (4.5-9.0) 
ASPECTS- CBV 
(Median +IQR) 
8.0 (6.0-9.0) 
ASPECTS CBF  
(Median +IQR) 
4.0 (1.0-7.0) 
ASPECTS MTT (Median 
+IQR) 
4.0 (3.0-6.0) 
ASPECTS TTP  
(Median +IQR) 
4.0 (3.0-6.0) 
24 hr NCCT ASPECTS          
(Median +IQR) 
6.0(3.0-6.0) 
Table 7.1 Clinical Characteristics of patients included in analysis of core pixels on NCCT 
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A total of 320845 pixels were included in the analysis, comprising 180960 grey 
matter and 139885 white matter pixels. AUCs for CT based quantification of 
infarct core were 0.641 and 0.601 for grey and white matter respectively (Figure 
7.2 and 7.3) 
 
Figure 7-2 ROC Curve for Presence of Grey Matter Core Pixels on CT 
AUC for detecting core in grey matter based on HU value alone=0.641 
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Figure 7-3 ROC curve for presence of White Matter core pixels on CT 
AUC for detecting core in white matter based on HU value alone=0.601 
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Frequency distribution for the best performing grey matter thresholds showed 29 
HU to be the most frequent threshold (Figure 7.4). The most frequently 
occurring threshold for white matter core was 28 HU (Figure 7.5) 
 
Figure 7-4Frequency Distribution for Grey Matter Cut Points 
Optimum cut points for each patient varied with 29 HU being the most frequently recorded 
threshold. 
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Figure 7-5 Frequency Distribution for White Matter Cut Points 
Optimum cut points for each patient varied with 28 HU being the most frequently recorded 
threshold. 
29 HU had a median sensitivity of 0.79 and specificity of 0.48 for detecting 
infarct core in grey matter. Lower HU thresholds had increased specificity but 
reduced sensitivity. Examples are shown in Table 7.1 
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HU Sensitivity 
(Median %+IQR) 
Specificity 
(Median %+IQR) 
29 79 
(62-87) 
48 
(32-59) 
 
 20 15 
(9-23) 
 
86 
(80-91) 
 
25 44 
(28-57) 
                              
70 
(62-79) 
 
30 81 
(72-90) 
47 
(25-52) 
 
Table 7-1 Sensitivity and Specificity of HU Thresholds for Detecting Infarct Core in Grey 
Matter 
Lower HU values demonstrate higher specificity for infarct core but at the expense of sensitivity 
28 HU had a median sensitivity of 0.83 and specificity of 0.36 for detecting 
infarct core in white matter. Again, lower HU thresholds demonstrated increased 
specificity with reducing sensitivity. Examples are shown in Table 7.2 
HU Sensitivity 
(Median % +IQR) 
Specificity 
(Median % +IQR) 
28 83 
(74-89) 
 
36 
(26-43) 
 
20 17 
(8-23) 
 
88 
(82-94) 
 
25 57 
(43-69) 
 
60 
(50-70) 
 
30 92 
(86-96) 
 
19 
(12-25) 
 
Table 7-2 Sensitivity and Specificity of HU Thresholds for Detecting Infarct Core in White 
Matter 
Areas with lowest HU values were most specific for detecting infarct core, but these were relatively 
insensitive  
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7.4 Discussion 
This study has evaluated the predictive value of CT for detecting CBF defined 
infarct core based on absolute HU values for grey and white matter. Even with 
expert review of images, CT scans for ECASS II and NINDS were reported as 
normal in approximately 1/3 cases which were found to have infarction on 
follow up imaging, reflecting a limited sensitivity for detecting ischemic changes 
(74, 365). Hypoattenuation on CT is caused by net increase of water in cells 
experiencing reduced cerebral blood flow (78). Animal studies have suggested a 
1% increase in brain water results in a reduction of 2-3 HU on CT(366).The 
detection of hypoattenuation in practice may be difficult with CT as large water 
shifts are needed for the human eye to detect hypoattenuation(367). As large 
shifts are needed before hypoattenuation can be visually appreciated, this study 
was performed to evaluate whether or not attenuation changes may be present 
on CT if not necessarily visible to the human eye. By performing a pixel based 
quantification of the attenuation values of infarct core on CT this study has 
revealed that pixels which are likely to represent infarct core on CTP are not 
reliably detected on CT based on an absolute HU value. The AUC for grey and 
white matter of 0.641 and 0.601 demonstrate only a modest ability for core to 
be quantified on CT based on HU value alone. Irreversibly damaged tissue which 
can be seen on CTP is therefore not necessarily detectable on a concurrently 
acquired non-contrast CT. As subjective interpretation of CT was not 
undertaken, the present findings suggest that CT has limited ability to identify 
core tissue in hyperacute stroke regardless of the interpreter’s experience. A 
“normal” CT scan, therefore, which may represent a good imaging target, does 
not exclude the presence of irreversibly damaged brain tissue. 
The HU values of 29 and 28 for grey and white matter were associated with 
modest sensitivity and low specificity. This initially appears at odds with the 
generally accepted view that hypodensity is specific if not sensitive for infarct 
core(74, 363) but how hypodense any given HU value appears to a reader was 
not evaluated in the study and the trend for increasing specificity with lower 
attenuation values (Table  7.1 and 7.2) confirm that increasingly hypodense 
parenchymal pixels are highly specific for infarct core. While low HU value pixels 
in this study confirm a high probability of tissue infarction, the overall 
performance of CT is limited by the compensatory reduction in sensitivity as 
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indicated by the overall ROC curve values. The two chosen cut-points are close 
to each other in terms of absolute attenuation values and this difference is 
unlikely to be appreciated clinically (367). The AUC for grey matter was higher 
than that of white matter for detection of infarct core. As grey matter 
attenuation is higher at baseline that the adjacent white matter(368), a relative 
reduction from baseline may be more easily detected. However the values for 
both reflect a limited capacity for CT to reveal all core pixels in this time 
window after stroke onset.  
The definition for core on CTP used was reflective of progress in the literature 
and previous results within the thesis, but independent validation of relative CBF 
of 45% as the best measure of core has not been performed which limits the 
interpretation of the results. Not all core pixels measured by CTP may have been 
truly core, while others may have been considered penumbral or even normal on 
CTP. Therefore the choice of a “gold standard” reference for this work is 
potentially questionable. However relative CBF is increasingly recognised as a 
marker for core and has the advantage of being acquired at virtually the same 
time as the CT which limits any natural progression of the stroke lesion being 
responsible for the differences between modalities(104, 134, 355). An additional 
measure could have been to use follow up imaging to confirm that those pixels 
defined as core on CTP were infarcted on follow up but the likely evolution of 
the infarct over time would have limited this as a “gold standard” comparison. 
Only two scan slices were examined per patient but other studies based on pixel 
based comparisons have shown large numbers of pixels can be studied when 
performing a single scan slice comparison and in this study the same scan slices 
based on anatomical landmarks were used for each patient(355). Only pixels 
ipsilateral to the stroke lesion were quantified as the measurement for “normal” 
grey and white matter pixels. Incorporating those in the contralateral 
hemisphere as well would result in a disproportionately large number of negative 
(non –core) pixels and potentially influence the AUC values derived from the ROC 
curves. 
 Strengths of this study include the pixel based analysis of CT which provided a 
novel quantitative approach to assessing stroke on non contrast CT, the large 
number of pixels examined for the ROC curve generation, and the separation of 
grey and white matter into compartments for individual analysis. Limitations of 
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this study include the lack of a validated definition for infarct core as a gold 
standard reference using CTP. In addition , using ROIs from a processed CTP scan 
to measure core and penumbra is potentially an over-simplistic method, as 
within a given ROI, there are likely to be pixels with various different perfusion 
values which may have different predictive value to detect core. The use of an 
ROI based on the “penumbragram” output from CTP ignores the individual 
perfusion characteristics of single pixels.  In addition only a limited number of 
slices were examined per patient which may limit any conclusions, although the 
absolute number of pixels examined overall was large. An additional step which 
could have made the work stronger would have been to prospectively evaluate 
the accuracy of absolute HU values in a validation cohort rather than relying on 
the low AUC values alone from the dataset alone to infer the limited ability for 
plain CT to define core based on HU value.  
The results of this study are of importance when interpreting imaging in acute 
stroke for clinical decision making. The presence of a normal or nearly normal 
scan in clinical practice is seen as a good prognostic sign while extensive changes 
on CT are excluded from treatment as little benefit is likely to be achieved (45). 
Scans in practice may be reported as having “no established change” if obvious 
hypodensity is not seen. This pixel based quantification of core tissue suggests 
that a scan with little or no hypodensity could in fact have irreversibly damaged 
tissue which is not salvageable with treatment but that this tissue cannot be 
detected with certainty on CT. Absence of hypodensity on CT therefore may not 
imply absence of core tissue. The impact this may have in practice is unclear 
however as selection criteria for thrombolysis based on additional imaging with 
CTP are not available. Large core volumes on DWI have a crucial influence on 
outcome (152) but it is unclear who should / should not be treated with 
reperfusion strategies based on additional imaging criteria with CTP. Core on 
CTP still requires validation and thereafter evaluation in clinical trials to assess 
if additional imaging should be used to select patients for therapy, while 
treatment with IV thrombolysis based on a non contrast CT and clinical 
examination is supported by a strong evidence base (369). Imaging based 
methods to improve patient selection for acute stroke treatments have been 
suggested previously(130, 363). This study illustrates the inherent limitations of 
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CT compared to other imaging modalities, but the impact this may have on 
patients receiving treatment should be the subject of further study. 
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Chapter 8. Conclusion 
8.1 Summary 
The work presented within this thesis has evaluated a number of areas of 
importance with regard to acute stroke imaging for both clinical and research 
purposes. There is certainly a need for additional imaging beyond a non-contrast 
CT which was used in most trials of IV alteplase for stroke, as trials evaluating 
novel treatment options have already begun to use imaging markers as 
surrogates for clinical outcome(52, 154). The rationale for using imaging markers 
in trials is clear, but what has been incompletely evaluated previously is the 
range of possible means of which could be employed and how reliable they may 
be in practice. Recanalisation offers an insight into possible effect of lytic 
agents, but reperfusion or infarct growth may provide additional information 
about the usefulness of any vessel recanalisation in terms of tissue salvage. 
Reperfusion and infarct growth are measurements which are feasible to 
determine using multimodal CT but are not the only predictors of outcome. 
 
8.2 Clinical Importance and Future Research 
Considerations 
The contents of the preceding chapters are of relevance for clinical practice in 
acute stroke and highlight areas of uncertainty which should be addressed in 
future research projects. 
Choice of imaging modality in acute stroke assessment has been debated, with 
MRI and CT each having pros and cons. In the MASIS study, centres recruited 
more frequently using CT rather than MRI even though both modalities were 
available at each site. Those who underwent MRI on admission had milder 
degrees of stroke severity at baseline, while MRI was contraindicated or not 
tolerated in some patients suggesting that ongoing focus using CT is important 
for patients with acute stroke. This work cannot answer the question over which 
modality should be used In practice or for trials, but suggests that flexibility 
with use of imaging modality may result in a wider /more clinically relevant 
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population being recruited to studies if CT is used. Given contraindications, 
additional patient factors and access issues, the need for ongoing access to and 
used of CT for acute stroke evaluation remains essential for clinical practice.  
Multimodal CT is being used in many centres as part of routine clinical imaging, 
but the results of the threshold derivation chapter show that further evaluation 
of the accuracy of perfusion thresholds is needed in the first instance prior to 
their use in clinical practice. Anecdotally, CTP appearances have been used to 
justify treatment in late time windows and in wake-up strokes, as well as 
withholding treatment in the current 4.5hr window ( e.g. large volumes of core, 
little or no penumbra)  based on the attractive prospect of tailoring treatment 
towards an imaging target, but the results show that the proposed thresholds 
must be validated first as relying on previously derived thresholds could result in 
less accurate measures of core and penumbra. Finding what the range of 
perfusion-imaging targets for acute stroke therapy exist (if any) is likely to form 
part of future stroke research trials. In order to treat based on imaging targets 
however, they must be reliable measures of different tissue states before a trial 
of treating based on mismatch or other marker can be considered. Use of 
perfusion imaging as a surrogate marker for outcome in other trials is also 
limited until thorough validation of thresholds is completed. Which CTP based 
measures most accurately represent core and penumbra? This difficult question 
has yet to be fully answered but the current work suggests relative CBF is the 
best marker for core , while DT may be the best marker for penumbra, which are 
supported by other studies which evaluated perfusion thresholds (355, 357).  
As absolute HU values do not appear to identify core tissue on a pixel by pixel 
basis, it suggests that treating based on NCCT alone could mean administering 
thrombolysis to patients with established core which could not be detected on 
CT. The reassurance of a “normal” CT scan may be limited therefore due to 
impaired sensitivity for detecting core as core volumes at baseline may identify 
patients who have no benefit from rt-PA(152). This analysis is preliminary and 
did not take lesion volume and time from symptom onset into account, both of 
which could affect the predictive value of a given HU to measure core and these 
could be assessed in future. 
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The question of whether or not collateral flow augmentation can impact on 
outcome is being evaluated in stroke trials which are ongoing at present. The 
impact of collaterals on outcomes seems to be secure despite the current lack of 
consensus on how to best grade collateral flow. This work has presented a novel 
method to quantify collateral vessel filling and should be evaluated by additional 
raters and in additional populations to assess its suitability as a collateral 
measurement. This simple system could potentially then be used to measure an 
effect from the proposed measures of collateral flow enhancement such as 
volume expansion, induced hypertension and partial aortic occlusion (237, 241). 
The mechanisms which control collateral flow adequacy remain unclear however 
and may require much more study before treatments based on collateral flow 
enhancement can be found. Future questions which should be addressed include 
whether or not stroke mechanism influences collateral flow, whether blood 
biomarkers( such as fibrinogen) can be confirmed to have a relationship with 
collateral flow adequacy, and whether the grading scale employed can be used 
in additional populations in order to study the factors which govern collateral 
flow.     
8.3 Concluding remarks 
 The work presented advances what was previously known about each 
component of a multimodal CT examination in hyperacute stroke; the limited 
sensitivity of CT based on absolute HU values, the potential of CTA to quantify 
leptomeningeal collateral flow, the accuracy of both previously accepted and 
novel measures of infarct core and ischemic penumbra, as well as the individual 
advantages of CT for obtaining imaging in a way that is rapid, feasible and 
acceptable for patients compared to MRI in acute stroke. Each component is 
worthy of further study in an effort to improve selection for current treatments, 
and hopefully as part of the process in demonstrating the benefit of new 
treatments for acute stoke, all of which is of the utmost importance for stroke 
patients in the future. 
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Appendices 
Appendix 1: Search Strategy for Literature review( Chapter 2) 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     stroke.mp. or *Stroke/ (116364) 
2     acute stroke.mp. or *Stroke/ (26935) 
3     *Adult/ or *Aged/ or *Ischemic Attack, Transient/ or *Cerebrovascular 
Circulation/ or *Cerebrovascular Disorders/ or *Brain/ or *Middle Aged/ or *Brain 
Ischemia/ or ischemic stroke.mp. or *Cerebral Infarction/ (292864) 
4     cerebral infarction.mp. or *Cerebral Infarction/ (20246) 
5     occlusion.mp. (104641) 
6     stenosis.mp. or Constriction, Pathologic/ (124777) 
7     carotid stenosis.mp. or *Carotid Stenosis/ (9718) 
8     *Cerebral Arteries/ or *Cerebrovascular Disorders/ or *Aged/ or *Carotid 
Artery Diseases/ or *Ischemic Attack, Transient/ or *Cerebral Infarction/ or 
*Arterial Occlusive Diseases/ or intracranial occlusion.mp. or *Stroke/ (121544) 
9     middle cerebral artery occlusion.mp. or *Infarction, Middle Cerebral Artery/ 
(4891) 
10     *Thrombosis/ or *Intracranial Thrombosis/ or *Carotid Artery Thrombosis/ 
or *"Intracranial Embolism and Thrombosis"/ or thrombosis.mp. (113612) 
11     clinical outcome.mp. (28006) 
12     contrast media.mp. or *Contrast Media/ (50776) 
13     tomography, x-ray computed.mp. or *Tomography, X-Ray Computed/ 
(211017) 
14     *Angiography, Digital Subtraction/ or *Angiography/ or Angiography.mp. or 
*Cerebral Angiography/ or *Magnetic Resonance Angiography/ (169715) 
15     ct angiography.mp. (2950) 
16     CT angiogram.mp. (129) 
17     CT angiography source images.mp. (8) 
18     *Brain Ischemia/ or *Brain/ or *Diffusion Magnetic Resonance Imaging/ or 
*Magnetic Resonance Imaging/ or Magnetic resonance, diffusion weighted.mp. 
(278212) 
19     Magnetic resonance angiography.mp. or *Magnetic Resonance Angiography/ 
(12426) 
20     digital subtraction angiography.mp. or *Angiography, Digital Subtraction/ 
(5088) 
21     angiogram.mp. (6160) 
22     *Ultrasonography, Doppler, Transcranial/ or transcranial.mp. (13511) 
23     *Cerebrovascular Circulation/ or *Collateral Circulation/ or pial 
collaterals.mp. or *Cerebral Arteries/ (32495) 
24     leptomeningeal collaterals.mp. (31) 
25     collateral circulation.mp. or *Collateral Circulation/ (11376) 
26     collateral vessels.mp. (1561) 
27     collateral flow.mp. (1430) 
28     collateral blood supply.mp. (246) 
29     CT perfusion.mp. (278) 
30     recanalization.mp. (4939) 
31     *Thrombolytic Therapy/ or thrombolysis.mp. or *Stroke/ (40155) 
32     angiogram.m_titl. (580) 
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33     angiography.m_titl. (22374) 
34     collateral.m_titl. (5252) 
35     33 or 32 or 21 or 17 or 12 or 20 or 15 or 14 or 22 or 34 or 30 or 13 or 16 or 
19 (414417) 
36     6 or 11 or 3 or 7 or 9 or 2 or 8 or 1 or 4 or 30 or 10 or 5 (714893) 
37     27 or 25 or 28 or 30 or 24 or 26 or 23 (46110) 
38     35 or 29 (414446) 
39     38 and 36 and 37 (14037) 
40     limit 39 to humans (12346) 
41     limit 40 to English language (9487) 
42     from 41 keep 7-8,12,29,41,52-53,58,70,72,78,102,113,116,141-
142,168,174,198,202,211,218,225-226,230,232,243,248,259-260,283,301-
302,307,309,313,326,342,348,357-358,360,370-372,391,397,416-
417,438,447,457,486,505-507,512,528-
529,538,585,636,674,688,725,733,735,744,758,778,780,797,805,811,813,825,832
-833,849,856,885,910,916,930,958 (85) 
 
Appendix 2: MRI acquisition parameters for MASIS study 
General 
 Edinburgh Aberdeen Glasgow 
(1.5T) 
Glasgow (3T) 
B0 1.5T 3.0T 1.5T 3T 
Manufacturer GE Philips GE GE 
System HDx Excite Achieva Signa Excite Signa Excite 
Software 14.04 R2.5 11.0_0403a 12.0_0606.b 
Gradients Echospeed+ Quasar Dual Twin Twin 
Head coil Quadrature SENSE NV-16 8 channel 8 channel 
 
Gradient Echo 
 Edinburgh Aberdeen Glasgow (1.5T) Glasgow (3T) 
Sequence Axial T2 GRE T2W-FFE Ax T2* GRE Ax T2* GRE 
TR 660ms 780ms 500 670 
TE 15ms 16.11 20 22 
Flip angle 20° 18° 20° 10° 
NEX 1 1 1 1 
# slices 28 24 24 24 
Slice thickness 5 5 5 5 
Slice gap 0 0 0 0 
Matrix 256*192 286x170 256x224 256x256 
Φ FOV 0.75 0.8 0.75 0.75 
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FOV 24 x 24 240x240 24 24 
Slice orient Straight axial Straight axial AC-PC AC-PC 
Tscan  
 
1:42 2:14 2:56 2:11 
 
DWI 
 Recommended Edinburgh Aberdeen Glasgow 
(1.5T) 
Glasgow (3T) 
Sequence Single-shot DW 
EPI 
Single-shot 
DW EPI 
Single-shot 
DW EPI 
Ax DWI DWI ASSET 
TR >4000ms 10000 7600 8000 9000 
TE min Min (87.3) Min (68) Min 65.7 
B (s/mm2) 0 and 1000  0 and 1000 0 and 1000 0 and 
1000 
0 and 1000 
# directions >3 3 3 3 3 
Flip angle 90° 90° 90 90 90 
# slices >12 (whole brain) 28 24 28 24 
Slice 
thickness 
5mm 5 5 5 5 
Slice gap 0-1mm 0 0 1.5 0 
Matrix 128 x 128 128 x 128 256x256 128x128 256x256 
Φ encoding 
dirn 
AP R/L  AP AP 
FOV 24 cm 24 x 24 cm 256x256 26 24 
Slice orient // to hard palate Straight axial Straight axial AC-PC AC-PC 
Tscan 90-120secs 0:40 1:39 2:08 3:36 (plus 
12secs for 
calibration) 
 
Circle of Willis MRA 
 Edinburgh Aberdeen Glasgow (1.5T) Glasgow (3T) 
Sequence 3D TOF 2 slab 
HR 
  3D TOF 
TR (ms) 23   21ms 
TE (1) (ms) 2.7   3ms 
TE (1) (ms) 20 / 2000    
Flip angle 20°   15 
Locs / slab 32   50 
Slice thickness 1.6   1.2 
Slice gap 0   0 
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Matrix 320 x 224   512 x 320 
Φ FOV 1   1 
FOV 16   22 
Slice orient Straight axial   Oblique 
Tscan  
 
5:46   2:52 
 
Perfusion 
 Recommended Edinburgh Aberdeen Glasgow 
(1.5T) 
Glasgow 
(3T) 
Sequence Single-shot EPI Single-shot 
EPI 
Single-shot 
EPI 
GRE-EPI SS-EPI 
TR 1500±250ms 1600 1600 2000 1500 
TE 35-45ms@1.5T 
25-30ms@3T 
30 30 60 22.1 
Flip angle 90°@1.5T 
60°@3T 
90 90 90 60 
Tscan 90-120seconds 2:08 2:06 1:05 2:00 
T before 
contrast 
10secs (10-12 
baseline images) 
16 16 sec (10 
baseline 
scans) 
6-8 sec 15s 
# slices >12 (whole brain) 22 30 18 Whole brain 
Slice 
thickness 
5mm 5 5 5 5 
Slice gap 0-1mm 0 0 1 0 
Matrix 128x128 96 x 96* 96x96* 128x64 128x128 
Φ encoding 
dirn 
AP AP AP AP AP 
FOV 24 cm 24 x 24 240x240 26 24 
Slice 
orientation 
// to hard palate Straight axial Straight axial AC-PC AC-PC 
Contrast Gad-based Gad-based Gad-based Gad-
based 
Gad-based 
Contrast flow 
rate 
4-6ml/sec 5ml/sec 5ml/sec 5 5 
Contrast vol ~20ml for 100kl 
person 
20ml 20ml 20 Per Patient 
Saline flow 
rate 
 5ml/sec 5ml/sec 5 5 
Saline volume 20-40ml 20ml 20ml 20 20 
# phases  80 75 32 per 
location 
40 per 
location 
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Post Contrast FLAIR 
 Edinburgh Aberdeen Glasgow (1.5T) Glasgow (3T) 
Sequence Ax FLAIR IR-TSE Ax T2 FLAIR Ax T2 FLAIR 
TR (ms) 9000 11000 8000 10000 
TE (ms) 140 125 120 144.4 
TI (ms) 2200 2800 2000 2250 
# slices 28 24 24 24 
Slice thickness 5 5 5 5 
Slice gap 0 0 1.5 0 
Matrix 256*224 368x216 256x224 384x256 
Φ FOV 1 0.8 0.7-1 0.7-1 
FOV 24 x 24 240x190 24 24 
Slice orient Straight axial Straight axial AC-PC AC-PC 
Tscan  
 
4:12 6:36 3:44 3:20 
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